Bicyclic compounds and their uses as dual c-src / jak inhibitors

ABSTRACT

The present invention relates to substituted aromatic bicyclic compounds containing pyrimidine and pyridine rings of formula (I) having the structure as well as pharmaceutically acceptable salts thereof. The compounds of the present invention are useful as tyrosine kinase inhibitors, preferably SRC family kinases (SFKs) inhibitors, in particular as multi SFK/JAK. kinases inhibitors and even preferably as dual c-SRC/JAK kinases inhibitors, thereby inhibiting the STAT3 activation and therefore abnormal growth of particular cell types. Notably, the compounds of the present invention are useful for the treatment or inhibition of certain diseases that are the result of deregulation of STAT3.

FIELD OF THE INVENTION

The present invention relates to substituted aromatic bicyclic compoundscontaining pyrimidine and pyridine rings as well as pharmaceuticallyacceptable salts thereof. The compounds of the present invention areuseful as tyrosine kinase inhibitors, preferably SRC family kinases(SFKs) inhibitors, in particular as multi SFK/JAK kinases inhibitors andeven preferably as dual c-SRC/JAK kinases inhibitors, thereby inhibitingthe STAT3 activation and therefore abnormal growth of particular celltypes. Notably, the compounds of the present invention are useful forthe treatment or inhibition of certain diseases that are the result ofderegulation of STAT3.

BACKGROUND OF THE INVENTION

Inflammation and cancer are linked by both oncogenic (intrinsic) andenvironmental (extrinsic) pathways (Yu et al., Nature Reviews Cancer2009). The intrinsic pathway is activated by genetic or epigeneticalterations in transformed cells. Such alterations include those thatcause the overexpression or the persistent activation of growth factorreceptors with intrinsic tyrosine kinase activity and cytokine receptorswith associated Janus kinase (JAK) family tyrosine kinases. Oncogenicmutations in receptor-associated JAK family members also underlie sometypes of cancer. These receptors, as well as non-receptor tyrosinekinases such as c-SRC, can be activated by extrinsicpathways—environmental factors that are associated with cancerinflammation—which include ultraviolet (UV) radiation, chemicalcarcinogens, infection, stress and cigarette smoke. Activated tyrosinekinases induced by both intrinsic and extrinsic pathways phosphorylateand activate the transcription factor signal transducer and activator oftranscription 3 (STAT3), which in turn forms dimers that translocate tothe nucleus, where they directly regulate the expression of a battery oftarget genes. In addition to upregulating numerous genes involved inproliferation, survival, invasion and metastasis, STAT3 induces theexpression of many cytokines, chemokines and other mediators, such asinterleukin-6 and cyclooxygenase 4 that are associated withcancer-promoting inflammation. Importantly, receptors for many of thesecytokines, chemokines and mediators in turn further activate STAT3, thusforming autocrine and paracrine feedforward loops that result in astable change to the genetic program and the promotion of cancerinflammation.

STAT3 is suggested to have a crucial role in selectively inducing andmaintaining a procarcinogenic inflammatory microenvironment, both at theinitiation of malignant transformation and during cancer progression.Persistent activation of STAT3 mediates the propagation oftumor-promoting inflammation and increases tumor cell proliferation,survival and invasion while suppressing anti-tumor immunity. Thus, STAT3is an attractive molecular target for the development of novel cancertherapeutics or for modulating immune responses to improve cancertherapy.

Several small molecule inhibitors, that effectively block the STAT3signaling pathway, are already known in the prior art (Deng et al.,Current Cancer Drug Targets, 2007). These inhibitors, from a structuralpoint of view, are divided into five classes of compounds. They include(1) natural products and derivatives, such as curcumin, resveratrol andothers, (2) tyrphostins, (3) platinum-containing complexes, (4)peptidomimetics, and (5) azaspiranes.

It is also known from the prior art that instead of directly andspecifically inhibiting STAT3, it is possible to effectively block theSTAT3 signaling pathway by inhibiting the upstream targets. Indeed, asmentioned above, the STAT3 transcription factor is a downstream effectorof both JAK and c-SRC kinases and is activated by tyrosinephosphorylation on tyrosine 705 (Y705) by these kinases, which is aprerequisite for STAT3 dimerization and activation of the transcriptionfactor function of STAT3.

Thus c-SRC and JAK act upstream of the transcription factor STAT3, andtheir inhibition will lead to block STAT3 signaling pathway in a subsetof STAT3 dependent tumors. It has been reported (Johnson et al., Clin.Cancer Res, 2007 and WO 2008/077062, Board of Regents, The University ofTexas System) that c-SRC and JAK inhibitors have synergistic antitumoreffects. Indeed, c-SRC can be rapidly and durably inhibited by, forexample, Dasatinib, whereas STAT3 undergoes only transient inactivation.The addition of JAK inhibitors, such as pyridone 6 or AG490, duringDasatinib incubation resulted in sustained inhibition of STAT3, althoughJAK activation by Dasatinib was not shown. Combined c-SRC and JAKinhibition resulted in synergistic cytotoxicity due to increasedapoptosis. Therefore with the combination treatment, the durableinhibition of several pathways, such as STAT3 signaling pathway, knownto be important for cancer cell survival and proliferation can beobtained.

The SRC family of kinases (SFKs) is composed of nonreceptor tyrosinekinases with key roles in regulating signal transduction pathways thatcontrol cell proliferation, motility, adhesion and survival. SFKs andcertain growth factor receptors are overexpressed in various cancers.Halpern M. S., England J. M., Kopen G. C, Christou A. A., Taylor R. L.Jr., Endogenous c-src as a Determinant of the Tumorigenicity of srcOncogenes, Proc Natl Acad Sd USA. 1996 93(2): 824-827. Haura, E. B.,Zheng, Z., Song, L., Cantor, A., Bepler, G., Activated Epidermal GrowthFactor Receptor-Stat-3 Signaling Promotes Tumor Survival In Vivo inNon-Small Cell Lung Cancer, Clin. Cancer Res. 2005, 11(23): 8288-8294.c-SRC plays a role in responses to regional hypoxia, limited nutrients,and internal cellular effects to self-destruct. Aberrant expressionand/or activity of c-SRC are observed in numerous solid and liquidtumors, and play critical roles in affecting chemoresistance. Almost anygrowth factor leading to activation of receptor tyrosine kinases can beshown to activate c-SRC, making c-SRC a very attractive target forcancer therapy. Since the activation and perhaps over-expression ofc-SRC has been implicated in cancer, osteoporosis, stroke, myocardialinfarction, and vascular leak, among others, a small molecule inhibitorof c-SRC can be beneficial for the treatment of several disease states.However, inhibition of SFKs using a tyrosine kinase inhibitor has beenshown to result in cytotoxicity, cell cycle arrest, and apoptosis inhead and neck squamous carcinoma and non-small cell lung cancer celllines. Johnson, F. M., Saigal, B., Talpaz, M., and Donate, N. J.,Dasatinib (BMS-354825) Tyrosine Kinase Inhibitor Suppresses Invasion andInduces Cell Cycle Arrest and Apoptosis of Head and Neck Squamous CellCarcinoma and Non-small Cell Lung Cancer Cells, Clin Cancer Res, 11:6924-6932, 2005. In head and neck squamous carcinoma and non-small celllung cancer cell lines, Dasatinib results in cytotoxicity, cell cyclearrest and apoptosis. However, despite the durable inhibition of SFKsand initial inhibition of STAT3, STAT3 is not durably inhibited.

The Janus kinases (JAKs) are cellular kinases and consist of fourmembers—JAK1, JAK2, JAK3 and TYK2. The JAKs may play a crucial role inregulating cell behavior induced by a number of cytokines and arecrucial components of diverse signal transduction pathways that governcellular survival, proliferation, differentiation and apoptosis. Theover-activation of JAK kinases has been implicated in tumorigenesis. In2005, a recurrent mutation in JAK2 (JAK2V617F) leading to aconstitutively active JAK2 was identified in a large number of patientswith myeloproliferative disorders, including polycythaemia vera,essential thrombocythaemia and primary myelo fibrosis.

Several selective SRC family kinase inhibitors, such as SU6656,Dasatinib, WO 99/61444 (Warner-Lambert Company) or WO 2007/088014 (F.Hoffmann La Roche AG), and selective JAK inhibitors, such as pyridone 6,AG490 or those disclosed in WO 2009/054941 (Merck & Co., Inc), WO2009/029998 (Cytopia Research PTY LTD) or WO/2008/157208 (IncyteCorporation), have been reported. SFKs also mediate STAT growth pathwaysin various cancers. Xi, S., Zhang, Q., Dyer, K. F., Lerner, E. C,Smithgall, T. E., Gooding, W. E., Kamens, J., and Grandis, J. R., Srckinases Mediate STAT Growth Pathways in Squamous Cell Carcinoma of theHead and Neck, J Biol Chem, 278: 31574-31583, 2003. An important needexists, therefore, for pharmaceutical composition and/or method oftreatment for cancer that will inhibit both SFKs and STATs.

However there is a further need to develop a multi-targeted kinaseinhibitor. A single compound which inhibits a combination of severaltargets, such as SFKs and JAKs, offers the advantage of inhibitingsimultaneously several key signal transduction pathways, therebyinterfering with several oncogenic processes, while making the treatmenteasier and improving the patients comfort. It would therefore bedesirable to generate small molecule kinase inhibitor molecules able tosimultaneously inhibit SFKs (in particular c-SRC) and JAKs.

By combining a dual inhibitory activity, such as SFKs (in particularc-SRC) and JAKs, in a single molecule, the advantage resides in (i)reducing the risks related to off-target toxicity encountered when twodifferent kinase inhibitors targeting SFKs (in particular c-SRC) andJAKs are administered, (ii) reducing the costs of treatment, (iii)increasing the patients compliance, and (iv) blocking simultaneouslyparallel ways of activating the STAT3 pathway will lead to a betteranti-tumoral response. Moreover, as the status of STAT3 activation canbe monitored across tumor types, a multi SFKs (in particular c-SRC) andJAKs targeted kinase inhibitor could be used in various types ofdiseases based on the status of STAT3 in those tumors.

Accordingly, the present invention aims to provide compounds whichsimultaneously inhibit several key signal transduction pathwaysespecially directed towards the status of STAT3 activation. Thosecompounds have the unexpected advantage to present either:

-   -   an inhibition for efficient STAT3 blockade following the        inhibition of c-Src and JAK2;    -   an inhibition of STAT3 phosphorylation by in-cell Western        preferably having an IC50≦500 nM;    -   in an established xenograft models using A431 and A549 (STAT3        positive cell lines) an inhibition of growth (>60%) of        established tumors at a dose below MTD with a clear        dose-response (highest dose close to MTD) and an inhibition of        STAT3 phosphorylation in tumors.

The compounds of the invention represent compounds showing a particularand unexpected good compromise between these 3 criteria.

SUMMARY OF THE INVENTION

This goal has been achieved by the Applicants, who surprisinglygenerated novel small kinase inhibitor molecules of c-SRC, JAK-1, JAK-2.

The present invention provides compounds which affect the STAT3 pathway.The compounds of the invention are useful as pharmaceuticalcompositions, for example where modulation of the STAT3 pathway isindicated for the treatment of various human diseases, such as cancerand/or auto-immune diseases.

The present invention provides a compound of formula (I) having thestructure

wherein

-   -   R1 is H, aryl, substituted aryl, alkyl, substituted alkyl,        heteroaryl, substituted hetero aryl, heterocyclyl, substituted        heterocyclyl, heterocyclylalkyl or substituted        heterocyclylalkyl,    -   X is CH₂ or C═O    -   R2 is H, (C₁-C₆)alkyl, halogen, CF₃, or —O—(C₁-C₆)alkyl    -   Y is —NHCO—, —CONH—, —NHSO₂ ⁻, —NH—, —NCH₃—CO—, —NHCH₂—, O,        —NHCONH— or —NHCOCH₂—    -   R3 is alkyl, substituted alkyl, aryl, or substituted aryl,        heteroaryl, substituted heteroaryl, cyclo alkyl, substituted        cycloalkyl or heterocycloalkyl    -   or a pharmaceutically acceptable salt thereof.

Preferably the present invention provides a compound of formula (II)having the structure

wherein

R1 is hydrogen, (C₁-C₄)alkyl, phenyl, substituted phenyl, pyridine, orsubstituted pyridine, preferably R1 is substituted phenyl or substitutedpyridine,

X is CH₂ or C═O

R2 is H, (C₁-C₆)alkyl, halogen, or —O—(C₁-C₆)alkyl, preferably R2 is H,CH₃, Cl or F

R3 is (C₁-C₆)alkyl, cycloalkyl, substituted cycloalkyl,heterocycloalkyl, aryl, substituted aryl, heteroaryl, substitutedheteroaryl,

-   -   and wherein the substituents are selected from the group        comprising C₁-C₄ linear or branched alkyl, halo or nitrile        substituted C₁-C₄ alkyl, —O-alkyl(C₁-C₄), halogen;        or a pharmaceutically acceptable salt thereof.

Preferably R3 is selected from the group consisting of:

-   -   substituted phenyl, wherein the substituents are selected from        the group comprising Cl, F, Br, CF₃ and CH₃.

The compounds of the invention for use in therapy and for use in amethod for treating diseases associated with activation of STAT3pathway, through multi-target inhibition of c-SRC and JAK2 are alsoencompassed in the present invention.

Preferably the diseases associated with activation of STAT3 pathway arecancer, auto-immune, bone related and heamatological diseases.

Further object of the present invention is to provide a pharmaceuticalcomposition comprising the compounds of the invention and at least onepharmaceutically acceptable excipient, carrier or diluent.

BRIEF DESCRIPTION OF FIGURES

FIG. 1 shows inhibition activity of the compounds of the inventioncompared to Taxol®

FIG. 2 shows inhibition activity of the compounds of the inventioncompared to Taxol®

FIG. 3 shows the inhibition of tumour growth of the compounds of theinvention compared to Erlotinib

FIG. 4 shows Tyrosine 705 phosphorylated-STAT (pSTAT) inhibition intumours of the compounds of the invention

DETAILED DESCRIPTION OF THE INVENTION

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as is commonly understood by one of skill in artto which the subject matter herein belongs. As used herein, thefollowing definitions are supplied in order to facilitate theunderstanding of the present invention. In the case of conflict, thepresent specification, including definitions, will control.

The term “comprise” is generally used in the sense of include, that isto say permitting the presence of one or more features or components.

As used in the specification and claims, the singular form “a”, “an” and“the” include plural references unless the context clearly dictatesotherwise.

The term “alkyl” refers to saturated aliphatic groups, includingstraight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl(alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkylsubstituted alkyl groups. In certain embodiments, a straight chain orbranched chain alkyl has about 30 or fewer carbon atoms in its backbone(e.g., C₁-C₃₀ for straight chain, C₃-C₃₀ for branched chain), andalternatively, about 20 or fewer, e.g. from 1 to 6 carbons.

Likewise, “cycloalkyl” refers to a saturated or partially saturated,monocyclic or fused or spiro polycyclic, carbocycle preferablycontaining from 3 to 10 carbons per ring, such as cyclopropyl,cyclobutyl, cyclopentyl, cyclohexyl and the like, unless otherwisespecified. It includes monocyclic systems such as cyclopropyl andcyclohexyl, bicyclic systems such as decalin, and polycyclic systemssuch as adamantane. The group may be a terminal group or a bridginggroup.

The term “substituted alkyls” refers to alkyl moieties havingsubstituents replacing a hydrogen on one or more carbons of thehydrocarbon backbone. Such substituents may include, for example, ahydroxyl, a carbonyl (such as a carboxyl, an alkoxycarbonyl, a formyl,or an acyl), a thiocarbonyl (such as a thioester, a thioacetate, or athioformate), an alkoxyl, a phosphoryl, a phosphonate, a phosphinate, anamino, an amido, an amidine, an imine, a cyano, a nitro, an azido, asulfhydryl, an alkylthio, a sulfate, a sulfonate, a sulfamoyl, asulfonamido, a sulfonyl, a heterocyclyl, an aralkyl, or an aromatic orheteroaromatic moiety. It will be understood by those skilled in the artthat the moieties substituted on the hydrocarbon chain may themselves besubstituted, if appropriate. For instance, the substituents of asubstituted alkyl may include substituted and unsubstituted forms ofamino, azido, imino, amido, phosphoryl (including phosphonate andphosphinate), sulfonyl (including sulfate, sulfonamido, sulfamoyl andsulfonate), and silyl groups, as well as ethers, alkylthios, carbonyls(including ketones, aldehydes, carboxylates, and esters), —CN and thelike. Exemplary substituted alkyls are described below. Cycloalkyls maybe further substituted with alkyls, alkenyls, alkoxys, alkylthios,aminoalkyls, carbonyl-substituted alkyls, —CN, and the like.

The term “heterocycloalkyl” or “heterocyclyl” as used herein, refers toa non-aromatic partially unsaturated or fully saturated 3 to 10 memberedring system, which includes single rings of 3 to 8 atoms in size and bi-or tri-cyclic ring systems which may include aromatic six-membered arylor heteroaryl rings fused to a non-aromatic ring. These heterocycloalkylrings include those having from one to three heteroatoms independentlyselected from oxygen, sulfur and nitrogen, in which the nitrogen andsulfur heteroatoms may optionally be oxidized and the nitrogenheteroatom may optionally be quaternized. The heterocyclic ring may besubstituted at one or more ring positions with substituents such asalkyl, carbonyl, halogen, alkoxy, hydroxyalkyl and the like.Representative heterocycles include, but are not limited to,pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl,piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl,thiazolidinyl, isothiazolidinyl, and tetrahydrofuryl. The group may be aterminal group or a bridging group.

The term “heteroatom” refers to an atom of any element other than carbonor hydrogen. Illustrative heteroatoms include boron, nitrogen, oxygen,phosphorus, sulfur and selenium.

The term “aralkyl” refers to an alkyl group substituted with an arylgroup (e.g., an aromatic or heteroaromatic group).

The terms “alkenyl” and “alkynyl” refer to unsaturated aliphatic groupsanalogous in length and possible substitution to the alkyls describedabove, but that contain at least one double or triple bond respectively.The term “alkylene” refers to an organic radical formed from anunsaturated aliphatic hydrocarbon; “alkenylene” denotes an acycliccarbon chain which includes a carbon-to-carbon double bond.

The term “nitro” refers to —NO₂.

The term “halogen” represents chlorine, fluorine, bromine or iodine.

The term “sulfhydryl” refers to —SH.

The term “hydroxyl” means —OH.

The term “sulfonyl” refers to —SO₂.

The terms “amine” and “amino” refer to both unsubstituted andsubstituted amines (—NH₂). The substituted amine may be substituted atone or both hydrogen positions with, for example, an alkyl, an alkenyl,an aryl, a cycloalkyl, a cycloalkenyl, or a heterocycle. Thus, the term“alkylamine” includes an amine group, as defined above, having asubstituted or unsubstituted alkyl attached thereto.

The term “amido” refers to an amino-substituted carbonyl (—CONH₂—),wherein the amine moiety may be substituted at one or both hydrogenpositions with, for example, an alkyl, hydroxyalkyl, an alkenyl, anaryl, a cycloalkyl, a cycloalkenyl, heterocycloalkylalkyl or aheterocycle.

The term “acylamino” may be represented by the general formula:

wherein one or both hydrogen positions may be substituted with, forexample, an alkyl, an alkenyl, an aryl, a cycloalkyl, a cycloalkenyl, ora heterocycle.

The term “alkylthio” refers to an alkyl group, as defined above, havinga sulfur radical attached thereto. In certain embodiments, the“alkylthio” moiety is represented by one of —S-alkyl, —S-alkenyl, or—S-alkynyl. Representative alkylthio groups include methylthio, ethylthio, and the like.

The term “carbonyl” refers to the general formula:

wherein the hydrogen atom may be substituted with, for example, analkyl, an alkenyl, an aryl, a cycloalkyl, a cycloalkenyl, or aheterocycle.

The term “aryl” as used herein refers to a mono-, bi-, or othermulti-carbocyclic, aromatic ring system. The aromatic ring may besubstituted at one or more ring positions with such substituents asdescribed above, for example, halogen, azide, alkyl, aralkyl, alkenyl,alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino,amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether,alkylthio, sulfonyl, alkylsulfonyl, sulfonamido, cycloalkyl sulfonamido,ketone, aldehyde, ester, heterocyclyl, heterocyclyl carbonyl,heterocyclyl alkoxy, heterocycloalkylalkyl, aromatic or heteroaromaticmoieties, —CF₃, —CN, or the like. The term “aryl” also includespolycyclic ring systems having two or more cyclic rings in which two ormore carbons are common to two adjoining rings (the rings are “fusedrings”) wherein at least one of the rings is aromatic, e.g., the othercyclic rings may be cycloalkyls, heterocycloalkyls, cycloalkenyls,cycloalkynyls, and/or aryls. Exemplary aryl groups include, but are notlimited to, phenyl, tolyl, anthracenyl, fluorenyl, indenyl, azulenyl,and naphthyl, as well as benzo-fused carbocyclic or heterocyclicmoieties such as 5,6,7,8-tetrahydronaphthyl, benzo[1,3]dioxolyl,benzo[1,4]dioxinyl.

The terms “heteroaryl” refers to a 5-15 membered mono-, bi-, or othermulti-cyclic, aromatic ring system containing one or more heteroatoms,for example one to four heteroatoms, such as nitrogen, oxygen, andsulfur. Heteroaryls can also be fused to non-aromatic rings. Theheteroaryl ring may be substituted at one or more positions with suchsubstituents as described above, as for example, halogen, alkyl,aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro,sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl,silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, aheterocyclyl, an aromatic or heteroaromatic moiety, —CF₃, —CN, or thelike. Illustrative examples of heteroaryl groups include, but are notlimited to, acridinyl, benzimidazolyl, benzofuryl, benzothiazolyl,benzothienyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl,furazanyl, furyl, imidazolyl, indazolyl, indolizinyl, indolyl,isobenzofuryl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl,naphthyridinyl, oxadiazolyl, oxazolyl, phenanthridinyl, phenanthrolinyl,phenarsazinyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl,pteridinyl, purinyl, pyrazinyl, pyrazolyl, pyrazyl, pyridazinyl,pyridinyl, pyrimidilyl, pyrimidyl, pyrrolyl, quinolinyl, quinolizinyl,quinoxalinyl, quinoxaloyl, quinazolinyl, tetrazolyl, thiadiazolyl,thianthrenyl, thiazolyl, thienyl, thiophenyl, triazinyl, (1,2,3,)- and(1,2,4)-triazolyl, and the like. Exemplary heteroaryl groups include,but are not limited to, a monocyclic aromatic ring, wherein the ringcomprises 2 to 5 carbon atoms and 1 to 3 heteroatoms.

The term “carbocycle” is art-recognized and refers to an aromatic ornon-aromatic ring in which each atom of the ring is carbon.

The term “cycloalkylalkyl” refers to a cyclic ring-containing radicalhaving 3 to about 8 carbon atoms directly attached to an alkyl group.The cycloalkylalkyl group may be attached to the main structure at anycarbon atom in the alkyl group that results in the creation of a stablestructure. Non-limiting examples of such groups includecyclopropylmethyl, cyclobutylethyl and cyclopentylethyl.

The term “alkoxy” refers to a straight or branched, saturated aliphatichydrocarbon radical bonded to an oxygen atom that is attached to a corestructure. Examples of alkoxy groups include but are not limited tomethoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy,pentoxy, 3-methyl butoxy and the like.

The term “haloalkyl” and “haloalkoxy” means alkyl or alkoxy, as the casemay be, substituted with one or more halogen atoms, where alkyl andalkoxy groups are as defined above. The term “halo” is used hereininterchangeably with the term “halogen” means F, Cl, Br or I. Examplesof “haloalkyl” include but are not limited to trifluoromethyl,difluoromethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, pentachloroethyl4,4,4-trifluorobutyl, 4,4-difluorocyclohexyl, chloromethyl,dichloromethyl, trichloromethyl, 1-bromoethyl and the like. Examples of“haloalkoxy” include but are not limited to fluoromethoxy,difluoromethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy,pentafluoroethoxy, pentachloroethoxy, chloromethoxy, dichlorormethoxy,trichloromethoxy, 1-bromoethoxy and the like.

The term “heterocyclylcarbonyl” or “heterocyclylalkoxy” means carbonylor alkoxy, as the case may be, linked with heterocyclyl group, wherealkoxy and heterocyclyl groups are as defined above.

The term “heterocyclylalkyl” or “heterocycloalkylalkyl” refers to aheterocyclic ring radical directly bonded to an alkyl group. Theheterocyclyl or heterocycloalkyl radical as defined above may beattached to the main structure at any carbon atom in the alkyl groupthat results in the creation of a stable structure.

Unless otherwise specified, the term “substituted” as used herein refersto substitution with any one or more or any combination of the followingsubstituents: hydroxy, halogen, carboxyl, cyano, nitro, oxo (═O), thio(═S), substituted or unsubstituted alkyl, substituted or unsubstitutedhaloalkyl, substituted or unsubstituted alkoxy, substituted orunsubstituted haloalkoxy, substituted or unsubstituted alkenyl,substituted or unsubstituted alkynyl, substituted or unsubstituted aryl,substituted or unsubstituted arylalkyl, substituted or unsubstitutedcycloalkyl, substituted or unsubstituted cycloalkenylalkyl, substitutedor unsubstituted cycloalkenyl, substituted or unsubstituted amino,substituted or unsubstituted aryl, substituted or unsubstitutedheteroaryl, substituted or unsubstituted heterocyclylalkyl ring,substituted or unsubstituted heteroarylalkyl, substituted orunsubstituted heterocyclic ring, substituted or unsubstituted guanidine.

The terms ortho, meta and para refer to 1,2-, 1,3- and 1,4-disubstitutedbenzenes, respectively. For example, the names 1,2-dimethylbenzene andortho-dimethylbenzene are synonymous.

The present invention provides a compound of formula (I) having thestructure

wherein

-   -   R1 is H, aryl, substituted aryl, alkyl, substituted alkyl,        heteroaryl, substituted hetero aryl, heterocyclyl, substituted        heterocyclyl, heterocyclylalkyl or substituted        heterocyclylalkyl,    -   X is CH₂ or C═O    -   R2 is H, (C₁-C₆)alkyl, halogen, CF₃, or —O—(C₁-C₆)alkyl    -   Y is —NHCO—, —CONH—, —NHSO₂ ⁻, —NH—, —NCH₃—CO—, —NHCH₂—, O,        —NHCONH— or —NHCOCH₂    -   —R3 is alkyl, substituted alkyl, aryl, or substituted aryl,        heteroaryl, substituted heteroaryl, cycloalkyl, substituted        cycloalkyl or heterocycloalkyl;    -   or a pharmaceutically acceptable salt thereof.

Preferably Y is —NHCO—.

According to a particular embodiment, the invention provides a compoundof formula (II) having the structure

wherein

R1 is hydrogen, (C₁-C₄)alkyl, phenyl, substituted phenyl, pyridine, orsubstituted pyridine,

X is CH₂ or C═O

R2 is H, (C₁-C₆)alkyl, halogen, or —O—(C₁-C₆)alkyl,

R3 is (C₁-C₆)alkyl, cycloalkyl, substituted cycloalkyl,heterocycloalkyl, aryl, substituted aryl, heteroaryl, substitutedheteroaryl,

-   -   and wherein the substituents are selected from the group        comprising C₁-C₄ linear or branched alkyl, halo or nitrile        substituted C₁-C₄ alkyl, —O-alkyl(C₁-C₄), halogen;    -   or a pharmaceutically acceptable salt thereof.

Preferably R3 is selected from the group consisting of

Preferably R1 is substituted phenyl or substituted pyridine,

Preferably X is CH₂ or C═O

Preferably R2 is H, CH₃, Cl or F;

More preferably R3 is selected from the group consisting of:

-   -   substituted phenyl, wherein the substituents are selected from        the group comprising Cl, F, Br, CF₃ and CH₃.

More preferably R1 is selected from the group consisting of:

Even more preferably R3 is selected from the group consisting of:

Preferably the present invention comprises a compound selected from thegroup consisting of:

-   N-(4-Methyl-3-{2-[4-(4-methyl-piperazine-1-carbonyl)-phenylamino]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-trifluoromethyl-benzamide-   N-(4-Methyl-3-{2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-trifluoromethyl-benzamide-   5-{6-[2-Methyl-5-(3-trifluoromethyl-benzoylamino)-phenyl]-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-ylamino}-pyridine-2-carboxylic    acid cyclopropylamide-   N-{3-[2-(4-Cyclopropylsulfamoyl-phenylamino)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-4-methyl-phenyl}-3-trifluoromethyl-benzamide-   N-(4-Chloro-3-{2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-trifluoromethyl-benzamide-   4-Trifluoromethyl-pyridine-2-carboxylic acid    {4-chloro-3-[2-(4-methylcarbamoyl-phenylamino)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-phenyl}-amide-   4,4,4-Trifluoro-3-methyl-N-[4-methyl-3-(2-{4-[2-(4-methyl-piperazin-1-yl)-ethoxy]-phenylamino}-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)-phenyl]-butyramide-   1-Cyclopentyl-3-(4-methyl-3-{2-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylamino]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-urea-   N-(4-Methyl-3-{5-oxo-2-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylamino]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-trifluoromethyl-benzamide-   N-{4-Chloro-3-[2-(4-(cyclopropylcarbamoylmethoxy)phenylamino)-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-phenyl}-3-trifluoromethyl-benzamide-   N-(4-Chloro-3-{2-[3-methyl-4-(4-methyl-piperazin-1-yl)-phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-trifluoromethyl-benzamide-   3-Bromo-N-(4-methyl-3-{2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-benzamide-   N-(4-Chloro-3-{2-[4-(4-methyl-piperazin-1-ylmethyl)-phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-trifluoromethyl-benzamide    -   or a pharmaceutically acceptable salt thereof.

According to another particular embodiment, the present inventionprovides a compound selected from the group consisting of:

-   N-(4-Methyl-3-{2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-trifluoromethyl-benzamide-   5-{6-[2-Methyl-5-(3-trifluoromethyl-benzoylamino)-phenyl]-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-ylamino}-pyridine-2-carboxylic    acid cyclopropylamide-   4-Trifluoromethyl-pyridine-2-carboxylic acid    {4-chloro-3-[2-(4-methylcarbamoyl-phenylamino)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-phenyl}-amide    -   or a pharmaceutically acceptable salt thereof.

According to further particular embodiment, the present inventionprovides a compound selected from the group consisting of:

-   N-(4-Chloro-3-{2-[3-methyl-4-(4-methyl-piperazin-1-yl)-phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-trifluoromethyl-benzamide-   N-{4-Chloro-3-[2-(4-(cyclopropylcarbamoylmethoxy)phenylamino)-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-phenyl}-3-trifluoromethyl-benzamide    -   or a pharmaceutically acceptable salt thereof.

Further examples of compounds encompassed by the present inventioninclude the compounds of Table 1. Last column represents the examplenumber (Ex) used for the preparation of each compound appearing on thefollowing table.

TABLE 1 Physical Data No Structure [¹HNMR and/or MS] IUPAC NAME Ex 1

¹H NMR (300 MHz, CD₃OD) δ 8.15-8.0 (m, 3H), 7.9-7.76 (m, 2H), 7.66-7.55(m, 2H), 7.22-7.12 (m, 2H), 4.95 (s, 2H), 4.0 (s, 2H), 3.3-3.2 (m, 2H),2.96-2.85 (m, 2H), 2.3 (s, 3H) MS: m/z 428.0 (M + 1). N-[3-(2-Amino-7.8-dihydro-5H- pyrido[4,3-d] pyrimidin-6-yl)-4- methyl-phenyl]-3-trifluoromethyl- benzamide 1 6

¹H NMR (300 MHz, DMSO- D₆) δ 10.5 (s, 1H), 8.62 (s, 1H), 8.32- 8.29 (brs, 1H), 8.29-8.23 (d, 1H), 8.0-7.95 (m, 1H), 7.8 (t, 1H), 7.7-7.62 (m,2H), 7.46-7.36 (br s, 2H), 7.34-7.27 (m, 1H), 4.0-3.88 (m, 1H), 3.76-3.66 (m, 1H), 3.18-3.04 (m, 1H), 2.78-2.86 (m, 1H), 2.16 (s, 3H) MS m/z442.2 (M + 1), N-[3-(2-Amino-5- oxo-7.8-dihydro- 5H-pyrido[4,3-d]pyrimidin-6-yl)- 4-methyl-phenyl]- 3-trifluoromethyl- benzamide 3 7

¹H NMR (300 MHz, CDCl₃) δ 9.4-9.1 (br s, 1H), 8.95-8.85 (m, 2H), 8.2-8.0(m, 2H), 7.8- 7.7 (m, 1H), 7.7-7.5 (m, 5H), 7.2-7.1 (d, 1H), 6.9-6.8 (d,2H), 4.4-4.3 (t, 2H), 4.05-3.7 (m, 4H), 3.5 (t, 2H), 3.2-3.1 (m, 2H),3.05-2.9 (m, 2H), 2.2-2.0 (m, 4H), 1.95 (s, 3H) MS: m/z 631.2 (M + 1),N-(4-Methyl-3- {5-oxo-2-[4-(2- pyrrolidin-1-yl- ethoxy)-phenylamino]-7,8- dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl} phenyl)-3-trifluoromethyl- benzamide 3 8

¹H NMR (300 MHz, CD₃OD) δ 8.74 (s, 1H), 8.29-8.18 (m, 2H), 7.94-7.87 (m,1H), 7.83 (t, 1H), 7.78-7.7 (m, 1H), 7.68-7.62 (m, 1H), 7.44 (t, 1H),7.23-6.96 (m, 1H), 4.05 (t, 2H), 3.1 (t, 2H) MS m/z 428.1 (M + 1),N-[3-(2-Amino-5- oxo-7,8-dihydro- 5H-pyrido[4,3- d]pyrimidin-6-yl)-trifluoromethyl- benzamide 3 9

¹H NMR (300 MHz, CDCl₃) δ 12.5-12.2 (br. s, 1H), 11.9 (s, 1H), 8.16-8.12(br s, 1H), 8.1- 8.04 (m, 1H), 8.0-7.96 (br s, 1H), 7.86-7.8 (m, 1H),7.76- 7.72 (br s, 1H), 7.7-7.58 (m, 2H), 7.24-7.22 (br s, 1H), 7.16-7.1(m, 1H), 6.9-6.86 (m, 2H), 4.4-4.3 (t, 2H), 4.1 (s, 2H), 4.0-3.7 (m,2H), 3.55 (t, 2H), 3.3 (t, 2H), 3.2 (t, 2H), 3.1-2.9 (m, 2H), 2.3 (s,3H), 2.2-2.1 (m, 4H) MS m/z 617.2 (M + 1), N-(4-Methyl-3-{2-[4-(2-pyrrolidin-1- yl-ethoxy)- phenylamino]-7,8- dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-3- trifluoromethyl- benzamide 214

¹H NMR (300 MHz, CDCl₃) δ 8.22 (s, 1H), 8.13 (s, 1H), 8.06 (d, 1H),7.84-7.78 (m, 1H), 7.75-7.7 (br s, 1H), 7.68-7.6 (m, 3H), 7.34-7.27 (m,2H), 7.24-7.19 (m, 1H), 7.15-7.08 (m, 1H), 4.06 (s, 2H), 3.35- 3.26 (m,2H), 3.18-3.09 (m, 2H), 2.3 (s, 3H) MS m/z 538.1 (M + 1),N-{3-[2-(4-Chloro- phenylamino)-7,8- dihydro-5H- pyrido[4,3-d]pyrimidin-6-yl]-4- methyl-phenyl}-3- trilfuoromethyl- benzamide 15

¹H NMR (300 MHz, DMSO-D₆) δ 9.1-8.9 (m, 1H), 8.35-8.14 (m, 5H),7.76-7.66 (m, 4H), 7.56 (t, 1H), 7.46-7.37 (m, 1H), 7.32-7.26 (m, 1H),7.16-704 (m, 1H), 4.02 (s, 2H), 3.3- 3.2 (m, 2H), 3.05-2.96 (m, 2H),2.25 (s, 3H) MS m/z 505.0 (M + 1), N-{4-Methyl-3-[2- (pyridin-4-yl-amino)- 7,8-dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl]- phenyl}-3-trifluoromethyl- benzamide 2 16

¹H NMR (300 MHz, DMSO-D₆) δ 10.34 (s, 1H), 8.32-8.22 (m, 2H), 8.11 (s,1H), 7.98 (d, 1H), 7.8 (t, 1H), 7.5-7.4 (br s, 1H), 7.3-7.15 (m, 2H),6.85-6.76 (m, 1H), 6.41 (s, 2H), 4.21 (s, 2H), 3.58 (t, 2H), 2.75 (t,2H) MS m/z 414.1 (M + 1), N-[3-(2-Amino- 7,8-dihydro-5H- pyrido[4,3-d]pyrimidin-6-yl)- phenyl]-3- trilfuoromethyl- benzamide 1 17

¹H NMR (300 MHz, DMSO-D₆) δ 10.4 (s, 1H), 9.8 (s, 1H), 8.36 (s, 1H),8.32-8.24 (m, 2H), 8.0-7.76 (m, 1H), 7.9- 7.74 (m, 3H), 7.66-7.62 (m,1H), 7.52-7.44 (m, 1H), 7.38-7.3 (m, 2H), 7.24-7.18 (m, 1H), 4.05 (s,2H), 3.6- 3.49 (m, 2H), 3.3-3.1 (m, 2H), 3.0-2.9 (m, 2H), 2.75-2.7 (m,2H), 2.6- 2.55 (m, 2H), 2.45-2.4 (m, 2H), 2.3 (s, 3H), 1.9 (s, 3H) MSm/z 630.2 (M + 1), N-(4-Methyl-3-{2- [4-(4-methyl- piperazine-1-carbonyl)- phenylamino]-7,8- dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl}-phenyl)-3- trifluoromethyl- benzamide 2 18

¹H NMR (300 MHz, CD₃OD) δ 8.3-8.16 (m, 3H), 7.94-7.86 (m, 1H), 7.64-7.78(m, 2H), 7.48-7.2 (m, 4H), 6.84-6.92 (m, 1H), 4.1 (s, 2H), 3.4-3.3 (m,2H), 3.1-2.9 (m, 4H), 2.6 (t, 2H), 2.3 (s, 3H) MS m/z 573.1 (M + 1),N-{4-Methyl-3-[2- (2-oxo-1,2,3,4- tetrahydro- quinolin- 6-ylamino)-7,8-dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl]- phenyl}-3- trifluoromethyl-benzamide 2 19

¹H NMR (300 MHz, CDCl₃) δ 10.37 (s, 1H), 8.32-8.24 (m, 2H), 8.14 (s,1H), 7.98 (d, 1H), 7.8 (t, 1H), 7.48-7.42 (m, 1H), 7.3-7.18 (m, 2H),6.96 (t, 1H), 6.84-6.78 (m, 1H), 4.22 (s, 2H), 3.58 (t, 2H), 3.2 (q,2H), 2.76 (t, 2H), 1.5 (quin, 2H), 0.87 (t, 3H) MS m/z 456.1 (M + 1),N-[3-(2-Propyl- amino- 7,8-dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl)-phenyl]-3- trilfuoromethyl- benzamide 1 20

¹H NMR (300 MHz, CDCl₃) δ 8.62 (d, 2H), 8.42 (s, 1H), 8.19-8.04 (m, 3H),7.9-7.8 (m, 2H), 7.7-7.6 (m, 2H), 7.26- 7.14 (m, 2H), 6.92 (t, 1H), 4.14(s, 2H), 3.38-3.28 (t, 2H), 3.14-3.04 (m, 2H), 2.34 (s, 3H) MS m/z 506.1(M + 1), N-{4-Methyl-3- [2-(pyrimidin-2- ylamino)-7,8- dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl]- phenyl}-3- trilfuoromethyl- benzamide 221

¹H NMR (300 MHz, CDCl₃) δ 8.77 (s, 1H), 8.42 (d, 1H), 8.3- 8.24 (m, 1H),8.22 (s, 2H), 8.12 (d, 1H), 8.01 (s, 1H), 7.82-7.58 (m, 4H), 7.25-7.16(m, 2H), 6.94-6.86 (m, 1H), 4.06 (s, 2H), 3.32-3.26 (t, 2H), 3.8-3.0 (t,2H), 2.3 (s, 3H) MS m/z 505.0 (M + 1), N-{4-Methyl- 3-[2-(pyridin-2-ylamino)- 7,8-dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl]- phenyl}-3-trifluoromethyl- benzamide 2 22

¹H NMR (300 MHz, CD₃OD) δ 8.25 (s, 1H), 8.2 (d, 1H), 8.05 (s, 1H),7.91-7.86 (m, 1H), 7.76-7.68 (m, 1H), 7.6-7.55 (m, 1H), 7.35 (dd, 1H),7.24- 7.18 (m, 1H), 5.5 (s, 1H), 3.97 (s, 2H), 3.36-3.32 (m, 2H),3.28-3.24 (m, 2H), 2.9 (t, 2H), 2.32 (s, 3H), 1.62 (quin, 2H), 1.0-0.98(m, 3H) MS m/z 470.1 (M + 1), N-[4-Methyl-3-(2- propylamino-7,8-dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl)- phenyl]-3- trifluoromethyl-benzamide 1 23

¹H NMR (300 MHz, CDCl₃) δ 8.8-8.76 (m, 1H), 8.3-8.04 (m, 6H), 7.84-7.78(m, 1H), 7.68- 7.6 (m, 2H), 7.32-7.28 (m, 1H), 7.24-7.16 (m, 2H), 4.06(s, 2H), 3.3 (t, 2H), 3.04 (t, 2H), 2.33 (s, 3H) MS m/z 504.7 (M + 1),N-{4-Methyl- 3-[2-(pyridin- 3-ylamino)- 7,8-dihydro-5H- pyrido[4,3-d]pyrimidin-6-yl]- phenyl}-3- trifluoromethyl- benzamide 2 25

¹H NMR (300 MHz, CDCl₃) δ 8.25 (s, 1H), 8.21-8.12 (m, 3H), 8.08 (d, 1H),7.98-7.89 (m, 2H), 7.82 (d, 1H), 7.72-7.6 (m, 2H), 7.44 (dd, 1H),7.25-7.2 (m, 1H), 7.16-7.1 (m, 1H), 4.1 (s, 2H), 3.32 (t, 2H), 3.08 (t,2H), 2.32 (s, 3H) MS m/z 539.1 (M + 1), N-{3-[2-(2- Chloro-pyridin-4-ylamino)- 7,8-dihydro-5H- pyrido[4,3-d] pyrimidin-6-yl]-4-methyl-phenyl}-3- trifluoromethyl- benzamide 2 26

¹H NMR (300 MHz, CD₃OD) δ 9.14 (s, 1H), 8.6-8.5 (m, 2H), 8.48-8.39 (m,2H), 8.3-8.16 (m, 2H), 7.94-7.83 (m, 2H), 7.78-7.7 (t, 1H), 7.6-7.52 (m,1H), 7.42-7.34 (m, 1H), 4.3- 4.1 (m ,1H), 4.08-3.9 (m, 1H), 3.58-3.36(m, 2H), 2.3 (s, 3H) MS m/z 518.6 (M + 1), N-{4-Methyl-3-[5-oxo-2-(pyridin-4- ylamino)-7,8- dihydro-5H- pyrido[4,3-d]pyrimidin-6-yl]- phenyl}-3- trifluoromethyl- benzamide 4 27

¹H NMR (300 MHz, CDCl₃) δ 8.82-8.74 (br s, 2H), 8.54 (d, 2H), 8.32 (s,1H), 8.2-8.1 (m, 2H), 7.85-7.8 (m, 1H), 7.2-7.1 (m, 1H), 6.9-6.8 (m,1H), 4.1 (s, 2H), 3.3 (t, 2H), 3.1 (t, 2H), 2.3 (s, 3H), 2.25-2.15 (m,1H), 2.0-1.9 (m, 2H), 1.9-1.8 (m, 2H), 1.75-1.65 (m, 1H), 1.6- 1.49 (m,2H), 1.44-1.3 (m, 2H) MS m/z 442.9 (M + 1), Cyclohexane- carboxylic acid{4-methyl-3- [2-(pyridin-4- ylamino)-7,8- dihydro-5H- pyrido[4,3-d]pyrimidin-6-yl]- phenyl}-amide 2 29

¹H NMR (300 MHz, CDCl₃) δ 8.38 (d, 1H), 8.25 (s, 2H), 8.08 (d, 1H), 7.94(dd, 1H), 7.88 (s, 1H), 7.82 (d, 1H), 7.7-7.6 (m, 2H), 7.26-7.1 (m, 3H),6.76 (d, 1H), 4.05 (s, 2H), 3.93 (s, 3H), 3.28 (t, 2H), 3.02 (t, 2H),2.32 (s, 3H) MS m/z 535.2 (M + 1), N-{3-[2-(6- Methoxy- pyridin-3-ylamino)- 7,8-dihydro-5H- pyrido[4,3-d] pyrimidin-6-yl]-4-methyl-phenyl]-3- trifluoromethyl- benzamide 2 30

¹H NMR (300 MHz, CD3OD) δ 8.49 (s, 1H), 8.45-8.4 (m, 2H), 8.4-8.2 (br s,2H), 7.78- 7.82 (m, 2H), 7.69-7.46 (m, 3H), 7.33-7.19 (m, 2H), 4.16 (s,2H), 3.4-3.32 (m, 2H), 3.18-3.08 (m, 2H), 2.33 (s, 3H) MS m/z 471.0 (M +1), 3-Chloro-N-{4- methyl-3-[2-(pyri- din-4-ylamino)- 7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl]- phenyl}- benzamide 2 31

¹H NMR (300 MHz, CDCl₃) δ 8.2-8.12 (m, 2H), 8.06 (s, 1H), 7.88-7.78 (m,3H), 7.7-7.6 (m, 2H), 7.26-7.1 (m, 3H), 7.03- 6.96 (m, 2H), 4.06 (s,2H), 3.3 (t, 2H), 3.02 (t, 2H), 2.32 (s, 3H) MS m/z 584.1 (M + 1),N-{3-[2-(2,2- Difluoro- benzo[1,3]dioxol- 5-ylamino)- 7,8-dihydro-5H-pyrido [4,3-d] pyrimidin-6-yl]-4- methyl-phenyl}-3- trifluoromethyl-benzamide 2 32

¹H NMR (300 MHz, CD₃OD) δ 8.5 (s, 1H), 8.47-8.25 (m, 4H), 7.94-7.86 (m,1H), 7.72-7.6 (m, 3H), 7.3-7.2 (m, 2H), 4.17 (s, 2H), 3.36 (t, 2H), 3.14(t, 2H), 2.35 (s, 3H) MS m/z 523.1 (M + 1), 2-Fluoro-N-{4- methyl-3-[2-(pyridin- 4-ylamino)-7,8- dihydro-5H- pyrido[4,3- d ]pyrimidin-6-yl]-phenyl}-4- trifluoromethyl- benzamide 2 34

¹H NMR (300 MHz, CD₃OD) δ 8.53-8.19 (m, 5H), 7.8-7.6 (m, 3H), 7.45-7.15(m, 4H), 4.15 (s, 2H), 3.42-3.32 (m, 2H), 3.18-3.1 (m, 2H), 2.44 (s,3H), 2.34 (s, 3H) MS m/z 451.0 (M + 1) 3-Methyl-N-{4- methyl-3-[2-(pyridin- 4-ylamino)-7,8- dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl]-phenyl}- benzamide 2 36

¹H NMR (300 MHz, CDCl₃) δ 8.48-8.42 (m, 2H), 8.25 (s, 1H), 8.04-7.92 (m,3H), 7.81- 7.62 (m, 6H), 7.25-7.2 (m, 1H), 7.15-7.08 (m, 1H), 4.1 (s,2H), 3.32 (t, 2H), 3.08 (t, 2H), 2.33 (s, 3H) MS m/z 505.1 (M + 1),N-{4-Methyl-3-[2- (pyridin-4- ylamino)- 7,8-dihydro-5H- pyrido[4,3-d]pyrimidin-6-yl]- phenyl}-4- trilfuoromethyl- benzamide 2 37

¹H NMR (300 MHz, CDCl₃) δ 8.55 (s, 1H), 8.18 (s, 1H), 8.1 (d, 1H), 7.95(s, 1H), 7.76 (d, 1H), 7.64-7.52 (m, 2H), 7.26- 7.12 (m, 2H), 6.66-6.58(m, 1H), 3.75 (s, 2H), 3.3-3.4 (m, 2H), 3.22-3.08 (m, 5H), 2.86 (t, 2H),2.28 (s, 3H), 2.13-1.98 (m, 9H) MS m/z 539.2 (M + 1), N-{4-Methyl-3-[2-(3-pyrrolidin-1-yl- propylamino)-7,8- dihydro-5H- pyrido[4,3-d]pyrimidin-6-yl]- phenyl}-3- trilfuoromethyl- benzamide 1 38

¹H NMR (300 MHz, DMSO-D₆) δ 10.16 (s, 1H), 8.24 (s, 1H), 7.7-7.38 (m,7H), 7.2-7.1 (m, 2H), 6.95 (d, 2H), 3.97 (s, 2H), 3.83 (s, 3H), 3.4-3.1(m, 8H), 2.96-2.86 (m, 2H), 2.8 (s, 3H), 2.24 (s, 3H) MS m/z 564.2 (M +1), 3-Methoxy-N-(4- methyl-3-{2-[4-(4 methyl-piperazin-1-yl)-phenylamino]- 7,8-dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl}-phenyl)-benzamide 1 39

¹H NMR (300 MHz, CDCl₃) δ 11.76 (s, 1H), 8.3-8.18 (br s, 1H), 8.16-8.04(m, 3H), 7.82 (d, 1H), 7.73 (s, 1H), 7.7-7.56 (m, 3H), 7.24-7.18 (m,1H), 7.16-7.02 (m, 1H), 6.94 (d, 2H), 4.07 (s, 2H), 3.76-3.56 (m, 4H),3.4-3.02 (m, 8H), 2.92 (s, 3H), 2.29 (s, 3H) MS m/z 602.2 (M + 1),N-(4-Methyl-3- {2-[4-(4-methyl- piperazin-1- 1-yl)-phenyl- amino]-7,8-dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-3-trifluoromethyl- benzamide 1 40

¹H NMR (300 MHz, CD₃OD) δ 8.28-8.16 (m, 3H), 7.92-7.86 (m, 1H), 7.78-7.7(m, 1H), 7.61 (d, 1H), 7.35 (dd, 1H), 7.28-7.2 (m, 2H), 6.96 (dd, 1H),6.81-6.76 (m, 1H), 4.3- 4.2 (m, 4H), 4.05 (s, 2H), 3.3-3.26 (m, 2H),3.05-2.96 (m, 2H), 2.35 (s, 3H) MS m/z 562.2 (M + 1), N-{3-[2-(2,3-Dihydro- benzo[1,4] dioxin-6- ylamino)-7,8- dihydro-5H- pyrido[4,3-d]pyrimidin-6-yl]-4- methyl-phenyl}-3- trifluoromethyl- benzamide 2 41

¹H NMR (300 MHz, CD₃OD) δ 9.0-8.92 (m, 2H), 8.53 (s, 1H), 8.46 (d, 2H),8.4-8.3 (br s, 2H), 7.85 (d, 1H), 7.66 (s, 1H), 7.28-7.22 (m, 2H), 4.18(s, 2H), 3.39-3.37 (m, 2H), 3.2- 3.1 (m, 2H), 2.35 (s, 3H) MS m/z 506.1(M + 1), N-{4-Methyl-3-[2- (pyridin-4- ylamino)- 7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl]- phenyl}-4- trifluoromethyl- nicotinamide2 42

1H NMR (300 MHz, CDCl₃) δ 8.45 (d, 2H), 8.25 (s, 1H), 7.72-7.56 (m, 4H),7.4 (d, 1H), 7.32-7.28 (m, 1H), 7.22-7.18 (m, 1H), 7.06-7.0 (m, 1H),6.97 (d, 1H), 4.08 (s, 2H), 3.3 (t, 2H), 3.07 (t, 2H), 2.32 (s, 3H) MSm/z 477.0 (M + 1), 5-Chloro- thiophene- 2-carboxylic acid{4-methyl-3-[2- (pyridin- 4-ylamino)-7,8- dihydro-5H- pyrido[4,3-d]pyrimidin-6-yl]- phenyl}-amide 2 43

¹H NMR (300 MHz, CD₃OD) δ 8.3-8.16 (m, 3H), 7.93-7.86 (m, 1H), 7.82-7.7(m, 2H), 7.68-7.62 (m, 1H), 7.38-7.2 (m, 3H), 7.05 (m, 1H), 4.06 (s,2H), 3.67-3.48 (m, 4H), 3.2-2.9 (m, 8H), 2.34 (s, 3H) MS m/z 620.2 (M +1), N-(3-{2-[3-Fluoro- 4-(4-methyl- piperazin- 1-yl)-phenyl- amino]-7,8-dihydro-5H- pyrido[4,3-d] pyrimidin-6-yl}-4- methyl-phenyl)-3-trifluoromethyl- benzamide 1 44

¹H NMR (300 MHz, DMSO-D₆) δ 10.15 (s, 1H), 9.25 (s, 1H), 8.24 (s, 1H),7.9 (d, 2H), 7.68-7.55 (m, 3H), 7.5-7.4 (m, 3H), 7.15 (d, 1H), 6.88 (d,2H), 3.95 (s, 2H), 3.52 (s, 3H), 3.22-3.16 (m, 4H), 2.92-2.86 (s, 2H),2.45-2.32 (m, 9H), 2.26-2.20 (m, 6H), 2.14 (s, 3H), 1.86 (s, 10H) MS m/z646.2 (M + 1), N-(4-Methyl- 3-{2-[4-(4-methyl- piperazin-1-yl)-phenylamino]- 7,8-dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl}-phenyl)-4-(4- methyl-piperazin- 1-ylmethyl)- benzamide 1 45

¹H NMR (300 MHz, CD₃OD) δ 8.84 (s, 1H), 8.3-8.14 (m, 2H), 7.9 (d, 1H),7.83-7.61 (m, 4H), 7.61-7.52 (dd, 1H), 7.35 (d, 1H), 7.04 (d, 2H),4.18-3.98 (m, 2H), 3.95-3.25 (m, 3H), 3.7-3.55 (m, 2H), 3.28-3.01 (m,5H), 2.98 (s, 3H), 2.28 (s, 3H) MS m/z 616.2 (M + 1), N-(4-Methyl-3-{2-[4-(4- methyl-piperazin- 1-yl)-phenyl- amino]-5-oxo- 7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-3- trilfuoromethyl- benzamide3 46

¹H NMR (300 MHz, CDCl₃) δ 8.18 (s, 1H), 7.8-7.59 (m, 4H), 7.45-7.32 (m,2H), 7.25-6.9 (m, 5H), 4.08 (s, 2H), 3.35- 3.0 (m, 8H), 2.9-2.72 (br s,4H), 2.6 (s, 3H), 2.5 (s, 3H), 2.34 (s, 3H) MS m/z 634.2 (M + 1),N-(3-{2-[3-Fluoro- 4-(4-methyl- piperazin-1- yl)-phenylamino]-7,8-dihydro-5H- pyrido[4,3-d] pyrimidin-6-yl}-4- methyl-phenyl)-2-methyl-3- trifluoromethyl- benzamide 1 47

¹H NMR (300 MHz, CDCl₃) δ 8.15 (d, 2H), 7.95 (d, 1H), 7.81 (s, 1H),7.7-7.6 (m, 2H), 7.45 (d, 1H), 7.25-7.1 (m, 3H), 7.03-6.9 (m, 2H), 4.06(s, 2H), 3.5 (s, 1H), 3.3 (t, 2H), 3.35- 3.25 (m, 6H), 2.7-2.56 (m, 7H),2.38 (s, 3H), 2.33 (s, 3H) MS m/z 633.9 (M + 1), N-(3-{2-[3-Fluoro-4-(4- methyl-piperazin- 1-yl)-phenyl- amino]- 7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl}- 4-methyl-phenyl)-4- methyl-3-trifluoromethyl- benzamide 1 48

¹H NMR (300 MHz, DMSO-D₆) δ 10.6 (s, 1H), 10.32 (s, 1H), 9.9-9.7 (br s,1H), 8.35 (s, 1H), 8.3-8.2 (m, 1H), 8.04- 7.14 (m, 5H), 7.52-7.4 (m,2H), 7.2-7.06 (m, 2H), 4.04 (t, 2H), 3.58-3.45 (m, 4H), 3.28- 3.12 (m,4H), 3.05-2.96 (m, 2H), 2.88 (s, 3H) MS m/z 620.1 (M + 1), N-(3-{2-[3-Fluoro-4-(4- methyl-piperazin- 1-yl)-phenyl- amino]-5- oxo-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-3- trilfuoromethyl- benzamide3 49

¹H NMR (300 MHz, CD₃OD) δ 8.36-8.2 (m, 3H), 7.98-7.66 (m, 5H), 7.45-7.35(m, 2H), 7.28-7.12 (m, 2H), 4.12 (s, 4H), 3.54-3.46 (m, 4H), 3.41-3.36(m, 5H), 3.31-3.21 (m, 4H), 3.1-3.02 (m, 2H), 2.95 (s, 3H), 2.36 (s, 3H)MS m/z 616.2 (M + 1), N-(4-Methyl-3- {2-[3-(4-methyl- piperazin-1-ylmethyl)- phenylamino]-7,8- dihydro-5H- pyrido[4,3-d]pyrimidin-6-yl}- phenyl)-3- trifluoromethyl- benzamide 1 50

¹H NMR (300 MHz, CD₃OD) δ 8.9 (s, 1H), 8.3-8.2 (m, 2H), 8.0-7.9 (m, 2H),7.82-7.72 (m, 3H), 7.62-7.58 (m, 1H), 7.42-7.36 (m, 1H), 7.1-7.0 (m,1H), 4.1-3.9 (m, 4H), 3.2-3.0 (m, 4), 2.8-2.6 (m, 4H), 2.4 (s, 3H) MSm/z 653.9 (M + 1), N-(4-Chloro-3- {2-[3-fluoro-4- (4-methyl-piperazin-1-yl)- phenylamino]-5- oxo-7,8- dihydro-5H- pyrido[4,3-d]pyrimidin-6-yl}- phenyl)-3- trifluoromethyl- benzamide 3 51

¹H NMR (300 MHz, CD₃OD) δ 9.77 (s, 1H), 9.26 (s, 1H), 8.22 (s, 1H), 7.6(d, 2H), 7.46 (s, 1H), 7.3-7.04 (m, 2H), 6.49 (d, 2H), 3.92 (s, 2H),3.2-3.02 (m, 7H), 2.95-2.65 (m, 7H), 2.35- 2.12 (m, 6H), 1.91 (s, 2H),1.85-1.45 (m, 6H), 1.03-1.01 (m, 2H) MS m/z 540.3 (M + 1),2-Cyclopentyl- N-(4-methyl-3- {2-[4-(4-methyl- piperazin-1-yl)-phenylamino]- 7,8-dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl}-phenyl)-acetamide 1 52

¹H NMR (300 MHz, DMSO-D₆) δ 10.4 (s, 1H), 9.84 (s, 1H), 8.4-8.2 (m, 3H),8.02-7.7 (m, 6H), 7.63 (s, 1H), 7.52-7.44 (d, 1H), 7.25-7.16 (d, 1H),4.05 (s, 2H), 3.2-3.1 (m, 2H), 3.0 (s, 2H), 2.76 (s, 3H), 2.3 (s, 3H),1.88 (s, 1H) MS m/z 561.0 (M + 1), N-{3-[2-(4- (Methylamino- carbonyl)-phenylamino)-7,8- dihydro-5H- pyrido[4,3-d] pyrimidin-6-yl]-4-methyl-phenyl}-3- trifluoromethyl- benzamide 2 53

¹H NMR (300 MHz, DMSO-D₆) δ 10.2-9.6 (m, 2H), 9.35 (s, 1H), 8.4-8.2 (m,2H), 7.75-7.4 (m, 6H), 7.2-7.1 (m, 1H), 7.02- 6.9 (m, 3H), 4.3 (s, 4H),3.98 (s, 2H), 3.28-3.1 (m, 5H), 3.0-2.8 (m, 7H), 2.25 (s, 3H) MS m/z591.3 (M + 1), 2,3-Dihydro- benzo[1,4]dioxine- 6-carboxylic acid(4-methyl-3- {2-[4-(4-methyl- piperazin-1-yl)- phenylamino]-7,8-dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-amide 1 54

¹H NMR (300 MHz, CD₃OD) δ 8.85 (s, 1H), 8.37 (s, 1H), 8.1 (d, 1H),7.8-7.7 (m, 1H), 7.2- 7.54 (m, 4H), 7.38 (d, 1H), 7.04 (d, 1H),4.18-4.02 (m, 1H), 3.95-3.82 (m, 1H), 3.3- 3.2 (m, 4H), 3.2-3.1 (m, 2H),2.82-2.7 (m, 4H), 2.6 (s, 3H), 2.48 (s, 3H), 2.3 (s, 3H) MS m/z 630.1(M + 1), 4-Methyl-N-(4- methyl-3-{2-[4-(4- methyl-piperazin-1-yl)-phenyl- amino]- 5-oxo-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidin-6-yl}- phenyl)-3- trifluoromethyl- benzamide 3 55

¹H NMR (300 MHz, CD₃OD) δ 8.82 (s, 1H), 7.85-7.42 (m, 7H), 7.4-7.28 (m,1H), 7.02 (d, 2H), 4.1- 3.95 (m, 1H), 3.9-3.7 (m, 3H), 3.7-3.5 (m, 2H),3.3- 2.9 (m, 9H), 2.5 (s, 3H), 2.2 (s, 3H) MS m/z 630.2 (M + 1)2-Methyl-N-(4- methyl-3-{2-[4-(4- methyl- piperazin-1- yl)-phenylamino]-5-oxo-7,8-dihydro- 5H-pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-3-trifluoromethyl- benzamide 3 56

¹H NMR (300 MHz, CD₃OD) δ 8.35-8.12 (m, 3H), 7.96-7.83 (m, 1H),7.78-7.61 (m, 2H), 7.58-7.42 (m, 2H), 7.38-7.29 (m, 1H), 7.26-7.19 (m,1H), 7.14-7.04 (m, 1H), 4.07 (s, 2H), 3.6-3.55 (m, 2H), 3.4 (t, 2H),3.12-2.95 (m, 8H), 2.95 (s, 3H), 2.35 (s, 6H) MS m/z 616.2 (M + 1),N-(4-Methyl-3- {2-[3-methyl- 4-(4-methyl- piperazin-1-yl)-phenylamino]-7,8- dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-3-trifluoromethyl- benzamide 1 57

¹H NMR (300 MHz, CD₃OD )δ 8.3-8.15 (m, 3H), 7.9-7.8 (m, 1H), 7.75-7.65(t, 1H), 7.6 (s, 1H), 7.45 (s, 1H), 7.4-7.3 (m, 1H), 7.25-7.1 (m, 3H),6.7-6.55 (m, 1H), 4.1-4.05 (s, 2H), 3.35-3.2 (m, 6H), 3.05-2.95 (m, 2H),2.7-2.6 (m, 4H), 2.4 (s, 3H), 2.3 (s, 3H) MS m/z 601.9 (M + 1),N-(4-Methyl-3- {2-[3-(4-methyl- piperazin-1-yl)- phenylamino]-7,8-dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-3-trifluoromethyl- benzamide 1 58

¹H NMR (300 MHz, CD₃OD) δ 8.82 (s, 1H) 8.12-8.08 (t, 1H), 7.94- 7.86 (m,1H), 7.78-7.68 (m, 2H), 7.64-7.54 (m, 3H), 7.5-7.4 (m, 1H), 7.38-7.3 (m,1H), 7.04-6.94 (m, 2H), 4.15- 4.0 (m, 1H), 3.8-3.7 (m, 1H), 3.25-3.15(m, 4H), 3.05-2.95 (m, 2H), 2.75-2.65 (m, 4H), 2.25 (s, 3H), 2.15 (s,3H) MS m/z 625.8 (M + 1), 3-Bromo-N-(4- methyl- 3-{2-[4-(4-methyl-piperazin-1- yl)-phenylamino]- 5-oxo-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidin-6-yl}- phenyl)-benzamide 3 59

¹H NMR (300 MHz, DMSO-D₆) δ 10.43 (s, 1H), 9.28 (s, 1H), 8.36 (s, 1H),8.25 (s, 1H), 8.12-7.98 (m, 2H), 7.69-7.44 (m, 6H), 7.25-7.15 (d, 1H),6.86 (d, 2H), 4.12 (q, 1H), 4.0 (s, 2H), 3.25-3.15 (m, 5H), 3.1-3.02 (m,4H), 2.96-2.88 (m, 2H), 2.28 (s, 3H), 2.22 (s, 3H) MS m/z 590.2 (M + 1),Benzo[b] thiophene- 2-carboxylic acid (4-methyl-3- {2-[4-(4-methyl-piperazin-1- yl)-phenylamino]- 7,8-dihydro-5H- pyrido[4,3-d]pyrimidin-6-yl}- phenyl)-amide 1 60

¹H NMR (300 MHz, CDCl₃) δ 8.13 (s, 1H), 8.06-7.98 (br s, 1H), 7.92-7.78(m, 2H), 7.72- 7.48 (m, 4H), 7.44-7.32 (m, 2H), 7.24-7.06 (m ,3H), 7.0-6.9 (m, 2H), 4.02 (s, 2H), 3.36-3.16 (m, 6H), 3.06-2.95 (m, 3H),2.76-2.62 (m, 4H), 2.5-2.25 (d, 7H) MS m/z 612.1 (M + 1), 3-Bromo-N-(4-methyl-3-{2-[4-(4- methyl-piperazin- 1-yl)-phenyl- amino]-7,8-dihydro-5H- pyrido[4,3- d]pyrimidin-6- yl}-phenyl)- benzamide 1 61

¹H NMR (300 MHz, CDCl₃) δ 8.33 (d, 1H), 8.26-8.05 (m, 4H), 7.85-7.75 (m,1H), 7.7- 7.58 (m, 2H), 7.52-7.4 (m, 2H), 7.3-7.15 (m, 3H), 4.06 (s,2H), 3.4-3.22 (m, 2H), 3.14-2.98 (m, 2H), 2.52 (s, 3H), 2.32 (s, 3H) MSm/z 518.8 (M + 1), N-{4-Methyl-3-[2- (2-methyl-pyridin- 4-ylamino)-7,8-dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl]- phenyl}-3- trifluoromethyl-benzamide 2 62

¹H NMR (300 MHz, CD₃OD) δ 8.38 (m, 3H) , 7.94-7.62 (m, 5H), 7.42-7.3 (m,2H), 7.28- 7.2 (m, 1H), 7.14-7.05 (m, 1H), 4.05 (d, 4H), 3.2-3.0 (m,7H), 2.9 (s, 3H), 2.34 (s, 3H) MS m/z 616.2 (M + 1), N-(4-Methyl-3-{2-[4-(4-methyl- piperazin- 1-ylmethyl)- phenylamino]-7,8- dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-3- trifluoromethyl- benzamide 163

¹H NMR (300 MHz, DMSO-D₆) δ 10.2 (s, 1H), 8.4-8.18 (m, 4H), 8.04-7.74(m, 5H), 7.68- 7.42 (m, 2H), 7.26-7.16 (m, 1H), 6.7-6.6 (m ,1H), 6.54-6.44 (m, 1H), 3.98 (s, 3H), 3.82 (s, 5H), 3.22-3.1 (m, 8H), 2.94-2.84(m, 3H), 2.32-2.22 (m, 9H) MS m/z 632.0 (M + 1), N-(3-{2-[2- Methoxy-4-(4-methyl- piperazin-1-yl)- phenylamino]-7,8- dihydro-5H-pyrido[4,3-d] pyrimidin-6-yl}-4- methyl-phenyl)-3- trifluoromethyl-benzamide 1 64

¹H NMR (300 MHz, CD₃OD) δ 8.76 (s, 1H), 8.23-8.06 (m, 3H), 7.84- 7.59(m, 3H), 7.56-7.41 (m, 3H), 7.3-7.2 (m, 1H), 6.98 (d, 1H), 4.04-3.92 (m,1H), 3.8-3.7 (m, 1H), 3.11- 2.94 (m, 9H), 2.64 (s, 3H), 2.26 (s, 3H),2.18 (s, 3H) MS m/z 629.8 (M + 1), N-(4-Methyl-3- {2-[3-methyl-4-(4-methyl- piperazin-1-yl)- phenylamino]-5- oxo-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-3- trifluoromethyl- benzamide3 65

¹H NMR (300 MHz, DMSO-D₆) δ 10.15- 10.0 (d, 2H), 8.75 (s, 1H), 7.7-7.55(m, 3H), 7.5- 7.4 (m, 1H), 7.25-7.15 (m, 1H), 7.05-6.95 (d, 2H), 4.0-3.9(m, 1H), 3.75-3.65 (m, 1H), 3.2- 3.1 (m, 4H), 3.3-3.1 (m, 4H), 3.1-2.95(m, 2H), 2.75-2.65 (m, 4H), 2.3-2.2 (m, 2H), 2.1 (s, 3H), 1.8-1.4 (m,9H), 1.3- 1.1 (m, 4H) MS m/z 554.2 (M + 1), 2-Cyclopentyl- N-(4-methyl-3-{2-[4-(4- methyl- piperazin-1-yl)- phenylamino]-5- oxo-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-acetamide 3 66

¹H NMR (300 MHz, DMSO-D₆) δ 10.32 (s, 1H), 9.28 (s, 1H), 8.3-8.2 (m,2H), 8.0-7.78 (m, 2H), 7.65-7.4 (m, 4H), 7.18 (d, 1H), 6.88 (d, 2H),3.98 (s, 2H), 3.24-3.18 (m, 2H), 3.14-3.06 (m, 4H), 2.94-2.86 (m, 3H),2.38-2.22 (m, 8H) MS m/z 602.1 (M + 1), 3,4-Dichloro- N-(4-methyl-3-{2-[4-(4-methyl- piperazin-1-yl)- phenylamino]- 7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-benzamide 1 67

¹H NMR (300 MHz, DMSO-D₆) δ 10.46 (s, 1H), 9.9 (s, 1H), 8.5-8.2 (m, 3H),8.05-7.7 (m, 5H), 7.68-7.42 (m, 2H), 7.25- 7.15 (d, 1H), 4.05-4.0 (br s,2H), 3.35-3.15 (m, 4H), 3.05-2.95 (br s, 2H), 2.28 (s, 2H), 2.0-1.6 (m,13H) MS m/z 658.2 (M + 1), N-{3-[2-(4-(3- Pyrrolidin-1-yl- propylamino-carbonyl)- phenylamino)- 7,8-dihydro-5H- pyrido[4,3-d]pyrimidin-6-yl]-4- methyl-phenyl}-3- trifluoromethyl- benzamide 2 68

1H NMR (300 MHz, CD₃OD) δ 8.2-8.05 (m, 2H), 7.66-7.49 (m, 3H), 7.4-6.8(m, 6H), 4.4-4.2 (m, 2H), 3.98 (s, 2H), 3.7- 3.6 (m, 2H), 3.35-3.15 (m,6H), 3.05-2.85 (m, 2H), 2.32 (s, 3H), 2.2-1.9 (m, 12H) MS m/z 619.2(M + 1) N-(4-Methyl-3- {2-[4- (2-pyrrolidin-1-yl- ethoxy)-phenylamino]-7,8- dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-2-pyrrolidin-1-yl- isonicotinamide 2 69

¹H NMR (300 MHz, DMSO-D₆) δ 10.5 (d, 2H), 8.4-8.2 (m, 3H), 8.0-7.6 (m,9H), 7.4-7.2 (d, 1H), 4.1-3.9 (m, 1H), 3.9- 3.7 (m, 1H), 3.2-3.1 (m,1H), 2.8-2.7 (m, 4H), 2.2-2.1 (s, 3H) MS m/z 575.1 (M + 1),N-[4-Methyl-3-(5- oxo-2-(4-Methyl- aminocarbonyl)- phenylamino-7,8-dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl)- phenyl]-3- trilfuoromethyl-benzamide 4 70

¹H NMR (300 MHz, CDCl₃) δ 9.2-8.8 (d, 2H), 8.3-7.9 (m, 2H), 7.9-7.3 (m,7H), 7.2-6.8 (m, 3H), 4.1-3.8 (t, 2H), 3.4- 3.2 (m, 4H), 3.2-3.0 (t,2H), 2.9-2.6 (m, 4H), 2.4 (s, 3H) MS m/z 620.1 (M + 1), N-(4-Fluoro-3-{2-[4-(4- methyl-piperazin- 1-yl)-phenyl- amino]-5-oxo- 7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-3- trilfuoromethyl- benzamide3 71

¹H NMR (300 MHz, CD₃OD) δ 8.1 (s, 1H), 7.6-7.36 (m, 4H), 7.3-7.03 (m,4H), 7.02-6.92 (d, 2H), 4.0 (s, 2H), 3.7 (s, 2H), 3.3-3.2 (m, 2H),3.2-3.1 (m, 4H), 3.0-2.9 (m, 2H), 2.8-2.6 (m, 4H), 2.4 (s, 3H), 2.3 (s,3H) MS m/z 554.2 (M + 1), N-(4-Methyl-3- {2-[4-(4- methyl-piperazin-1-yl)-phenyl- amino]- 7,8-dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl}-phenyl)-2- thiophen- 3-yl-acetamide 1 72

¹H NMR (300 MHz, CD₃OD) δ 8.82 (s, 1H), 8.15-8.04 (m, 1H), 7.96-7.48 (m,7H), 7.4- 7.3 (m ,1H), 7.0 (d, 2H), 4.15-3.96 (m, 1H), 3.94-3.8 (m, 1H),3.26-3.1 (m, 6H), 2.8-2.6 (m, 4H), 2.4 (s, 3H), 2.25 (s, 3H), 1.8 (s,6H) MS m/z 615.3 (M + 1), 3-(Cyano-dimethyl- methyl)-N-(4-methyl-3-{2-[4-(4- methyl-piperazin- 1-yl)-phenyl- amino]-5-oxo-7,8-dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-benzamide 3 73

¹H NMR (300 MHz, CDCl₃) δ 9.62 (s, 1H), 8.18 (s, 1H), 7.6 (d, 2H), 7.44(s, 1H), 7.12 (s, 2H), 6.9 (d, 3H), 6.09 (s, 1H), 3.99 (s, 2H),3.78-3.52 (m, 4H), 3.38-3.02 (m, 8H), 2.86 (s, 4H), 2.42 (d, 7H), 2.22(s, 3H) MS m/z 566.1 (M + 1), 2-(3,5-Dimethyl- pyrazol-1-yl)-N-(4-methyl-3-{2-[4-(4- methyl-piperazin-1- yl)-phenylamino]- 7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-acetamide 1 75

¹H NMR (300 MHz, CD3OD) δ 8.9 (s, 1H), 8.25-8.4 (m, 2H), 7.82-7.9 (m,3H), 7.6-7.8 (m, 3H), 7.25-7.35 (dd, 3H), 4.05-4.15 (m, 2H), 3.6-3.92(m, 6H), 2.5 (m, 4H), 2.2- 2.4 (m, 6H) MS m/z 644.1 (M + 1),N-(4-Methyl-3-{2- [4-(4-methyl- piperazine-1- carbonyl)-phenyl-amino]-5-oxo- 7,8-dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-3-trifluoromethyl- benzamide 4 76

¹H NMR (300 MHz, CDCl₃) δ 9.1 (d, 2H), 8.1-8.3 (m, 2H), 7.5-7.9 (m, 5H),7.0-7.5 (m, 5H), 3.3-4.2 (m, 6H), 3.0-3.3 (d, 2H), 2.1-2.45 (m, 7H),1.7-1.8 (s, 4H), MS m/z 658.0 (M + 1), N-[4-Methyl-3-(2-{4-[2-(4-methyl- piperazin-1-yl)-2- oxo-ethyl]-phenyl- amino}-5-oxo-7,8-dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl)- phenyl]-3-trilfuoromethyl- benzamide 4 77

MS m/z 672.1 (M + 1), 1H NMR (300 MHz, CD₃OD) δ 8.92 (s, 1H), 8.36-8.12(m, 2H), 8.05- 7.66 (m, 9H), 7.66-7.50 (m, 1H), 7.45-7.22 (m, 1H), 4.1-4.0 (m, 3H), 3.6-3.4 (br s, 3H), 2.4-2.2 (s, 4H), 2.2-1.8 (m, 11H)N-(4-methyl-3-(5- oxo-2-(4-(3- (pyrrolidin-1-yl) propylcarbamoyl)phenylamino)-7,8- dihydropyrido[4,3- d]pyrimidin-6(5H)- yl)phenyl)-3-(trifluoromethyl) benzamide 4 78

1H NMR (300 MHz, CD₃OD) δ 9.02-8.70 (br s, 1H), 8.26-8.02 (m, 1H),8.02-7.18 (m, 8H), 7.18-6.80 (m, 2H), 4.4-4.2 (br s, 2H), 4.1-4.0 (br s,2H), 3.62-3.42 (br s, 3H), 2.25 (s, 3H), 2.1-1.9 (m, 9H) MS m/z 642.9(M + 2) 3-Bromo-N-(4- methyl-3-{5-oxo- 2-[4-(2-pyrrolidin- 1-yl-ethoxy)-phenylamino]-7,8- dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl}-phenyl)-benzamide 3 79

1H NMR (300 MHz, CD₃OD) δ 8.95-8.65 (br s, 1H), 8.2-7.9 (m, 2H), 7.8-7.5(m, 5H), 7.45- 7.25 (d, 1H), 7.15-6.90 (d, 2H), 4.2-3.8 (m, 2H), 3.3-3.1(m, 6H), 2.75-2.6 (m, 4H), 2.4 (s, 3H), 2.2 (s, 3H) MS m/z 634.1 (M + 1)3-Fluoro-N-(4- methyl-3-{2-[4-(4- methyl-piperazin- 1-yl)-phenyl-amino]- 5-oxo-7,8-dihydro- 5H-pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-5-trifluoromethyl- benzamide 3 80

1H NMR (300 MHz, CDCl₃) δ 9.28 (s, 1H), 9.0 (s, 1H), 8.25 (s, 1H),8.15-7.95 (m 1H), 7.65-7.45 (m, 4H), 7.45-7.36 (m, 2H), 7.1-6.9 (m, 3H),4.00- 3.82 (m, 1H), 3.82-3.65 (m, 1H), 3.4-3.0 (m, 6H), 2.7-2.5 (m, 4H),2.36 (s, 3H), 1.76 (s, 3H) MS m/z 650.1 (M + 1) 4-Chloro-N-(4-methyl-3-{2-[4-(4- methyl-piperazin- 1-yl)-phenyl- amino]-5-oxo-7,8-dihydro- 5H-pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-3-trifluoromethyl- benzamide 3 81

1H NMR (300 MHz, CDCl₃) δ 9.30-8.82 (m, 2H), 8.2 (s, 1H), 8.10- 7.88 (m,1H), 7.7-7.3 (m, 6H), 7.08-6.74 (m, 3H), 4.25- 3.99 (m, 2H), 3.99-3.52(m, 2H), 3.3-2.8 (m, 4H), 2.80- 2.2 (br s, 3H), 1.85-1.7 (m, 8H) MS m/z664.9 (M + 1) 4-Chloro-N-(4- methyl-3-{5-oxo- 2-[4-(2-pyrrolidin-1-yl-ethoxy)- phenylamino]-7,8- dihydro-5H- pyrido[4,3-d]pyrimidin-6-yl}- phenyl)-3- trifluoromethyl- benzamide 3 82

1H NMR (300 MHz, CDCl₃) δ 8.85 (s, 1H), 8.6-8.4 (m, 1H), 8.0 (s, 1H),7.78-7.48 (m, 4H), 7.38-7.18 (m, 4H), 7.18-6.88 (m, 2H), 4.08-3.90 (m,1H), 3.86-3.70 (m, 1H), 3.35-3.05 (m, 6H), 2.72-2.52 (m, 4H), 2.36 (s,3H), 2.12 (s, 3H) MS m/z 650.1 (M + 1) 2-Chloro-N-(4- methyl-3-{2-[4-(4-methyl-piperazin- 1-yl)-phenyl- amino]- 5-oxo-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-5- trifluoromethyl- benzamide3 83

1H NMR (300 MHz, CDCl₃) δ 8.72 (s, 1H), 8.48-8.32 (m, 1H), 8.3-8.02 (m,3H), 8.0-7.54 (m, 5H), 7.4-7.05 (s, 4H), 4.1 (s, 2H), 3.43-3.21 (m, 2H),3.18-2.95 (m, 5H), 2.32 (s, 3H) MS m/z 562.1 (M + 1) 5-{6-[2-Methyl-5-(3-trifluoromethyl- benozylamino)- phenyl]-5,6,7,8- tetrahydro-pyrido[4,3- d]pyrimidin-2- ylamino}-pyridine- 2-carboxylic acidmethylamide 2 84

1H NMR (300 MHz, CDCl₃) δ 9.0 (s, 1H), 8.49 (s, 1H), 7.68 (s, 1H), 7.53(d, 2H), 7.45- 7.09 (m, 5H), 6.96 (d, 2H), 6.82 (s, 1H), 4.1-3.82 (m,1H), 3.82-3.68 (m, 1H), 3.42-3.0 (m, 8H), 2.6 (s, 3H), 2.35 (s, 3H),2.12 (s, 3H), 2.1-1.89 (m, 7H) MS m/z 685.2 (M + 1) N-(4-Methyl-3-{2-[4-(4-methyl- piperazin-1-yl)- phenylamino]- 5-oxo-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-3- pyrrolidin-1-yl-5-trifluoromethyl- benzamide 3 85

1H NMR (300 MHz, DMSO) δ 10.59 (s, 1H), 9.99 (s, 1H), 8.79 (s, 1H), 8.48(s, 1H), 8.25 (d, 2H), 7.79-7.51 (m, 4H), 7.3 (d, 1H), 6.9 (d, 2H), 4.1-3.9 (s, 2H), 3.8-3.6 (m, 2H), 3.2-2.9 (m, 8H), 2.24-2.0 (m, 6H) MS m/z693.9 (M + 1) 3-Bromo-N-(4- methyl-3-{2-[4-(4- methyl- piperazin-1-yl)-phenylamino]- 5-oxo-7,8-dihydro- 5H-pyrido[4,3- d]pyrimidin-6-yl}-phenyl)-5- trifluoromethyl- benzamide 3 86

1H NMR (300 MHz, DMSO-D₆) δ 10.21 (s, 1H), 9.9 (s, 1H), 8.76 (s, 1H),7.94 (s, 1H), 7.9-7.1 (m, 8H), 7.1-6.76 (m, 2H), 4.82-4.12 (m, 2H),4.05-3.6 (m, 2H), 3.2-2.9 (s, 6H), 2.2 (d, 8H), 1.7-1.1 (s, 9H) MS m/z604.2 (M + 1) tert-Butyl-N-(4- methyl-3-{2-[4-(4- methyl- piperazin-1-yl)-phenylamino]- 5-oxo-7,8-dihydro- 5H-pyrido[4,3- d]pyrimidin-6-yl}-phenyl)-benzamide 3 87

1H NMR (300 MHz, CDCl₃) δ 10.00- 9.65 (br s, 1H), 9.25-8.85 (br s, 1H),8.7-8.3 (br s, 2H), 8.1-7.8 (br s, 1H), 7.7-7.3 (m, 5H), 7.15-6.85 (m,3H), 4.0-3.4 (m, 2H), 3.4-3.0 (m, 6H), 2.8-2.6 (m, 4H), 2.4 (s, 3H), 1.5(s, 3H) MS m/z 684.1 (M + 1) N-(4-Methyl-3-{2- [4-(4-methyl-piperazin-1-yl)- phenylamino]- 5-oxo-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidin-6-yl}- phenyl)-3,5-bis- trifluoromethyl- benzamide 3 88

1H NMR (300 MHz, CDCl₃) δ 8.99 (s, 1H), 8.28 (s, 1H), 7.8-6.8 (m, 10H),6.6 (s, 1H), 4.08- 3.90 (m, 1H), 3.9-3.6 (m, 7H), 3.35-3.05 (m, 6H),2.92-2.75 (m, 4H), 2.36 (s, 3H), 2.17 (s, 3H) MS m/z 608.2 (M + 1),3,5-Dimethoxy-N- (4-methyl-3-{2-[4- (4-methyl- piperazin-1-yl)-phenylamino]- 5-oxo-7,8-dihydro- 5H-pyrido[4,3- d]pyrimidin-6-yl}-phenyl)-benzamide 3 89

1H NMR (300 MHz, DMSO) δ 8.75 (s, 1H), 8.49-8.2 (m, 1H), 8.19-7.82 (m,1H), 7.81-7.4 (m, 5H), 7.4-7.19 (m, 1H), 7.1-6.8 (m, 2H), 4.08-3.90 (m,1H), 3.86-3.70 (m, 1H), 3.35-3.05 (m, 6H), 2.92-2.75 (m, 4H), 2.36 (s,3H), 2.17 (s, 3H) MS m/z 646.0 (M + 3) 3-Bromo-4-fluoro- N-(4-methyl-3-{2-[4-(4- methyl-piperazin- 1-yl)-phenyl- amino]- 5-oxo-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-benzamide 3 90

1H NMR (300 MHz, CDCl₃) δ 8.30- 7.05 (m, 9H), 5.0 (s, 1H), 4.0 (s, 2H),3.4-3.15 (m, 2H), 3.15-2.80 (m, 5H), 2.3 (s, 3H) MS m/z 442.4 (M + 1)N-[4-Methyl-3-(2- methylamino-7,8- dihydro-5H- pyrido[4,3-d]pyrimidin-6-yl)- phenyl]-3- trifluoromethyl- benzamide 1 91

1H NMR (300 MHz, CD₃OD) δ 8.56 (s, 2H), 8.4-7.94 (m, 2H), 7.6 (s, 1H),7.5-7.04 (m, 2H), 4.0 (s, 2H), 3.3-3.2 (m, 2H), 2.92 (s, 5H), 2.32 (s,3H) MS m/z 510.0 (M + 1) N-[4-Methyl-3-(2- methylamino-7,8- dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl)- phenyl]-3,5-bis- trifluoromethyl-benzamide 1 92

1H NMR (300 MHz, CD₃OD) δ 8.4-7.56 (m, 10H), 7.4-7.1 (m, 2H), 4.0 (s,2H), 3.1-3.0 (m, 2H), 2.8-2.5 (m, 5H), 2.3 (s, 3H), 2.2-2.0 (m, 3H),1.9-1.6 (m, 2H), 1.5-1.1 (m, 4H) MS m/z 644.0 (M + 1) 3-(2-Amino-7,8-dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl)- 4-methyl-N- phenyl- benzamide2 93

1H NMR (300 MHz, DMSO) δ 10.5 (s, 1H), 9.98 (s, 1H), 8.75 (s, 1H),8.5-8.25 (m, 2H), 7.8- 7.5 (m, 5H), 7.32 (d, 1H), 6.9 (d, 2H), 4.10-3.82(m, 1H), 3.8-3.6 (m, 1H), 3.15-2.98 (m, 6H), 2.4-2.5 (m, 4H), 2.35 (s,3H), 2.2 (s, 3H) MS m/z 634.0 (M + 1) 4-Fluoro-N-(4- methyl-3-{2-[4-(4-methyl-piperazin-1- yl)-phenylamino]- 5-oxo-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidin-6-yl}- phenyl)-3- trifluoromethyl- benzamide 3 94

1H NMR (300 MHz, CDCl₃) δ 9.12 (s, 2H), 8.88 (s, 1H), 8.30-8.02 (m, 2H),7.97-7.55 (m, 4H), 7.33-7.00 (m, 4H), 4.09 (s, 2H), 3.3 (t, 2H), 3.02(t, 2H), 2.31 (s, 3H) MS m/z 506.1 (M + 1) N-{4-Methyl-3-[2-(pyrimidin-5- ylamino)-7,8- dihydro-5H- pyrido-5H- pyrido[4,3-d]pyrimidin-6-yl]- phenyl}-3- trifluoromethyl- benzamide 2 95

1H NMR (300 MHz, CD₃OD) δ 8.8 (s, 1H), 8.05-7.4 (m, 6H), 7.3 (d, 1H),6.95 (d, 2H), 4.12-3.7 (m, 2H), 3.4-3.0 (m, 6H), 2.8-2.5 (m, 4H), 2.4(s, 3H), 2.25 (s, 3H) MS m/z 622.1 (M + 1) 5-Trifluoromethyl-thiophene-2- carboxylic acid (4- methyl-3-{2-[4-(4- methyl-piperazin-1-yl)-phenylamino]- 5-oxo-7,8-dihydro- 5H-pyrido[4,3- d]pyrimidin-6-yl}-phenyl)-amide 3 96

1H NMR (300 MHz, CDCl₃) δ 11.4 (s, 1H), 8.15 (s, 1H), 7.8- 7.5 (m, 3H),7.45-6.70 (m, 4H), 4.32 (s, 2H), 4.18-3.80 (m, 4H), 3.72-2.90 (m, 9H),2.49-2.00 (m, 8H), 1.4-1.0 (m, 9H) MS m/z 543.2 (M + 1) 3,3-Dimethyl-N-(4-methyl- 3-{2-[4-(2- pyrrolidin-1-yl- ethoxy)- phenylamino]-7,8-dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl}- phenyl)- butyramide 1 97

1H NMR (300 MHz, CD₃OD) δ 8.54 (s, 2H), 8.3-7.96 (m, 2H), 7.6 (s, 1H),7.6-7.16 (m, 2H), 3.98 (s, 2H), 3.2-3.1 (t, 2H), 2.9 (t, 2H), 2.3 (s,3H) MS m/z 496.0 (M + 1) N-[3-(2-Amino- 7,8-dihydro-5H- pyrido[4,3-d]pyrimidin-6-yl)-4- methyl-phenyl]- 3,5-bis- trifluoromethyl- benzamide 198

1H NMR (300 MHz, CD₃OD) δ 8.4-8.08 (m, 3H), 8.0-7.66 (m, 6H), 7.5-7.06(m, 3H), 4.03 (s, 2H), 3.7 (t, 2H), 3.5 (t, 2H), 3.3-3.2 (t, 2H),3.12-2.9 (m, 2H), 2.32 (s, 3H) MS m/z 591.1 (M + 1), N-(2-Aminol-3-{2-[4-(hydroxyphenyl amino]-5-oxo-7,8- dihydro-5H- pyrido[4,3-d]pyrimidin-6-yl}- phenyl)-3- trifluoromethyl- benzamide 2 99

1H NMR (300 MHz, CDCl₃) δ 8.5 (s, 1H), 8.4-7.00 (m, 13H), 3.9 (s, 2H),3.7-3.4 (br s, 4H), 3.4-2.9 (m, 4H), 2.3 (s, 3H), 2.0-1.8 (br s, 4H) MSm/z 601.1 (M + 1) N-(4-Methyl-3-{2- [4-pyrrolidine-1- carbonyl)-phenylamino]-7,8- dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-3-trilfuoromethyl- benzamide 2 100

1H NMR (300 MHz, CDCl₃) δ 8.08 (s, 1H), 7.96 (s, 1H), 7.86-7.56 (m, 4H),7.48-7.38 (m, 1H), 7.24-7.06 (m, 2H), 5.0 (s, 1H), 4.0 (s, 2H), 3.35-3.30 (m, 2H), 3.1-2.9 (m, 5H), 2.3 (s, 3H), 1.4 (s, 9H) MS m/z 430.1(M + 1) 3-tert-Butyl-N-[4- methyl-3-(2- methylamino-7,8- dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl)- phenyl]-benzamide 1 101

1H NMR (300 MHz, CDCl₃) δ 9.0 (s, 1H), 8.55 (s, 1H), 8.1 (s, 1H), 7.82(d, 1H), 7.69 (s, 1H), 7.62-7.40 (m, 6H), 7.12 (d, 1H), 6.94 (d, 2H),4.05-3.9 (m, 1H), 3.80-3.69 (m, 1H), 3.3-3.0 (m, 6H), 2.75-2.55 (m, 4H),2.4 (s, 3H), 2.25 (s, 3H), 2.0 (s, 3H) MS m/z 602.2 (M + 1) 3-Methyl-benzofuran-5- carboxylic acid (4- methyl-3-{2-[4-(4- methyl-piperazin-1-yl)-phenylamino]-5- oxo-7,8-dihydro- 5H-pyrido[4,3- d]pyrimidin-6-yl}-phenyl)-amide 3 102

1H NMR (300 MHz, CDCl₃) δ 8.95 (s, 1H), 8.28 (s, 1H), 7.72-7.44 (m, 4H),7.38-7.10 (m, 3H), 7.09-6.90 (m, 4H), 6.7-6.6 (m, 1H), 4.05-3.84 (m,1H), 3.80-3.62 (m, 1H), 3.36- 3.28 (m, 9H), 3.15-2.96 (m, 2H), 2.78-2.56(m, 4H), 2.36 (s, 3H), 2.13 (s, 3H), 2.05- 1.95 (m, 3H) MS m/z 617.2(M + 1) N-(4-Methyl-3-{2- [4-(4-methyl- piperazin-1-yl)- phenylamino]-5-oxo-7,8-dihydro- 5H-pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-3-pyrrolidin- 1-yl-benzamide 3 103

1H NMR (300 MHz, CDCl₃) δ 8.34-7.84 (m, 3H), 7.54-7.40 (m, 2H),7.39-7.04 (m, 3H), 5.2-4.9 (br s, 1H), 4.10-3.82 (s, 2H), 3.22-3.10 (m,2H), 3.09-2.80 (m, 5H), 2.47-2.12 (s, 3H) MS m/z 476.0 (M + 1)4-Chloro-N-[4- methyl-3-(2- methylamino-7,8- dihydro-5H- pyrido[4,3-d]pyrimidin-6-yl}- phenyl]-3- trifluoromethyl- benzamide 1 104

1H NMR (300 MHz, CDCl₃) δ 8.99 (s, 1H), 8.12-6.82 (m, 15H), 4.12-3.66(m, 2H), 3.42- 3.00 (m, 6H), 2.75-2.48 (m, 4H), 2.35 (s, 3H), 2.2 (s,3H) MS m/z 571.2 (M + 1) 6-[5-(Isoquinolin- 1-ylamino)- 2-methyl-phenyl]-2-[4-(4- methyl-piperazin- 1-yl)-phenyl- amino]- 7,8-dihydro-6H-pyrido[4,3- d]pyrimidin-5-one 11 105

1H NMR (300 MHz, CDCl₃) δ 9.0 (s, 1H), 8.1 (s, 1H), 7.6-7.4 (m, 3H),7.15-7.05 (d, 1H), 7.0-6.85 (m, 5H), 4.20-4.05 (m, 2H), 4.0 (s, 2H), 3.8(s, 2H), 3.30-3.15 (m, 2H), 3.00-2.85 (m, 4H), 2.75 (s, 3H), 2.72-2.60(br s, 4H), 2.25 (s, 3H), 1.85-1.75 (br s, 4H) MS m/z 584.1 (M + 1)N-(4-Methyl-3-{2- [4-(2-pyrrolidin-1- yl-ethoxy)- phenylamino]-7,8-dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-2-(2- methyl-thiazol-4-yl)-acetamide 1 106

1H NMR (300 MHz, CDCl₃) δ 8.12 (s, 1H), 7.8 (s, 1H), 7.60-7.42 (m, 5H),7.2 (d, 1H), 7.1 (d, 1H), 6.96-6.84 (m, 3H), 4.15-3.95 (m ,4H), 3.26 (t,2H), 3.05-2.85 (m, 4H), 2.7- 2.6 (m, 4H), 2.3 (s, 3H), 2.0- 1.65 (m, 4H)MS m/z 622.8 (M + 1) 5-Trifluoromethyl- thiophene-2- carboxylic acid (4-methyl-3-{2-[4-(2- pyrrolidin-1-yl- ethoxy)- phenylamino]-7,8-dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-amide 1 107

1H NMR (300 MHz, CDCl₃) δ 8.11 (s, 1H), 7.60-7.32 (m, 3H), 7.28-7.02 (m,1H), 7.00- 6.72 (m, 4H), 6.31 (s, 1H), 4.28-3.85 (m, 4H), 3.56-2.82 (m,10H), 2.75-2.50 (m, 4H), 2.26 (s, 3H), 1.90-1.75 (m, 4H), 1.7-1.6 (m,4H), 1.25 (s, 2H) MS m/z 556.2 (M + 1) Piperidine-1- carboxylic acid (4-methyl-3-{2-[4-(2- pyrrolidin-1-yl- ethoxy)- phenylamino]-7,8-dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-amide 1 108

1H NMR (300 MHz, CD₃OD) δ 8.1 (s, 1H), 7.6-7.4 (m, 3H), 7.25-7.05 (m,2H), 6.95-6.80 (d, 2H), 4.2-4.1 (t, 2H), 3.95 (s, 2H), 3.3-3.2 (t, 2H),3.05- 2.85 (m, 5H), 2.85-2.65 (m, 4H), 2.4-2.2 (m, 6H), 1.95- 1.50 (m,11H) MS m/z 555.2 (M + 1) 2-Cyclopentyl-N- (4- methyl-3-{2-[4-(2-pyrrolidin-1-yl- ethoxy)- phenylamino]-7,8- dihydro-5H- pyrido[4,3-d]pyrimidin-6-yl}- phenyl)-acetamide 1 109

1H NMR (300 MHz, CDCl₃) δ 8.45 (s, 1H), 7.84 (s, 1H), 7.63 (s, 1H),7.42-7.02 (m, 4H), 6.85 (s, 1H), 5.1-4.83 (br s, 1H), 4.0 (s, 2H),3.59-3.16 (m, 4H), 3.15-2.82 (m, 3H), 2.3 (s, 3H), 2.23-2.12 (m, 4H),2.11-1.98 (m, 4H) MS m/z 510.9 (M + 1) N-[4-Methyl-3-(2-methylamino-7,8- dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl)- phenyl]-3-pyrrolidin-1-yl-5- trifluoromethyl- benzamide 1 110

1H NMR (300 MHz, CDCl₃) δ 9.21 (s, 1H), 8.12 (s, 1H), 7.68-7.44 (m, 2H),7.21-7.10 (m, 1H), 7.08-6.82 (m, 4H), 4.23- 4.08 (t, 2H), 4.0 (s, 2H),3.3 (t, 2H), 3.1 (s, 2H), 3.0-2.9 (m, 4H), 2.8-2.7 (br s, 4H), 2.5-2.6(m, 4H), 2.3 (s, 3H), 1.9-1.8 (m, 6H), 1.7-1.6 (m, 4H) MS m/z 570.2(M + 1) N-(4-Methyl-3-{2- [4-(2-pyrrolidin-1- yl-ethoxy)-phenylamino]-7,8- dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-2-piperidin- 1-yl-acetamide 1 111

1H NMR (300 MHz, CDCl₃) δ 8.1 (s, 1H), 7.65-6.80 (m, 9H), 4.12 (t, 2H),3.98 (s, 2H), 3.45 (s, 3H), 3.2 (t, 1H), 3.1-2.9 (m, 4H), 2.89- 2.70 (brs, 3H), 2.40-2.22 (m, 5H), 1.97-1.70 (m, 5H), 1.10-0.92 (t, 3H) MS m/z515.2 (M + 1) N-(4-Methyl-3-{2- [4-(2-pyrrolidin-1- yl-ethoxy)-phenylamino]-7,8- dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl}-phenyl)-butyramide 1 112

1H NMR (300 MHz, CD₃OD) δ 8.15 (s, 1H), 7.65-7.45 (m, 3H), 7.15 (s, 2H),7.05-6.90 (d, 2H), 4.3-4.2 (d, 2H), 4.0 (s, 2H), 3.60-3.45 (d, 2H),3.4-3.3 (m, 2H), 3.3-3.2 (t, 2H), 3.3-2.9 (t, 2H), 2.50-2.25 (m, 5H),2.15- 2.00 (m ,4H), 1.7-1.5 (m, 3H), 1.4-1.3 (m, 2H), 1.05- 0.90 (d, 6H)MS m/z 543.2 (M + 1), 4-Methyl-pentanoic acid (4-methyl-3-{2-[4-(2-pyrrolidin- 1-yl-ethoxy)- phenylamino]-7,8- dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-amide 1 113

1H NMR (300 MHz, CD₃OD) δ 8.15 (s, 1H), 7.65-7.45 (m, 3H), 7.1 (s, 2H),7.05-6.90 (d, 2H), 4.3-4.2 (t, 2H), 4.0 (s, 2H), 3.4-3.3 (t, 2H),3.3-3.1 (m, 4H), 3.0-2.9 (t, 2H), 2.60-2.45 (m, 1H), 2.3 (s, 3H),2.1-1.5 (m, 18H) MS m/z 569.3 (M + 1), Cycloheptanecarbo xylic acid (4-methyl-3-{2-[4-(2- pyrrolidin- 1-yl-ethoxy)- phenylamino]-7,8-dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-amide 1 114

, 1H NMR (300 MHz, CDCl₃) δ 9.2 (s, 2H), 7.96 (s, 1H), 7.85 (d, 1H),7.8-7.6 (m, 2H), 7.60- 7.45 (m, 3H), 7.45-7.30 (m, 2H), 7.3-7.15 (m,1H), 7.1 (d, 1H), 7.05-6.90 (m, 2H), 4.0-3.8 (m, 1H), 3.80-3.65 (m, 1H),3.3-3.0 (m, 6H), 2.7-2.5 (m, 4H), 2.34 (s, 3H), 1.9 (s, 3H) MS m/z 604.1(M + 1) Benzo[b]thiophene- 2-carboxylic acid (4-methyl-3-{2-[4-(4-methyl- piperazin-1-yl)- phenylamino]-5- oxo-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-amide 3 115

1H NMR (300 MHz, CDCl₃) δ 8.18-7.97 (m, 3H), 7.81 (d, 2H), 7.54 (s, 1H),7.38-7.05 (m, 2H), 5.1-4.9 (br s, 1H), 4.15-3.90 (m, 2H), 3.40-3.15 (m,2H), 3.15-2.75 (m, 5H), 2.3 (s, 3) MS m/z 476.1 (M + 1), 3-Chloro-N-[4-methyl-3-(2- methylamino-7,8- dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl)-phenyl]-5- trifluoromethyl- benzamide 1 116

1H NMR (300 MHz, CDCl₃) δ 9.85 (s, 1H), 9.0 (s, 1H), 8.2 (d, 1H), 7.86(t, 1H), 7.82-7.76 (m, 1H), 7.65-7.46 (m, 4H), 7.43-7.30 (m, 2H), 6.95(d, 2H), 4.19-3.95 (m, 1H), 3.89-3.70 (m, 1H), 3.34-3.00 (m, 6H),2.68-2.55 (m, 4H), 2.36 (s, 3H), 2.25 (s, 3H) MS m/z 583.2 (M + 1),6-Chloro-pyridine- 2-carboxylic acid (4- methyl-3-{2-[4-(4-methyl-piperazin-1- yl)-phenylamino]- 5-oxo-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidin-6-yl}- phenyl)-amide 3 117

1H NMR (300 MHz, CDCl₃) δ 8.7 (d, 1H), 8.42-8.3 (m, 1H), 8.3-8.02 (m,4H), 8.00-7.76 (m, 3H), 7.74-7.54 (m, 2H), 7.40-7.02 (m, 4H), 4.1 (s,2H), 3.4-3.2 (m, 2H), 3.15-3.00 (m, 2H), 3.0- 2.9 (m, 1H), 2.35 (s, 3H),0.9-0.8 (m, 2H), 0.7-0.6 (m, 2H) MS m/z 588.0 (M + 1), 5-{6-[2-Methyl-5-(3-trifluoromethyl- benzoylamino)- phenyl]-5,6,7,8- tetrahydro-pyrido[4,3- d]pyrimidin-2- ylamino}-pyridine- 2-carboxylic acidcyclopropylamide 2 118

1H NMR (300 MHz, CDCl₃) δ 8.97 (d, 2H), 8.2 (s, 1H), 8.08- 7.32 (m,11H), 7.2-6.8 (m, 3H), 6.42 (s, 1H), 4.10-3.52 (m, 2H), 3.40-2.88 (m,6H), 2.8-2.5 (m, 4H), 2.38 (s, 3H), 1.9 (s, 3H) MS m/z 614.0 (M + 1),N-(4-Methyl- 3-{2-[4-(4- methyl-piperazin- 1-yl)-phenyl- amino]-5-oxo-7,8-dihydro- 5H-pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-3-pyrazol-1-yl-benzamide 3 119

1H NMR (300 MHz, DMSO-D₆) δ 10.42 (s, 1H), 10.15 (s, 1H), 9.0 (s, 1H),8.51-8.12 (m, 4H), 8.20- 7.61 (m, 4H), 7.61 (s, 1H), 7.60-7.32 (m, 2H),7.2 (d, 1H), 4.05 (s, 2H), 3.08-2.93 (m, 2H), 2.61-2.52 (m, 2H), 2.28(s, 3H) MS m/z 548.1 (M + 1), 5-{6-[2-Methyl-5- (3-trifluoromethyl-benzoylamino)- phenyl]-5,6,7,8- tetrahydro- pyrido[4,3- d]pyrimidin-2-ylamino}-pyridine- 2-carboxylic acid amide 2 120

1H NMR (300 MHz, CDCl₃) δ 9.39 (s, 1H), 9.11-9.00 (m, 1H), 8.13 (d, 2H),7.7 (s, 1H), 7.65-7.30 (m, 5H), 7.1-6.86 (m, 3H), 4.10-3.52 (m, 2H),3.40-2.88 (m, 6H), 2.8-2.5 (m, 4H), 2.38 (s, 3H), 1.9 (s, 3H) MS m/z650.1 (M + 1), 3-Chloro-N-(4- methyl-3-{2-[4-(4- methyl-piperazin-1-yl)-phenyl- amino]- 5-oxo-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidin-6-yl}- phenyl)-5- trifluoromethyl- benzamide 3 121

1H NMR (300 MHz, CDCl₃) δ 8.58 (s, 1H), 8.28-8.0 (m, 3H), 7.88-7.78 (m,2H), 7.72-7.58 (m, 2H), 7.26-7.08 (m, 3H), 6.61 (s, 1H), 4.02 (s, 2H),3.92-3.72 (m, 4H), 3.36-3.21 (m, 2H), 3.05-2.88 (m, 2H), 2.60-2.48 (m,4H), 2.36 (s, 3H), 2.32 (s, 3H) MS m/z 604.2 (M + 1), N-(4-Methyl-3-{2-[2-(4- methyl-piperazin- 1-yl)-pyrimidin-5- ylamino]-7,8-dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-3- trifluoromethyl-benzamide 2 122

1H NMR (300 MHz, CDCl₃) δ 9.1 (s, 1H), 9.0 (s, 1H), 8.85 (s, 1H), 8.6(s, 1H), 8.25-8.1 (d, 1H), 8.1-8.0 (m, 1H), 7.8-7.65 (m, 1H), 7.6-7.5(m, 2H), 7.45-7.30 (m, 2H), 7.20-7.05 (m, 2H), 7.05-6.90 (m, 2H),4.00-3.85 (m, 1H), 3.80-3.65 (m, 1H), 3.5 (s, 1H), 3.3-3.0 (m, 6H),2.70-2.55 (m, 4H), 2.4 (s, 3H), 1.9 (s, 3H) MS m/z 604.9 (M + 1),Benzothiazole-6- carboxylic acid (4- methyl-3-{2-[4-(4-methyl-piperazin-1- yl)-phenylamino]- 5-oxo-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidin-6-yl}- phenyl)-amide 3 123

1H NMR (300 MHz, CDCl₃) δ 8.12 (s, 1H), 7.56-7.46 (m, 2H), 7.32- 7.12(m, 3H), 7.06-6.89 (m, 4H), 4.0 (s, 2H), 3.3- 3.1 (m, 6H), 3.05-2.90 (m,3H), 2.85-2.70 (m, 1H), 2.65-2.60 (m, 4H), 2.4 (s, 3H), 2.3 (s, 3H), 1.3(s, 3H) MS m/z 568.2 (M + 1), 4,4,4-Trifluoro-3- methyl-N-(4- methyl-3-{2-[4-(4-methyl- piperazin-1-yl)- phenylamino]-7,8- dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl}- phenyl)- butyramide 1 124

1H NMR (300 MHz, CDCl₃) δ 9.2 (s, 1H), 8.95 (s, 1H), 7.95 (s, 1H),7.9-7.8 (m, 2H), 7.65- 7.34 (m, 7H), 7.10-7.01 (m, 2H), 7.00-6.89 (m,2H), 4.0- 3.8 (m, 1H), 3.8-3.6 (m ,1H), 3.3-2.9 (m, 6H), 2.7-2.5 (m,4H), 2.4 (s, 3H), 2.25 (s, 3H), 1.85 (s, 3H) MS m/z 628.1 (M + 1),3-(4-Methyl-imi- dazol-1-yl)-N-(4- methyl-3-{2-[4-(4-methyl-piperazin-1- yl)-phenylamino]- 5-oxo-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidin-6-yl}- phenyl)-benzamide 3 125

1H NMR (300 MHz, CD₃OD) δ 8.88 (s, 1H), 8.38-8.08 (m, 3H), 7.92-7.80 (m,1H), 7.80- 7.50 (m, 6H), 7.43-7.20 (m, 2H), 7.15-6.95 (d, 1H), 4.3- 3.7(m, 4H), 3.6 (s, 2H), 3.0- 2.6 (m, 8H), 2.45 (s, 3H), 2.25 (s, 3H) MSm/z 630.0 (M + 1), N-(4-Methyl- 3-{2-[3-(4- methyl-piperazin- ylmethyl)-phenylamino]-5- oxo-7,8-dihydro- 5H-pyrido[4,3- d]pyrimidin-6-yl}-phenyl)-3- trifluoromethyl- benzamide 3 126

1H NMR (300 MHz, CDCl₃) δ 9.0 (s, 1H), 8.2 (s, 1H), 7.65 (d, 1H),7.6-7.4 (m, 6H), 7.3-7.15 (m, 2H), 7.1-6.9 (m, 3H), 4.1-3.9 (m, 1H),3.85-3.65 (m, 1H), 3.3-3.0 (m, 10H), 2.7-2.5 (m, 8H), 2.4-2.3 (m, 6H),2.15 (s, 3H) MS m/z 646.0 (M + 1), N-(4-Methyl- 3-{2-[4-(4-methyl-piperazin-1-yl)- phenylamino]- 5-oxo-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidin-6-yl}- phenyl)-3-(4- methyl-piperazin- 1-yl)-benzamide 3 127

1H NMR (300 MHz, DMSO-D₆) δ 10.7 (s, 1H), 9.48 (s, 1H), 9.29 (s, 1H),8.7 (s, 1H), 8.4- 8.2 (m, 3H), 8.0-7.5 (m, 6H), 7.2 (d, 1H), 6.89 (d,2H), 4.0 (s, 2H), 3.25 (t, 2H), 3.1-3.0 (m, 4H), 2.9 (t, 2H), 2.5-2.4(m, 4H), 2.3 (s, 3H), 2.2 (s, 3H) MS m/z 585.1 (M + 1), Isoquinoline-3-carboxylic acid (4- methyl-3-{2-[4-(4- methyl-piperazin- 1-yl)-phenyl-amino]- 7,8-dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-amide 1128

1H NMR (300 MHz, CD₃OD) δ 9.37 (s, 1H), 8.83 (s, 1H), 8.66 (s, 1H), 8.22(d, 1H), 8.12 (d, 1H), 7.96-7.69 (m, 4H), 7.6 (d, 2H), 7.45-7.32 (m,1H), 7.0 (d, 2H), 4.25-4.0 (m, 1H), 3.95- 3.75 (m, 1H), 3.25-3.1 (m,6H), 2.8-2.65 (m, 4H), 2.4 (s, 3H), 2.25 (s, 3H) MS m/z 599.1 (M + 1),Isoquinoline-3- carboxylic acid (4- methyl-3-{2-[4-(4-methyl-piperazin-1- yl)-phenylamino]- 5-oxo-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidin--6-yl}- phenyl)-amide 3 129

1H NMR (300 MHz, CDCl₃) δ 8.05 (s, 1H), 7.76-7.60 (m, 2H), 7.44-6.88 (m,6H), 6.82- 6.58 (m, 1H), 5.12-4.82 (m, 1H), 4.01 (s, 2H), 3.49-2.82 (m,10H), 2.31 (s, 3H), 2.05 (s, 3H) MS m/z 442.9 (M + 1), N-[4-Methyl-3-(2-methylamino-7,8- dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl)- phenyl]-3-pyrrolidin- 1-yl-benzamide 1 131

1H NMR (300 MHz, CDCl₃) δ 8.11 (s, 1H), 7.54-7.42 (m, 3H), 7.24- 7.12(m, 2H), 7.04-6.86 (m, 4H), 4.0 (s, 2H), 3.3- 3.1 (m, 6H), 3.02-2.90 (m,2H), 2.7-2.5 (m, 8H), 2.35 (s, 3H), 2.3 (s, 3H) MS m/z 554.2 (M + 1),4,4,4-Trifluoro- N-(4-methyl- 3-{2-[4-(4-methyl- piperazin-1-yl)-phenylamino]- 7,8-dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl}-phenyl)- butyramide 1 132

1H NMR (300 MHz, CDCl₃) δ 8.85-8.64 (m, 1H), 8.40-7.96 (m, 5H),7.90-7.50 (m, 4H), 7.48-7.00 (m, 3H), 4.05 (s, 2H), 3.94-3.60 (m, 4H),3.4-3.1 (m, 2H), 3.1-2.9 (m, 2H), 2.60-2.15 (m, 10H) MS m/z 631.2 (M +1), N-(4-Methyl-3-{2- [6-(4-methyl- piperazine-1- carbonyl)-pyridin-3-ylamino]-7,8- dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-3-trifluoromethyl- benzamide 2 133

1H NMR (300 MHz, CDCl₃) δ 8.95 (s, 1H), 8.35 (s, 1H), 7.55-7.45 (m, 2H),7.4-7.3 (m, 2H), 7.20-7.15 (m, 2H), 7.0- 6.9 (m, 2H), 4.05-3.90 (m, 1H),3.85-3.70 (m, 1H), 3.7- 3.1 (m, 6H), 2.7-2.6 (m, 4H), 2.55-2.45 (m, 4H),2.4 (s, 3H), 2.25 (s, 3) MS m/z 568.1 (M + 1), 4,4,4-Trifluoro-N-(4-methyl-3-{2-[4- (4-methyl- piperazin-1-yl)- phenylamino]-5-oxo-7,8-dihydro- 5H-pyrido[4,3- d]pyrimidin-6-yl}- phenyl)- butyramide3 134

1H NMR (300 MHz, CDCl₃) δ 9.05 (s, 1H), 8.85-8.75 (br s, 1H), 8.2 (s,1H), 8.15-8.05 (m, 1H), 7.7-7.5 (m, 5H), 7.45- 7.35 (m, 2H), 7.2-7.1 (m,1H), 7.0-6.9 (m, 2H), 4.05-3.85 (m, 5H), 3.80-3.65 (m, 1H), 3.20- 3.05(m, 6H), 2.15 (s, 3H) MS m/z 602.9 (M + 1), N-{4-Methyl-3-[2-(4-morpholin-4-yl- phenylamino)-5- oxo-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidin-6-yl]- phenyl}-3- trifluoromethyl- benzamide 3 135

¹H NMR (300 MHz, DMSO-D₆) δ 10.1 (s, 1H), 8.8-8.74 (m, 1H), 8.06-8.0 (brs, 1H), 7.68- 7.6 (br s, 1H), 7.4-7.08 (m, 3H), 6.5-6.38 (br s, 2H), 3.9(s, 2H), 3.2-3.1 (m, 2H), 2.84-2.7 (m, 2H), 2.2 (s, 3H) MS m/z 402.1(M + 1) 6-[2-Methyl-5-(4- trifluoromethyl- pyrimidin-2-ylamino)-phenyl]- 5,6,7,8-tetrahydro- pyrido[4,3-d] pyrimidin-2- ylamine6 136

¹H NMR (300 MHz, CDCl₃) δ 8.65-8.55 (m, 3H), 8.5-8.4 (br s, 1H), 8.35(s, 1H), 8.2-8.1 (m, 2H), 7.85-7.75 (br s, 1H), 7.4 (s, 1H), 7.25-7.15(m, 1H), 7.1-7.0 (m, 2H), 4.2 (s, 2H), 3.35 (t, 2H), 3.15 (t, 2H), 2.3(s, 3H) MS m/z 478.9 (M + 1) {6-[2-Methyl-5-(4- trifluoromethyl-pyrimidin-2- ylamino)-phenyl]- 5,6,7,8-tetra- hydro-pyrido[4,3-d]pyrimidin-2-yl}- pyridin-4-yl-amine 6 137

¹H NMR (300 MHz, CD₃OD) δ 8.36-8.2 (m, 3H), 7.98-7.66 (m, 5H), 7.45-7.35(m, 2H), 7.28-7.12 (m, 2H), 4.12 (s, 2H), 3.54-3.46 (m, 2H), 3.41-3.36(m, 5H), 3.31-3.21 (m, 4H), 3.1-3.02 (m, 2H), 2.95 (s, 3H), 2.36 (s, 3H)MS m/z 616.2 (M + 1) N-(4-Methyl- 3-{2-[3-(4- methyl-piperazin-1-ylmethyl)- phenylamino]-7,8- dihydro-5H- pyrido[4,3-d]pyrimidin-6-yl}- phenyl)-3- trifluoromethyl- benzamide 1 138

¹H NMR (300 MHz, DMSO-D₆) δ 10.7 (s, 1H), 8.8 (s, 1H), 7.7-7.0 (m, 10H),6.95- 6.85 (d, 2H), 4.1-3.95 (m, 1H), 3.85-8.7 (m, 1H), 3.3- 3.0 (m,6H), 2.5-2.4 (m, 4H), 2.24 (s, 3H), 2.15 (s, 3H) MS m/z 561.2 (M + 1)6-{5-(Benzooxazol- 2-ylamino)- 2-methyl-phenyl]- 2-[4-(4-methyl-piperazin-1-yl)- phenylamino]- 7,8-dihydro-6H- pyrido[4,3-d]pyrimidin-5-one 10 139

¹H NMR (300 MHz, CD₃OD) δ 8.12 (s, 1H), 7.7-7.45 (m, 7H), 7.15 (s, 2H),6.96 (d, 2H), 3.98 (s, 2H), 3.77 (s, 2H), 3.25-3.15 (m, 6H), 2.99-2.75(m, 6H), 2.5 (s, 3H), 2.28 (s, 3H) MS m/z 615.9 (M + 1) N-(4-Methyl-3-{2-[4-(4-methyl- piperazin-1-yl)- phenylamino]-7,8- dihydro-5H-pyrido[4,3-d]pyrimidin- 6-yl}-phenyl)-2-(4- trifluoromethyl- phenyl)-acetamide1 140

¹H NMR (300 MHz, CDCl₃) δ 9.16 (s, 1H), 8.12 (s, 1H), 7.84 (s, 1H),7.7-7.4 (m, 3H), 7.25-6.8 (m, 4H), 4.02 (s, 2H), 3.4-3.14 (m, 7H), 3.08-2.92 (m, 2H), 2.85-2.65 (br s, 7H), 2.52-2.2 (d, 6H), 2.06 (s, 3H),1.95-1.8 (br s, 3H) MS m/z 541.2 (M + 1) N-(4-Methyl- 3-{2-[4-(4-methyl-piperazin-1-yl)- phenylamino]-7,8- dihydro-5H- pyrido[4,3-d]pyrimidin-6-yl}- phenyl)-2- pyrrolidin- 1-yl-acetamide 1 141

¹H NMR (300 MHz, CDCl₃) δ 9.0 (s, 1H), 7.7-6.6 (m, 11H), 8.2-7.7 (m,3H), 4.2- 3.7 (m, 2H), 3.5-2.8 (m, 10H), 2.2-1.9 (m, 6H) MS m/z 631.2(M + 1) 1-(4-Methyl- 3-{2-[4-(4-methyl- piperazin-1-yl)- phenylamino]-5-oxo-7,8-dihydro- 5H-pyrido[4,3-d] pyrimidin-6- yl}-phenyl)-3-(3-trifluoromethyl- phenyl)-urea 8 145

¹H NMR (300 MHz, CDCl₃) δ 9.15 (s, 1H), 9.02 (s, 1H), 8.45-8.37 (br s,1H), 8.23- 8.08 (m, 2H), 7.85 (dd, 1H), 7.74 (d, 1H), 7.66-7.52 (m, 2H),7.40-7.30 (m, 2H), 7.06 (d, 1H), 6.72 (d, 1H), 4.00- 3.88 (m, 1H),3.70-3.67 (m, 1H), 3.55 (t, 4H), 3.15-3.05 (m, 2H), 2.55 (t, 4H), 2.36(s, 3H), 1.75 (s, 3H) MS m/z 617.1 (M + 1) N-(4-Methyl-3-{2-[6-(4-methyl- piperazin-1-yl)- pyridin-3- ylamino]-5-oxo-7,8-dihydro- 5H-pyrido[4,3-d] pyrimidin- 6-yl}-phenyl)-3-trifluoromethyl- benzamide 3 146

¹H NMR (300 MHz, CDCl₃) δ 9.9 (s, 1H), 8.83 (d, 1H), 8.56 (s, 1H), 8.15(s, 1H), 7.8-7.7 (m, 2H), 7.50 (d, 2H), 7.0-6.9 (m, 5H), 4.08 (s, 2H),3.37-2.98 (m, 8H), 2.65-2.58 (m, 4H), 2.36 (s, 3H), 2.32 (s, 3H) MS m/z603.1 (M + 1) 4-Trifluoromethyl- pyridine-2- carboxylic acid(4-methyl-3- {2-[4-(4-methyl- piperazin-1-yl)- phenylamino]-7,8-dihydro-5H-pyrido [4,3-d]pyrimidin- 6-yl}-phenyl)- amide 1 147

¹H NMR (300 MHz, CDCl₃) δ 8.13 (s, 1H), 7.55-7.45 (m, 3H), 7.22-7.13 (m,2H), 7.00- 6.90 (m, 4H), 4.14 (t, 2H), 4.00 (s, 2H), 3.25 (t, 2H),3.00-2.90 (m, 4H), 2.70- 2.60 (m, 8H), 2.30 (s, 3H), 1.90-1.80 (m, 4H)MS m/z 569.2 (M + 1) 4,4,4-Trifluoro-N- (4-methyl-3-{2-[4-(2-pyrrolidin-1-yl- ethoxy)-phenyl- amino]-7,8- dihydro- 5H-pyrido[4,3-d]pyrimidin-6-yl}- phenyl)- butyramide 1 148

¹H NMR (300 MHz, CDCl₃) δ 8.75 (s, 1H), 8.40-7.95 (m, 6H), 7.90-7.50 (m,4H), 7.40- 7.10 (m, 3H), 4.12-3.90 (m, 3H), 3.35-3.25 (m, 2H), 3.15-3.00(m, 2H), 2.90- 2.76 (m, 2H), 2.40-1.95 (m, 12H) MS m/z 645.2 (M + 1)5-{6-[2-Methyl-5- (3-trifluoromethyl- benzoylamino)- phenyl]-5,6,7,8-tetrahydro-pyrido [4,3-d]pyrimidin-2- ylamino}-pyridine- 2-carboxylicacid (1-methyl- piperidin-4-yl)- amide 2 149

¹H NMR (300 MHz, CDCl₃) δ 8.15 (s, 1H), 7.50 (d, 2H), 7.19 (d, 1H),7.00-6.80 (m, 5H), 6.60-6.40 (m ,1H), 4.00 (s, 2H), 3.30-2.95 (m, 10H),2.60 (t, 4H), 2.38 (s, 3H), 2.30 (s, 3H), 1.85-1.75 (m, 2H), 1.50-1.36(m, 2H), 1.25 (s, 2H), MS m/z 550.2 (M + 1) Butane-1-sulfonic acid(4-methyl-3- {2-[4-(4-methyl- piperazin-1-yl)- phenylamino]-7,8-dihydro-5H- pyrido[4,3-d] pyrimidin-6- yl}-phenyl)-amide 9 150

1H NMR (300 MHz, CD₃OD) δ 8.5-8.4 (t, 3H), 8.35-8.25 (br s, 1H), 7.7-7.3 (m, 5H), 7.2-7.1 (d, 1H), 6.95-6.8 (m, 2H), 3.9 (s, 2H), 3.7 (s,3H), 3.15- 3.05 (m, 2H), 3.05-2.95 (m, 2H), . MS m/z 521.5 (M + 1)N-{4-Methoxy- 3-[2-(pyridin-4- ylamino)- 7,8-dihydro-5H- pyrido [4,3-d]pyrimidin-6-yl]- phenyl}-3- trifluoromethyl- benzamide 2 153

¹H NMR (400 MHz, CDCl₃) δ 8.11 (s, 1H), 7.50 (d, 2H), 7.23 (d, 1H), 7.13(d, 1H), 6.98-6.88 (m, 3H), 6.82 (dd, 1H), 6.54 (s, 1H), 4.73 (d, 1H),4.20-4.10 (m, 2H), 3.99 (s, 2H), 3.24 (t, 2H), 2.98 (t, 2H), 2.75-2.67(br s, 4H), 2.29 (s, 3H), 2.06-1.95 (m, 2H), 1.90-1.80 (m, 4H), 1.8-1.5(m, 10H) 1-Cyclopentyl-3- (4-methyl-3-{2-[4- (2-pyrrolidin-1-yl-ethoxy)-phenyl amino]-7,8- dihydro- 5H-pyrido[4,3- d]pyrimidin-6-yl}-phenyl)-urea 7 154

¹H NMR (300 MHz, DMSO-D₆) δ 10.4 (s, 1H), 9.84 (s, 1H), 8.42-8.24 (m,3H), 8.02-7.72 (m, 5H), 7.62 (s, 1H), 7.52-7.44 (m, 1H), 7.28-7.10 (m,4H), 4.0 (s, 2H), 3.3-3.2 (t, 2H), 3.05- 2.95 (t, 2H), 2.4 (s, 3H) MSm/z 547.1 (M + 1) 4-{6-[2-Methyl-5- (3-trifluoromethyl- benozylamino)-phenyl]-5,6,7,8- tetrahydro-pyrido [4,3-d]pyrimidin- 2-ylamino}-benzamide 2 155

¹H NMR (300 MHz, CDCl₃) δ 8.13 (s, 1H), 7.52-7.46 (m, 3H), 7.20-7.12 (m,2H), 7.04-6.86 (m, 4H), 4.12 (t, 2H), 4.0 (s, 2H), 3.27 (t, 2H),3.05-2.89 (m ,4H), 2.7-2.6 (m, 3H), 2.32-2.28 (m, 4H), 1.85-1.80 (m,3H), 1.3-1.2 (m, 6H). MS m/z 583.2 (M + 1) 4,4,4-Trifluoro-3-methyl-N-(4- methyl-3-{2-[4-(2- pyrrolidin-1-yl- ethoxy)-phenylamino]-7,8- dihydro-5H-pyrido [4,3-d]pyrimidin- 6-yl}-phenyl)-butyramide 1 156

¹H NMR (400 MHz, _(CD3OD)) δ 8.5-8.3 (bs, 1H), 7.8-7.6 (m, 3H), 7.5-6.94(m, 7H), 3.9- 3.5 (m, 8H), 3.3- 3.2 (m, 4H), 3.1 (s, 3H), 2.3 (s, 3H),6-{5-(5-Bromo-1H- benzoimidazol-2- ylamino)-2-methyl- phenyl]-2-{4-(4-methyl- piperazin-1-yl)- phenylamino]-7,8- dihydro-6H-pyrido[4,3-d]pyrimidin-5- one 10 157

¹H NMR (300 MHz, CDCl₃) δ 7.98 (s, 1H), 7.6-7.06 (m, 8H), 6.84 (d, 1H),5.1-5.0 (m, 1H), 3.85 (s, 2H), 3.2- 2.8 (m, 7H), 2.22 (s, 3H) MS m/z457.1 (M + 1) 1-{4-Methyl-3-(2- methylamino-7,8- dihydro-5H-pyrido[4,3-d] pyrimidin-6-yl)- phenyl]-3-(3- trilfuoromethyl- phenyl)-urea 7158

¹H NMR (300 MHz, DMSO- D₆) δ 11 (s, 1H), 10.0 (s, 1H), 8.70 (s, 1H),8.00 (s, 2H), 8.04 (s, 1H), 7.82 (t, 2H), 7.72-7.55 (m, 2H), 7.3 (d,1H), 6.92 (d, 2H), 4.05- 3.90 (m, 1H), 3.80-3.69 (m, 1H), 3.3-3.0 (m,6H), 2.5- 2.4 (m, 4H), 2.23 (s, 3H), 2.17 (s, 3H) 2-Fluoro-N- (4-methyl-3-{2-[4-(4-methyl- piperazin-1-yl)- phenylamino]-5- oxo-7,8-dihydro-5H-pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-5- trifluoromethyl- benzamide3 159

¹H NMR (400 MHz, DMSO- D₆) δ 10.43 (s, 1H), 10.2 (s, 1H), 8.42 (s, 1H),8.32-8.24 (m, 2H), 8.06-7.94 (m, 3H), 7.82-7.76 (m, 3H), 7.66- 7.62 (m,1H), 7.48 (dd, 1H), 7.21 (d, 1H), 4.05 (s, 2H), 3.26 (t, 2H), 3.14 (s,3H), 3.00 (t, 2H), 2.27 (s, 3H) N-{3-[2-(4- Methanesulfonyl-phenylamino)-7,8- dihydro-5H-pyrido [4,3-d] pyrimidin-6-yl]-4-methyl-phenyl]-3- trifluoromethyl- benzamide 2 160

¹H NMR (400 MHz, CD₃OD) δ 8.16 (s, 1H), 7.58-7.52 (m, 2H), 7.46 (s, 1H),7.20-7.14 (m, 2H), 6.94-6.89 (m, 2H), 4.15 (t, 2H), 4.00 (s, 2H), 3.29(t, 2H), 2.96 (t, 2H), 2.84 (t, 2H), 2.72 (dd, 2H), 2.7-2.5 (m, 8H),2.45-2.35 (m, 1H), 2.32 (s, 3H), 2.29 (s, 3H), 1.2 (d, 3H)4,4,4-Trifluoro-3- methyl-N-[4- methyl-3-(2-{4-[2- (4-methyl-piperazin-1-yl)- ethoxy]-phenyl- amino}-7,8- dihydro-5H-pyrido[4,3-d]pyrimidin- 6-yl)-phenyl]- butyramide 1 161

¹H NMR (300 MHz, DMSO-D₆) δ 10.45 (s, 1H), 10.0 (s, 1H), 8.77 (s, 1H),8.32 (s, 2H), 8.04 (s, 1H), 7.82 (t, 2H), 7.72-7.55 (m, 3H), 7.3 (d,1H), 6.92 (d, 2H), 4.05- 3.92 (m, 1H), 3.80-3.69 (m, 1H), 3.3-3.0 (m,6H), 2.5- 2.4 (m, 4H), 2.23 (s, 3H), 2.17 (s, 3H) MS m/z 644.0 (M + 1)3-Bromo-5- fluoro-N-(4- methyl-3-{2- [4-(4-methyl- piperazin-1-yl)-phenylamino]-5- oxo-7,8-dihydro- 5H-pyrido[4,3-d] pyrimidin-6-yl}-phenyl)- benzamide 3 162

¹H NMR (300 MHz, DMSO- D₆) δ 10.7 (s, 1H), 10.09 (s, 1H), 8.76 (s, 1H),8.34-8.24 (m, 2H), 8.04-7.93 (m, 2H), 7.86-7.76 (m, 2H), 7.66-7.56 (m,3H), 6.92 (d, 2H), 4.00- 3.78 (m, 2H), 3.15-3.00 (m, 6H), 2.5-2.4 (m,4H), 2.2 (s, 3H) MS m/z 635.7 (M + 1) N-(4-Chloro- 3-{2-[4-(4-methyl-piperazin-1-yl)- phenylamino]-5- oxo-7,8-dihydro- 5H-pyrido[4,3-d]pyrimidin- 6-yl}-phenyl)-3- trifluoromethyl- benzamide 3 163

¹H NMR (300 MHz, DMSO-D₆) δ 10.75 (s, 1H), 10.55 (s, 1H), 8.92 (s, 1H),8.35-8.25 (m, 2H), 8.1 (d, 2H), 8.05-7.63 (m, 6H), 7.35 (d, 1H),4.14-4.00 (m, 1H), 3.88-3.76 (m, 1H), 3.2-3.1 (m, 5H), 2.2 (s, 3H) MSm/z 596.0 (M + 1) N-{3-[2-(4- Methanesulfonyl- phenylamino)-5-oxo-7,8-dihydro- 5H-pyrido[4,3-d] pyrimidin-6-yl]-4- methyl-phenyl}-3-trifluoromethyl- benzamide 4 164

¹H NMR (300 MHz, CDCl₃) δ 8.16 (s, 1H), 7.76-7.64 (m, 3H), 7.46-7.32 (m,3H), 7.22- 7.08 (m, 3H), 3.92 (s, 2H), 3.7-3.6 (m, 5H), 3.2 (t, 2H), 3.0(t, 2H), 2.75-2.55 (m, 4H), 2.54-2.13 (m, 10H) MS m/z 582.2 (M + 1)4,4,4-Trifluoro-N- (4-methyl-3-{2-[4- (4-methyl-pipera-zine-1-carbonyl)- phenylamino]-7,8- dihydro-5H-pyrido [4,3-d]pyrimidin-6-yl}-phenyl)- butyramide 2 165

¹H NMR (300 MHz, CDCl₃) δ 8.25 (s, 1H), 8.15 (s, 1H), 8.1 (d, 1H),7.95-7.80 (m, 7H), 7.75-7.60 (m, 2H), 7.45 (s, 1H), 7.28-7.12 (m, 2H),4.88 (s, 1H), 4.1 (s, 2H), 3.3 (t, 2H), 3.08 (t, 2H), 2.32 (s, 3H),0.70-0.55 (m, 4H) MS m/z 623.1 (M + 1) N-{3-[2-(4-Cyclo-propylsulfamoyl- phenylamino)-7,8- dihydro-5H-pyrido [4,3-d]pyrimidin-6-yl]-4-methyl- phenyl}- 3-trifluoromethyl- benzamide 1 166

¹H NMR (300 MHz, CDCl₃) δ 9.1 (s, 1H), 9 (s, 1H), 8.45-8.35 (s, 1H), 8.2(s, 1H), 8.15-8.05 (d, 1H), 7.9-7.5 (m, 4H), 7.45-7.25 (m, 2H), 7.15-7.0 (d, 1H), 6.75-6.65 (d, 1H), 4.1-3.85 (m, 1H), 3.8-3.65 (m, 1H),3.15-3 (m, 2H), 2.6-2.5 (t, 4H), 2.35 (s, 3H), 1.75 (s, 3H). MS m/z617.4 (M + 1) 4-Trifluoromethyl- pyridine-2- carboxylic acid (4-methyl-3-{2-[4-(4-methyl- piperazin-1-yl)- phenylamino]-5- oxo-7,8-dihydro-5H-pyrido[4,3-d] pyrimidin-6- yl}-phenyl)-amide 3 167

¹H NMR (300 MHz, CDCl₃) δ 9.9 (s, 1H), 8.82 (d, 1H), 8.55 (s, 1H), 8.22(s, 1H), 7.81 (s, 1H), 7.75-7.68 (m, 3H) ,7.46- 7.38 (m, 2H), 7.32-7.20(m, 3H), 4.11 (s, 2H), 3.85-3.50 (m, 4H), 3.34 (t, 2H), 3.06 (t, 2H),2.52- 2.20 (m, 10H) MS m/z 631.3 (M + 1) 4-Trifluoromethyl- pyridine-2-carboxylic acid (4- methyl-3-{2-[4- (4-methyl-pipera- zine- 1-carbonyl)-phenylamino]-7,8- dihydro-5H-pyrido [4,3-d] pyrimidin-6-yl}-phenyl)-amide 2 168

¹H NMR( 300 MHz, DMSO-D₆) δ 10.7 (s, 1H), 10.58 (s, 1H), 9.06 (d, 1H),8.91 (s, 1H), 8.6 (d, 1H), 8.42 (dd, 1H), 8.15 (d, 2H), 8.04-7.9 (m,3H), 7.79-7.75 (m, 1H), 7.54 (dd, 1H), 7.32 (d, 1H), 4.11-3.98 (m, 1H),3.85-3.72 (m, 1H), 3.22- 3.10 (m, 1H), 2.95-2.82 (m, 1H), 2.18 (s, 3H),0.25-0.10 (m, 5H) MS m/z 602.2 (M + 1) 5-{6-[2-Methyl-5-(3-trifluoromethyl- benzoylamino)- phenyl]-5-oxo- 5,6,7,8-tetrahydro-pyrido[4,3- d]pyrimidin-2-yl- amino}- pyridine-2- carboxylic acidcyclopropylamide 4 169

¹H NMR (400 MHz, CD₃OD) δ 8.9 (s, 1H), 8.30-8.20 (m, 2H), 7.99 (s, 1H),7.91 (d, 1H), 7.84-7.72 (m, 5H), 7.62 (dd, 1H), 7.54 (d, 2H), 7.36 (d,1H), 4.23 (q, 2H), 4.15-4.05 (m, 1H), 3.93-3.85 (m, 1H), 3.23- 3.13 (m,2H), 2.30 (s, 3H), 1.50 (t, 3H) N-(3-{2-[4-(1- Ethyl-1H- pyrazol-4-yl)-phenylamino]-5- oxo-7,8-dihydro- 5H-pyrido [4,3-d]pyrimidin-6-yl}-4-methyl- phenyl)- 3-trifluoromethyl- benzamide 4 170

¹H NMR (300 MHz, CDCl₃) δ 9.99 (s, 1H), 9.07 (s, 1H), 8.82 (d, 1H), 8.52(s, 1H), 7.84 (d, 1H), 7.79-7.70 (m, 3H), 7.64-7.54 (m, 2H), 7.45 (d,2H), 7.34 (d, 1H), 4.15- 4.04 (m, 1H), 3.90-3.80 (m, 5H), 3.35-3.10 (m,2H), 2.50-2.25 (m, 10H) MS m/z 645.2 (M + 1) 4-Trifluoromethyl-pyridine-2- carboxylic acid (4-methyl- 3-{2-[4-(4-methyl- piperazine-1-carbonyl)-phenyl- amino]-5-oxo- 7,8-dihydro-5H- pyrido[4,3-d]pyrimidin-6- yl}-phenyl)-amide 4 171

¹H NMR (300 MHz, CDCl₃) δ 9.65 (s, 1H), 9.08 (s, 1H), 8.26-8.10 (m, 2H),7.9-7.7 (m, 2H), 7.65-7.45 (m, 3H), 7.23 (d, 1H), 7.1 (d, 1H), 4.0-3.8(m, 2H), 3.40-3.05 (m, 10H), 2.9 (s, 3H), 2.34 (s, 3H) MS m/z 650.3(M + 1) N-(4-Chloro-3-{2- [3-methyl-4-(4- methyl-piperazin-1-yl)-phenyl- amino]-5-oxo-7,8- dihydro-5H-pyrido [4,3-d]pyrimidin-6-yl}-phenyl)-3- trifluoromethyl- benzamide 3 172

¹H NMR (300 MHz, CDCl₃) δ 9.7 (s, 1H), 9.1 (s, 1H), 8.26-8.10 (m, 2H),7.9-7.7 (m, 3H), 7.65-7.45 (m, 3H), 7.23 (d, 1H), 7.1 (d, 1H), 4.0-3.8(m, 2H), 3.40-3.05 (m, 10H), 2.34 (s, 3H) MS m/z 655.2 (M + 1)N-(4-Chloro- 3-{2-[4-(4-methyl- piperazin-1-yl)- phenylamino]-5-oxo-7,8-dihydro- 5H-pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-3-fluoro-5-trifluoromethyl- benzamide 3 173

¹H NMR (300 MHz, CDCl₃) δ 10.1 (s, 1H), 9.5 (s, 1H), 8.9 (d, 1H), 8.52(s, 1H), 7.84 (d, 1H), 7.79-7.70 (m, 3H), 7.64-7.54 (m, 2H), 7.45 (d,2H), 7.34 (d, 1H), 4.15-4.04 (m, 1H), 3.90- 3.80 (m, 5H), 3.35-3.10 (m,2H), 2.50-2.25 (m, 10H) N-(4-Methyl- 3-{2-[6-(4-methyl- piperazine-1-carbonyl)-pyridin- 3-ylamino]- 5-oxo-7,8- dihydro-5H-pyrido[4,3-d]pyrimidin- 6-yl}-phenyl)-3- trifluoromethyl- benzamide 4 174

¹H NMR (400 Mhz, CD3OD) 8.3-8.18 (m, 3H), 8.0-7.88 (d, 1H), 7.8-7.7 (m,2H), 7.6-7.4 (m, 4H), 7.1-6.9 (m, 2H), 4.18 (s, 2H), 3.5-3.4 (t, 2H),3.2-3.14 (t, 4H), 3.05-2.95 (t, 2H), 2.7- 2.6 (t, 4H), 2.38 (s, 3H). MSm/z 623.2 (M + 1) N-(4-Chloro- 3-{2-[4-(4-methyl- piperazin-1-yl)-phenylamino]- 7,8-dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl}- phenyl)-3-trifluoromethyl- benzamide 1 175

¹H NMR (300 MHz, DMSO-D₆) δ 8.75 (s, 1H), 8.34-8.24 (m, 2H), 8.0 (d,1H), 7.83- 7.56 (m, 5H), 7.32 (d, 1H), 6.92 (d, 2H), 4.45 (t, 2H),4.05-3.92 (m, 1H), 3.8-3.7 (m, 1H), 3.53 (q, 2H), 3.12-3.04 (m, 6H),2.5-2.4 (m, 4H), 2.2 (s, 3H) MS m/z 646.1 (M + 1) N-[3-(2-{4-[4-(2-Hydroxy-ethyl)- piperazin-1-yl]- phenylamino}-5- oxo-7,8-dihydro-5H-pyrido[4,3-d] pyrimidin-6-yl)- 4-methyl-phenyl]- 3-trifluoromethyl-benzamide 3 176

¹H NMR (300 MHz, CD3OD) δ 8.4-8.18 (m, 3H), 7.94-7.7 (m, 7H), 7.5-7.4(m, 2H), 4.22 (s, 2H), 3.5 (t, 2H), 3.12-3.04 (t, 2H), 2.92 (s, 3H) MSm/z 581.2 (M + 1) N-{4-Chloro-3-[2- (4-methyl- carbamoyl- phenylamino)-7,8-dihydro- 5H-pyrido[4,3-d] pyrimidin-6-yl]- phenyl}- -5-trifluoromethyl- benzamide 2 177

¹H NMR (300 MHz, CD3OD δ 10.6 (s, 1H), 9.9 (s, 1H), 8.4 (s, 1H),8.3-7.94 (m, 4H), 7.9-7.7 (m, 5H), 7.6-7.4 (m, 2H) 4.22 (s, 2H), 3.4 (t,2H), 3.0 (t, 2H), 2.8-2.7 (d, 3H) MS m/z 599.1 (M + 1) N-{4-Chloro-3-[2-(4-methyl- carbamoyl- phenylamino)-7,8- dihydro-5H-pyrido [4,3-d]pyri-midin-6-yl]- phenyl}-3-fluoro- 5-trifluoromethyl- benzamide 2 178

¹H NMR (300 MHz, CDCl₃) δ 9.15 (s, 1H), 9.04 (s, 1H), 8.25-8.10 (m, 2H),7.73 (d, 1H), 7.65-7.50 (m, 4H), 7.42-7.33 (m, 2H), 7.0 (dd, 3H),4.00-3.87 (m, 1H), 3.80-3.67 (m, 1H), 3.2-3.0 (m, 11H), 1.75 (s, 3H) MSm/z 602.2 (M + 1) N-{4-Methyl-3-[5- oxo-2-(4-piperazin-1-yl-phenylamino)- 7,8- dihydro-5H-pyrido [4,3-d]pyrimidin-6-yl]-phenyl}-3- trifluoromethyl- benzamide 3 179

¹H NMR (300 MHz, DMSO-D₆) δ 11.0 (s, 1H), 8.9 (s, 1H), 9.05 (d, 1H),8.42-8.36 (m, 2H), 8.25 (d, 1H), 8.15- 8.10 (m, 1H), 7.98 (d, 1H),7.90-7.82 (m, 2H), 7.80- 7.72 (m, 3H), 7.48 (d, 1H), 4.17 (s, 2H),3.04-2.96 (m, 2H), 2.76 (d, 3H), 2.5 (s, 3H) MS m/z 582.0 (M + 1)4-Trifluoromethyl- pyridine- 2-carboxylic acid {4-chloro-3-[2-(4-methylcarbamoyl- phenylamino)-7,8- dihydro-5H-pyrido [4,3-d]pyrimidin-6-yl]-phenyl}- amide 2 180

¹H NMR (300 MHz, CDCl₃) δ 9.13-9.00 (m, 2H), 8.22-8.10 (m, 2H), 7.75 (d,1H), 7.65-7.50 (m, 4H), 7.42-7.35 (m, 2H), 7.08 (d, 1H), 6.94 (d, 2H),4.04 (t, 3H), 3.80- 3.68 (m, 1H), 3.16-3.10 (m, 2H), 2.6-2.4 (m, 10H),2.3 (s, 3H), 2.05-1.92 (m, 2H), 1.8 (s, 3H). MS m/z 674.3 (M + 1)N-[4-Methyl- 3-(2-{4-[3-(4- methyl-piperazin-1- yl)-propoxy]-phenylamino}-5- oxo-7,8-dihydro- 5H-pyrido[4,3-d] pyrimidin-6-yl)-phenyl]-3- trifluoromethyl- benzamide 3 181

¹H NMR (400 MHz, CD₃OD) δ 8.9 (s, 1H), 8.30-8.20 (m, 2H), 8.05- 7.95 (d,2H), 7.95-7.9 (m, 1H), 7.8-7.65 (m, 4H), 7.65-7.55 (m, 1H), 7.1- 7.00(m, 2H), 4.35 (t, 2H), 4.1- 3.9 (s, 2H), 3.7- 3.6 (t, 2H), 3.5- 3.4 (bs,4H), 3.3-3.1 (m, 2H), 2.2-2.1 (m, 4H). N-(4-Chloro- 3-{5-oxo-2-[4-(2-pyrrolidin-1-yl- ethoxy)- phenylamino]- 7,8-dihydro-5H-py-rido[4,3-d] pyrimidin- 6-yl}-phenyl)-3- trifluoromethyl- benzamide 3 182

¹H NMR (300 MHz, CDCl₃) δ 9.1-9.00 (m, 2H), 8.3-8.10 (m, 2H), 7.75 (d,1H), 7.65-7.50 (m, 4H), 7.42-7.35 (m, 2H), 7.08 (d, 1H), 6.94 (d, 2H),4.04 (t, 3H), 3.80- 3.68 (m, 1H), 3.16-3.10 (m, 2H), 2.6-2.4 (m, 6H),2.3 (s, 3H), 2.05-1.92 (m, 2H) MS m/z 661.2 (M + 1) N-(4-Methyl-3-{2-[4- (3-morpholin-4-yl- propoxy)-phenyl- amino]-5-oxo-7,8-dihydro-5H- pyrido[4,3-d] pyrimidin- 6-yl}-phenyl)-3-trifluoromethyl- benzamide 3 183

¹H NMR (300 MHz, CD₃OD) δ: 8.26 (s, 1H), 8.19-8.12 (m, 1H), 7.98- 7.92(m ,1H), 7.79-7.74 (m, 1H), 7.72-7.61 (m, 3H), 7.55 (t, 1H), 7.45- 7.36(m, 2H), 7.34-7.25 (m, 2H), 4.11 (s, 2H), 3.4- 3.32 (m, 2H), 3.05 (t,2H), 2.42 (s, 3H) MS: Calculated: m/z 538.1 (M + 1)⁺. 3-[2-(4-Chloro-phenylamino)-7,8- dihydro-5H- pyrido[4,3- d]pyrimidin-6-yl]-4-methyl-N-(3-tri- fluoromethyl- phenyl)-benzamide 5 184

¹H NMR (400 MHz, DMSO-d₆) δ 10.0 (s, 1H), 9.1 (s, 1H), 8.8 (s, 1H), 8.75(s, 1H), 8.05 (s, 1H), 7.7-7.45 (m, 6H), 7.35-7.25 (m, 3H), 6.95- 6.85(d, 2H), 4-3.9 (t, 2H), 3.22-3.0 (m, 6H), 2.6-2.5 (m, 4H), 2.25 (s, 3H),MS: m/z 617.2.0 (M + 1), 1-(4-{2-[4-(4- Methyl- piperazin-1-yl)-phenylamino]-5- oxo-7,8-dihydro- 5H-pyrido[4,3- d]pyrimidin-6-yl}-phenyl)-3-(3- trifluoromethyl- phenyl)-urea 8 185

¹HNMR: [CDCl₃, 400 MHz] □ 9.6-9.4 (s, 1H), 9.2-9.0 (s, 1H), 8.3-8.04 (m,2H), 7.96- 7.84 (bs, 1H), 7.84-7.7 (d, 1H), 7.7-7.5 (m, 3H), 7.5- 7.38(m, 2H), 7.28-7.2 (d, 1H), 7.04-6.88 (d, 2H), 6.74-6.6 (bs, 1H) 4.5 (s,2H), 4-3.75 (m, 2H), 3.35-3 (m, 2H), 2.9-2.7 (m, 1H), 0.95-0.8 (m, 2H),0.7-0.55 (m, 2H). Mass: 651.00 = [M + 1]⁺ N-{4-Chloro-3-[2-(4-(cyclopropyl- carbamoylmethoxy) phenylamino)- 5-oxo-7,8-dihydro-5H-pyrido[4,3-d] pyrimidin- 6-yl]-phenyl}-3- trifluoromethyl- benzamide3 186

¹H NMR: [DMSO-d₆, 400 MHz] δ 10.7 (s, 1H), 10.2 (s, 1H), 8.82 (s, 1H),8.38-8.24 (m, 2H), 8.04- 7.92 (m, 2H), 7.88-7.78 (m, 2H), 7.78-7.7 (m,2H), 7.68-7.58 (d, 1H), 7.3-7.2 (d, 2H), 4.05-3.8 (m, 2H), 3.4 (s, 2H),3.25-3.05 (m, 2H), 2.45-2.1 (m, 11H), Mass: 650.00 = [M + 1]⁺N-(4-Chloro-3-{2- [4-(4-methyl-pipe- razin-1-ylmethyl)- phenylamino]-5-oxo-7,8-dihydro- 5H-pyrido[4,3-d] pyrimidin- 6-yl}-phenyl)-3-trifluoromethyl- benzamide 3

According to the present invention, pharmaceutically acceptable saltsare produced from acidic inorganic or organic compounds, or alkalineinorganic or organic compounds. As used herein, the phrase“pharmaceutically acceptable salt” refers to a salt that retains thebiological effectiveness of the free acids and bases of a specifiedcompound and that is not biologically or otherwise undesirable.

A desired salt may be prepared by any suitable method known in the art,including treatment of the free base with an inorganic acid, such ashydrochloric acid, hydrobromic acid, sulphuric acid, nitric acid,phosphoric acid, and the like, or with an organic acid, such as formicacid, acetic acid, maleic acid, succinic acid, mandelic acid, maleicacid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolicacid, salicylic acid; a pyranosidyl acid, such as glucuronic acid orgalacturonic acid; an alpha-hydroxy acid, such as citric acid ortartaric acid; an amino acid, such as aspartic acid or glutamic acid; anaromatic acid, such as benzoic acid or cinnamic acid; a sulfonic acid,such as methanesulfonic acid, p-toluenesulfonic acid or ethanesulfonicacid; or the like.

Generally, the salts are prepared by reacting the free base withstoichiometric amounts or with an excess of the desired salt forminginorganic or organic acid in a suitable solvent or various combinationsof solvents. For example, the free base can be dissolved in a mixedaqueous solution of the appropriate acid and the salt recovered bystandard techniques, for example, by evaporation of the solution.Alternatively, the free base can be charged into an organic solvent suchas a lower alkanol, symmetrical or asymmetrical ethers containing 2 to10 carbon atoms, an alkyl ester, or mixtures thereof, and the like, andthen it is treated with the appropriate acid to form the correspondingsalt. The salt is recovered by standard recovery techniques, forexample, by filtration of the desired salt from the mixture, or it canbe precipitated by the addition of a solvent in which the salt isinsoluble and recovered there from.

Examples of suitable inorganic and organic solvents for performing thevarious reactions include any inorganic or organic solvent that does notadversely affect the reactants or the resulting product, includinghalogenated solvents such as methylene chloride, chloroform, ethersolvents such as diethyl ether, and other solvents such astetrahydrofuran, dioxane, diglyme, cyclooctane, benzene or toluene,heptane, cyclohexane, aliphatic as well as cycloaliphatic and aromatichydrocarbon solvents, water, acidified aqueous solutions, mixed organicand inorganic solutions, ethyl acetate, propyl acetate and mixturesthereof.

Also encompassed by the present invention are salts formed from acidicprodrugs, such as phosphates, and alkaline inorganic or organiccompounds. Preferred inorganic cations comprised in the salts arelithium, sodium, potassium, rubidium, ammonium, calcium, magnesium, zincand manganese. Production of phosphate salts are described in e.g. G. R.Pettit et al. Anti-Cancer Drug Design 16 (2001) 185-193.

Salts of the present invention also include those formed from acidicprodrugs and organic amines, including, but not limited to, imidazoleand morpholine. Alkaline amino acid salts may also be used. The term“amino acids” designates, according to the invention, in particular the[alpha]-amino acids occurring in nature, but moreover also includestheir homologues, isomers and derivatives. Enantiomers can be mentionedas an example of isomers. Derivatives can be, for example, amino acidsprovided with protective groups. Preferred alkaline amino acid arearginine, ornithine, diaminobutyric acid, lysine or hydroxy lysine andespecially L-arginine, L-lysine or L-hydroxy lysine; an alkalinedipeptide or a pharmaceutically acceptable alkaline amino acid derivate.

The compounds of the present invention contain at least one chiralcentre and therefore may exist in different enantiomeric forms. Althoughparticularly preferred compounds are enantiomerically pure the scope ofthe present invention is intended to cover both enantiomers per se, aswell as mixtures of them in any ratio, such as racemic mixtures.

Enantiomerically pure compounds of the present invention may also beobtained from their racemates by crystallization of their addition saltswith chiral acids (D. L. Minor et al. J. Med. Chem. 37 (1994) 4317-4328;U.S. Pat. No. 4,349,472), or alternatively, may be isolated bypreparative HPLC using commercially available chiral phases. Otherroutes to the pure enantiomers of compounds of the present invention arethe use of asymmetric synthesis (M. J. Munchhof et al. J. Org. Chem. 60(1995) 7086-7087; R. P. Polniaszek et al. Tetrahedron Letters 28 (1987)4511-4514), by asymmetric transfer hydrogenation of the intermediateimines (II) or iminium salts (III) (N. Uematsu et al. J. Am. Chem. Soc.118 (1996) 4916-4917; G. Meuzelaar et al. Eur. J. Org. Chem. 1999,2315-2321), or by resolution of chiral diastereometric derivativesthereof, as known by those skilled in the art.

The invention also encompasses prodrugs of the compounds of theinvention. “Prodrug” means a compound which is convertible in vivo bymetabolic means (e.g. by hydrolysis, reduction or oxidation) to acompound of formula (I). For example an ester prodrug of a compound offormula I containing a hydroxyl group may be convertible by hydrolysisin vivo to the parent molecule. Suitable esters of compounds of formula(I) containing a hydroxyl group, are for example acetates, citrates,lactates, tartrates, malonates, oxalates, salicylates, propionates,succinates, fumarates, maleates, methylene-bis-β-hydroxynaphthoates,gestisates, isethionates, di-p-toluoyltartrates, methanesulphonates,ethanesulphonates, benzenesulphonates, p-toluenesulphonates,cyclohexylsulphamates and quinates. As another example an ester prodrugof a compound of formula I containing a carboxy group may be convertibleby hydrolysis in vivo to the parent molecule. (Examples of esterprodrugs are those described by F. J. Leinweber, Drug Metab. Res.,18:379, 1987).

The invention also encompasses chemical modifications of the parentcompounds to prolong their circulating lifetimes. Examples of suitablepoly(ethylene glycol) derivatives that possess this property aredescribed in e.g. US 2005171328 (NEKTAR THERAPEUTICS AL CORP) or U.S.Pat. No. 6,713,454 (NOBEX CORP).

The present invention also provides a pharmaceutical compositioncomprising the compound of the present invention and at least onepharmaceutically acceptable excipient, carrier or diluent.

A pharmaceutical composition of the invention is formulated to becompatible with its intended route of administration, which ispreferably the oral administration. For example the pharmaceuticalcompositions of the invention may be formulated for administration byinhalation, such as aerosols or dry powders; for oral administration,such in the form of tablets, capsules, gels, syrups, suspensions,solutions, powders or granules; for rectal or vaginal administration,such as suppositories; or for parenteral injection (includingin-travenous, subcutaneous, intramuscular, intravascular, or infusion)such as a sterile solution, suspension or emulsion.

The compounds of the present invention and their pharmaceuticallyacceptable salts, where applicable, may be administered in the form of apharmaceutical composition in which they are in association with apharmaceutically acceptable excipient, carrier or diluent, in order totreat any STAT3 induced disorders. As to the appropriate excipients,carriers or diluents, reference may be made to the standard literaturedescribing these, for example to chapter 25.2 of Vol. 5 of“Comprehensive Medicinal Chemistry”, Pergamon Press 1990, and to“Lexikon der Hilfsstoffe für Pharmazie, Kosmetik and angrenzendeGebiete”, by H. P. Fiedler, Editio Cantor, 2002 (in German).

The compounds of the present invention may also be entrapped inmicrocapsules prepared, for example, by coacervation techniques or byinterfacial polymerization, for example, hydroxymethylcellulose orgelatin-microcapsules and poly-(methylmethacylate) microcapsules,respectively, in colloidal drug delivery systems (for example,liposomes, albumin microspheres, microemulsions, nano-particles andnanocapsules) or in macroemulsions. Such techniques are disclosed inRemington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).

Sustained-release preparations may be prepared. Suitable examples ofsustained-release preparations include semi permeable matrices of solidhydrophobic polymers containing the compounds of the present invention,which matrices are in the form of shaped articles, e.g. films, ormicrocapsules. Examples of sustained-release matrices includepolyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate),or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919),copolymers of L-glutamic acid and [gamma]ethyl-L-glutamate,non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolicacid copolymers such as the LUPRON DEPOT™ (injectable microspherescomposed of lactic acid-glycolic acid copolymer and leuprolide acetate),and poly-D-(−)-3-hydroxybutyric acid.

The pharmaceutical compositions of the invention will preferablycomprise from 0.001 to 50% by weight of compound of the presentinvention.

The daily dose of the compounds of the present invention willnecessarily be varied depending upon the host treated, the particularroute of administration, and the severity and kind of the illness beingtreated. Accordingly the optimum dosage may be determined by thepractitioner who is treating any particular patient.

The pharmaceutical compositions can be included in a container, pack, ordispenser together with instructions for administration.

The compounds of the present invention have the unexpected advantage topresent either:

-   -   an inhibition for efficient STAT3 blockade following the        inhibition of c-Src and JAK2;

an inhibition of STAT3 phosphorylation by in-cell Western preferablyhaving an IC50≦500 nM, more preferably ≦400 nM, and even more preferably≦300 nM,

-   -   in an established xenograft models using A431 and A549 (STAT3        positive cell lines) an inhibition of growth (>60%) of        established tumors at a dose below MTD with a clear        dose-response (highest dose close to MTD) and an inhibition of        STAT3 phosphorylation in tumors.

The compounds of the invention represent compounds showing asurprisingly good compromise between these 3 criteria. Preferredcompounds of the invention are compounds that fulfill at least one,preferably at least two and ideally the three above-listed criteria.

Another advantage of the compounds of the present invention is their lowselectivity and inhibition towards JAK3 and/or TYK2. Preferably theinhibition of JAK3 and/or TYK2 is 200 fold less compared to theinhibition towards c-SRC, JAK2 and/or JAK1.

The Src family of kinases (“SFKs”) has multiple substrates that lead todiverse biologic effects including changes in proliferation, motility,invasion, survival and angiogenesis. The role of SFKs in the initiationand/or progression of cancer has been demonstrated in colon cancer,pancreatic cancer, breast cancer, non-small cell lung cancer (NSCLC),head and neck squamous cell carcinoma (HNSCC), prostate cancer, othersolid tumors, several hematologic malignancies, hepatic cancer, certainB-cell leukemias and lymphomas. Talamonti et al., J. Clin. Invest., 91,53 (1993); Lutz et al., Biochem. Biophys. Res. 243, 503 (1998); Rosen etal., J. Biol. Chem., 261, 13754 (1986); Bolen et al., Proc. Natl. Acad.Sci. USA, 84, 2251 (1987); Masaki et al., Hepatology, 27, 1257 (1998);Biscardi et al., Adv. Cancer Res., 76, 61 (1999); and Lynch et al.,Leukemia, 7, 1416 (1993). The methods and compositions described hereinmay be used in any one or more cancers or carcinoma disorders.

A “tyrosine kinase” is an enzyme that transfers a phosphate group fromATP to a tyrosine residue in a protein. Tyrosine kinases are a subgroupof the larger class of protein kinases. Fundamentally, a protein kinaseis an enzyme that modifies a protein by chemically adding phosphategroups to a hydroxyl or phenolic functional group. Such modificationoften results in a functional change to the target protein or substrateby altering the enzyme structure, activity, cellular location orassociation with other proteins. Chemically, the kinase removes aphosphate group from ATP and covalently attaches it to one of threeamino acids (serine, threonine or tyrosine) that have a free hydroxylgroup. Many kinases act on both serine and threonine, and certainothers, tyrosine. There are also a number of kinases that act on allthree of these amino acids.

Tyrosine kinases are divided into two groups: cytoplasmic proteins andtransmembrane receptor kinases. In humans, there are 32 cytoplasmicprotein tyrosine kinases and 48 receptor-linked protein-tyrosinekinases.

Generally, tyrosine kinases play critical roles in signaling betweencells. Basically, the activation of cell surface receptors (e.g., theepidermal growth factor (EGF) receptor) by extracellular ligands resultsin the activation of tyrosine kinases. Then, the tyrosine kinasegenerates phosphotyrosine residues in the cell. The phosphotyrosineresidue acts as a “beacon” and attracts signaling proteins to thereceptor via SH2 domains. Hence, one important aspect of the signalingmechanism of a tyrosine kinase is the recognition of the phosphotyrosineby SH2 domains (also referred to herein as Src homology domain 2 or Srchomology-2).

Generally, kinases are enzymes known to regulate the majority ofcellular pathways, especially pathways involved in signal transductionor the transmission of signals within a cell. Because protein kinaseshave profound effect on a cell, kinase activity is highly regulated.Kinases can be turned on or off by phosphorylation (sometimes by thekinase itself—cis-phosphorylation/autophosphorylation) and by binding toactivator proteins, inhibitor proteins or small molecules.

Deregulated kinase activity is a frequent cause of disease, particularlycancer where kinases regulate many aspect that control cell growth,movement and death. For example, neoplastic transformation in whichmultiple genetic defects such as translocation, mutations withinoncogenes and the like, have been implicated in the development ofleukemia. Many of these genetic defects have been identified as keycomponents of signaling pathways responsible for proliferation anddifferentiation. The Src family of kinases, “SFKs,” are also referred toas the transforming (sarcoma inducing) gene of Rous sarcoma virus. SFKsare cytoplasmic proteins with tyrosine-specific protein kinase activitythat associates with the cytoplasmic face of the plasma membrane.Silverman L., Sigal C. T., Resh M. D., Binding of pp[delta]Ov-src toMembranes: Evidence for Multiple Membrane Interactions, Biochem CellBiol 1992 70(10-11):1187-92. There are 9 Src kinases in the humangenome: v-Src, c-Src, Fyn, Yes, Fgr, Lyn, Hck, Lck, and Blk. Theseproteins are all closely related to each other and share the sameregulatory mechanism. Brickell, P. M, The p60c-src Family ofProtein-Tyrosine Kinases: Structure, Regulation, and Function, Crit. RevOncog. 1992; 3(4):401-46. More specifically, Src kinases are 52-62 kDproteins having six distinct functional domains: SH4 (src homology 4), aunique domain, SH3, SH2, SH1 and a C-terminal regulatory region. Brown,M. T., Cooper, J. A., Regulations, Substrates, and Functions of Src,Biochim. Biophys. Acta. 1996, 1287(2-3): 121-49.

The “Src kinases” (herein also referred to as: “Src family of kinases”“Src proteins” and “SFKs”) are normally kept off by an autoinhibitoryinteraction between the phosphotyrosine-binding module (SH2) that islocated within the protein before the catalytic kinase domain, and itsC-terminal phosphotyrosine (Tyr 527).

Of the various STAT pathways, STAT3 has been identified as a mediatorcell proliferation. Inhibition of SFKs does not durably inhibit STAT3.While the SFK inhibitor may initially inhibit STAT3, within a shortperiod of time, STAT3 subsequently re-activiates and is expressed.Johnson, F. M., Saigal, B, Talpaz, M. and Donate, N. J., Dasatin[iota]b(BMS-354825) Tyrosine Kinase Inhibitor Suppresses Invasion and InducesCell Cycle Arrest and Apoptosis of Head and Neck Squamous Cell Carcinomaand Non-Small Cell Lung Cancer Cells, Clin. Cancer Res. 11:6924-6932,2005.

The STAT (Signal Transducers and Activators of Transcription) proteinsare transcription factors specifically activated to regulate genetranscription when cells encounter cytokines and growth factors. STATproteins act as signal transducers in the cytoplasm and transcriptionactivators in the nucleus. Kisseleva T., Bhattacharya S., Braunstein J.,Schindler C. W., Signaling Through the JAKJSTAT Pathway, Recent Advancesand Future Challenges, Gene 285: 1-24 (2002). STAT proteins regulatemany aspects of cell growth, survival and differentiation. Quadros, M.R., Peruzzi, F., Kari, C, and Rodeck, U., Complex Regulation of SignalTransducers and Activators of Transcription 3 Activation in Normal andMalignant Keratinocytes, Cancer Res, 64: 3934-3939, 2004. The sevenmammalian STAT family members identified are: STAT1, STAT2, STAT3,STAT4, STAT5a, STAT5b and STAT6.

STAT3 can be activated by growth factor receptors, cytokine receptorsand non-receptor tyrosine kinases (Src or JAK family kinases). Asreported, STAT3 activation mediated by EGFR, EPO-R, and IL-6 R via c-Srcor JAK2.

The JAK-STAT pathway is negatively regulated on multiple levels. Proteintyrosine phosphatases remove phosphates from cytokine receptors as wellas activated STATs Hebenstreit D. et al. (2005) Drug News Perspect. Vol.18 (4), pages 243-249. More recently, identified Suppressors of CytokineSignaling (SOCS) inhibit STAT phosphorylation by binding and inhibitingJAKs or competing with STATs for phosphotyrosine binding sites oncytokine receptors. Krebs, L. et al. (2001) Stem Cells Vol. 19, pages378-387. STATs are also negatively regulated by Protein Inhibitors ofActivated STATs (PIAS), which act in the nucleus through severalmechanisms. Shuai, K. (2006) Vol. 16 (2), pages 196-202. For example,PIAS1 and PIAS3 inhibit transcriptional activation by STAT1 and STAT3respectively by binding and blocking access to the DNA sequences theyrecognize.

The JAK-STAT signaling pathway takes part in the regulation of cellularresponses to cytokines and growth factors. Employing Janus kinases(JAKs) and Signal Transducers and Activators of Transcription (STATs),the pathway transduces the signal carried by these extracellularpolypeptides to the cell nucleus, where activated STAT proteins modifygene expression. Although STATs were originally discovered as targets ofJanus kinases, it is now reported that certain stimuli can activate themindependent of JAKs. D W Leaman, S Pisharody, T W Flickinger, M ACommane, J Schlessinger, I M Kerr, D E Levy, and G R Stark Roles of JAKsin Activation of STATs and Stimulation of c-fos Gene Expression byEpidermal Growth Factor, Mol Cell Biol. 1996 16(1): 369-375. Thispathway plays a central role in principal cell fate decisions,regulating the processes of cell proliferation, differentiation andapoptosis.

Without being bound to theory, the compounds of the present inventionwere found to block STAT3 signalling pathway by inhibiting the upstreamactivators c-SRC and JAK2 involved in the activation of STAT3 byphosphorylation of the residue Tyrosine 705 of STAT3. The compounds ofthe present invention are also found to be efficient JAK1 inhibitors.

Thus the present invention provides compounds which simultaneouslyinhibit c-SRC, JAK2 and JAK1. The compounds of the present invention aremulti-target inhibitors of c-SRC, JAK2 and JAK1, and more preferablydual inhibitors c-SRC and JAK2.

STAT3 pathway is suggested to have a crucial role in selectivelyinducing and maintaining a procarcinogenic inflammatorymicroenvironment, both at the initiation of malignant transformation andduring cancer progression. Persistent activation of STAT3 mediates thepropagation of tumor-promoting inflammation and increases tumor cellproliferation, survival and invasion while suppressing anti-tumorimmunity (Hua Yu et al.; Nature Reviews, Cancer, Volume 9, November2009, p. 798).

The compounds of the invention for use in therapy are encompassedherein. Preferably the compounds of the invention are used in a methodfor treating diseases associated with activation of STAT3 pathway,through multi-target inhibition of c-SRC, JAK2 and JAK1, preferablythrough multi-target inhibition of c-SRC and JAK2.

Another object of the invention is the use of the compound or thepharmaceutical composition of the invention in the manufacture of amedicament for treating or preventing diseases associated withactivation of STAT3 pathway, through multi-target inhibition of c-SRC,JAK2 and JAK1, preferably through multi-target inhibition of c-SRC andJAK2.

The present invention further provides a method of treating diseasesassociated with activation of STAT3 pathway, through multi-targetinhibition of c-SRC, JAK2 and JAK1, preferably through multi-targetinhibition of c-SRC and JAK2, comprising administering to a subject inneed thereof a therapeutically effective amount of the compound of theinvention and/or the pharmaceutical composition of the invention.

Preferably the administration is oral, transdermal or parenteral.

Preferably diseases associated with activation of STAT3 pathway arecancer, auto-immune, bone related and hematological diseases.

The cancer is either related to blood tumours or solid tumours. Bloodtumours are multiple myeloma, leukaemias (HTLV-1-dependent,Erythroleukaemia, acute myelogenous leukaemia (AML), chronic myelogenousleukaemia (CML), large granular lymphocyte leukaemia (LGL)),myeloproliferative neoplasms and lymphomas (EBV-related/Burkitt's,mycosis fungoides, cutaneous T-cell lymphoma, non-Hodgkins lymphoma(NHL), anaplastic large-cell lymphoma (ALCL)). Solid tumours are breastcancer, head and neck cancer, melanoma, ovarian cancer, lung cancer,pancreatic cancer, colon cancer, uterine cancer, gastric cancer, renalcancer, bladder cancer, liver cancer and prostate cancer.

Alternatively diseases are associated with activation of c-SRC and/oractivation of JAK1 and/or JAK2.

According to another particular embodiment of the present invention,when cancer is breast cancer, head and neck cancer, melanoma, ovariancancer, lung cancer, pancreatic cancer, colon cancer, uterine cancer,gastric cancer, renal cancer, bladder cancer, liver cancer and prostatecancer, the preferred compound used in the method for treating saiddiseases is selected from the group comprising:

-   N-(4-Methyl-3-{2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-trifluoromethyl-benzamide-   5-{6-[2-Methyl-5-(3-trifluoromethyl-benzoylamino)-phenyl]-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-ylamino}-pyridine-2-carboxylic    acid cyclopropylamide-   4-Trifluoromethyl-pyridine-2-carboxylic acid    {4-chloro-3-[2-(4-methylcarbamoyl-phenylamino)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-phenyl}-amide    -   or a pharmaceutically acceptable salts thereof.

According to a particular embodiment of the present invention, whencancer is multiple myeloma, leukaemias, myeloproliferative neoplasms andlymphomas, the preferred compound used in the method for treating saiddiseases is selected from the group comprising:

-   N-(4-Chloro-3-{2-[3-methyl-4-(4-methyl-piperazin-1-yl)-phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-trifluoromethyl-benzamide-   N-{4-Chloro-3-[2-(4-cyclopropylcarbamoylmethoxy-phenylamino)-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-phenyl}-3-trifluoromethyl-benzamide    -   or a pharmaceutically acceptable salts thereof.

The above listed compounds have a very low distribution volume (Vd inml/kg) and therefore are more suitable for treating blood tumours sincesaid compounds do not penetrate or weakly penetrate into organs andtissues.

“Treatment” or “treating” refers to both therapeutic treatment andprophylactic or preventative measures. Those in need of treatmentinclude those already with the disorder as well as those in which thedisorder is to be prevented. Hence, the subject to be treated herein mayhave been diagnosed as having the disorder or may be predisposed orsusceptible to the disorder.

As used herein the terms “subject” or “patient” are well-recognized inthe art, and, are used interchangeably herein to refer to a mammal,including dog, cat, rat, mouse, monkey, cow, horse, goat, sheep, pig,camel, and, most preferably, a human. In some embodiments, the subjectis a subject in need of treatment or a subject with a disease ordisorder. However, in other embodiments, the subject can be a normalsubject or subject who has already undergone a standard cancer therapy,such as standard chemotherapy, standard radiotherapy, targeted therapyor surgery. The term does not denote a particular age or sex. Thus,adult and newborn subjects, whether male or female, are intended to becovered.

The term “therapeutically effective amount” refers to an amount of adrug effective to treat a disease or disorder in a subject. In the caseof cancer, the therapeutically effective amount of the drug may reducethe number of cancer cells; reduce the tumour size; inhibit (i.e., slowto some extent and preferably stop) cancer cell infiltration intoperipheral organs; inhibit (i.e., slow to some extent and preferablystop) tumour metastasis; inhibit, to some extent, tumour growth;inhibit, to some extent, tumour angiogenesis; inhibit, to some extent,in the case of a tumour of epithelial origin (carcinoma) the epithelialto mesenchymal transition; inhibit, to some extent, cancer stem cellsgrowth; increase, to some extent, the immune response against thetumour; and/or relieve to some extent one or more of the symptomsassociated with the cancer. To the extent the drug may prevent growthand/or kill existing cancer cells, it may be cytostatic and/orcytotoxic. The phrase “therapeutically effective amount” is used hereinto mean an amount sufficient to prevent, or preferably reduce by atleast about 30 percent, preferably by at least 50 percent, preferably byat least 70 percent, preferably by at least 80 percent, preferably by atleast 90 percent, a clinically significant change in the growth orprogression or mitotic activity of a target cellular mass, group ofcancer cells or tumour, or other feature of pathology.

Optionally the compounds of the present invention may be used againstcell proliferating diseases in combination with conventional treatmentssuch as irradiation and/or one or more chemotherapeutic agents such asActinomycin, Altretamine, Bleomycin, Busulphan, Capecitabine,Carboplatin, Carmustine, Chlorambucil, Cisplatin, Cladribine,Crisantaspase, Cyclophosphamid, Cytarabine, Dacarbazine, Daunorubicin,Doxorubicin, Epirubicin, Etoposide, Fludarabine, Fluorouracil,Gemcitabine, Idarubicin, Ifosfamide, Irinotecan, Lomustine, Melphalan,Mercaptopurine, Methotrexate, Mitomycin, Mitoxantrone, Oxaliplatin,Pentostatin, Procarbazine, Streptozocin, Taxol, Temozolomide, Thiotepa,Tioguanine/Thioguanine, Topotecan, Treosulfan, Vinblastine, Vincristine,Vindesine or Vinorelbine.

Optionally the compounds of the present invention may be used againstcell proliferating diseases in combination with other targetedtherapies, including other kinase inhibitors.

Those skilled in the art will appreciate that the invention describedherein is susceptible to variations and modifications other than thosespecifically described. It is to be understood that the inventionincludes all such variations and modifications without departing fromthe spirit or essential characteristics thereof. The invention alsoincludes all of the steps, features, compositions and compounds referredto or indicated in this specification, individually or collectively, andany and all combinations or any two or more of said steps or features.The present disclosure is therefore to be considered as in all aspectsillustrated and not restrictive, the scope of the invention beingindicated by the appended Claims, and all changes which come within themeaning and range of equivalency are intended to be embraced therein.

All publications, patent applications, patents, and other referencesmentioned herein are incorporated by reference in their entirety. Thepublications and applications discussed herein are provided solely fortheir disclosure prior to the filing date of the present application.Nothing herein is to be construed as an admission that the presentinvention is not entitled to antedate such publication by virtue ofprior invention. In addition, the materials, methods, and examples areillustrative only and are not intended to be limiting.

The foregoing description will be more fully understood with referenceto the following Examples. Such Examples, are, however, exemplary ofmethods of practicing the present invention and are not intended tolimit the scope of the invention.

EXAMPLES

The present invention is further exemplified, but not limited, by thefollowing examples that illustrate the preparation of compoundsaccording to the invention.

The following compounds serve as common building blocks for the generalsynthetic schemes:

1) 3-Dimethylaminomethylene-1-(2-methyl-5-nitro-phenyl)piperidin-4-one[4]

A mixture of 2,2′-Bis(diphenylphosphino)1,1′-binaphthyl [BINAP] (54.35mg, 0.085 mmol) and Palladium(II)acetate [Pd(OAc)₂] (6.95 mg, 0.028mmol) in dry toluene (3 ml) was stirred vigorously and nitrogen wasbubbled through the suspension for 30 minutes. To this,14-Dioxa-8-aza-spiro[4.5]-decane (100 mg, 0.699 mmol),2-Bromo-1-methyl-4-nitro-benzene (181.29 mg, 0.839 mmol) and dry cesiumcarbonate (683.5 mg, 2.097 mmol) was added. Nitrogen was bubbled throughfor another 30 minutes; the mixture was allowed to reflux overnight. Themixture was cooled, diluted with ethyl acetate, water was added and thelayers separated. The aqueous layer was extracted with ethyl acetate andthe two organic extracts were combined. The organics were washed withbrine, then dried (sodium sulfate), filtered and concentrated. Furtherpurification by silica gel chromatography using 5-10% ethylacetate/hexane as eluent provided8-(2-Methyl-5-nitro-phenyl)-1,4-dioxa-8-aza-spiro[4.5]decane [2] as ayellow solid [Yield:—193 mg, 82.7%].

To a solution of Methyl-5-nitro-phenyl)-1,4-dioxa-8-aza-spiro[4.5]decane[50 mg, 0.179 mmol] in THF (1 ml) was added, 1 ml of 10% H₂SO₄ (aq). Thereaction mixture was heated at 60° C. for 6 hours, and then partitionedbetween ethyl acetate and water. The aqueous layer was extracted twicefurther with ethyl acetate and combined organic fractions were washedwith water, brine then dried (sodium sulfate), filtered. The filtratewas concentrated to give desired compound i.e.,1-(2-Methyl-5-nitro-phenyl)-piperidin-4-one [3] as brown viscous liquid.[Yield: 37.5 mg, 89.2%] The compound obtained was used in next stepwithout further purification.

A solution of 1-(2-Methyl-5-nitro-phenyl)-piperidin-4-one [100 mg, 0.426mmol] in N,N-Dimethylformamide dimethyl acetal (DMA.DMF) [1 ml] washeated to reflux for 12 hrs. After cooling to room temperature, reactionmixture was concentrated under vacuum. The dark brown crude productobtained was further purified by silica gel chromatography using 30-60%ethyl acetate/hexane as eluent to obtain pure desired product i.e.,3-Dimethylaminomethylene-1-(2-methyl-5-nitro-phenyl)-piperidin-4-one [4]as orange solid [Yield: 76.2 mg, 62.02%]

¹H NMR (300 MHz, CDCl₃): δ 7.9 (m, 1H), 7.8 (d, 1H), 7.6 (s, 1H), 7.3(s, 1H), 4.2 (s, 2H), 3.2 (t, 2H), 3.1 (s, 6H), 2.6 (t, 2H), 2.4 (s, 3H)

2)3-Dimethylaminomethylene-1-(2-methyl-5-nitro-phenyl)-piperidine-2,4-dione[9]

A mixture of 2,2′-Bis(diphenylphosphino)1,1′-binaphthyl [BINAP] (54.35mg, 0.085 mmol) and Palladium(II)acetate [Pd(OAc)₂] (6.95 mg, 0.028mmol) in dry toluene (3 ml) was stirred vigorously and nitrogen wasbubbled through the suspension for 30 minutes. To this,3-Amino-propionic acid methyl ester (72.00 mg, 0.699 mmol),2-Bromo-1-methyl-4-nitrobenzene (181.29 mg, 0.839 mmol) and dry CesiumCarbonate (683.5 mg, 2.097 mmol) were added. Nitrogen was bubbledthrough for another 30 minutes; the mixture was allowed to refluxovernight. The mixture was cooled, diluted with ethylacetate, water wasadded and the layers separated. The aqueous layer was extracted withethyl acetate and the two organic extracts were combined. The organicswere washed with brine, then dried (sodium sulfate), filtered andconcentrated. Further purification by silica gel chromatography using5-10% ethyl acetate/hexane as eluent provided3-(2-Methyl-5-nitro-phenylamino)propionic acid methyl ester [5] as ayellow solid [Yield: 149.00 mg, 74.7%]

A solution of 3-(2-Methyl-5-nitro-phenylamino)propionic acid methylester (100 mg, 0.419 mmol] in 3 ml of mixed solvent [1:0.3:0.5THF/water/methanol] was treated with lithium hydroxide [15.00 mg, 0.628mmol]. The mixture was stirred at room temperature for 6 hours,concentrated and acidified [pH=2] with 2M HCl. The precipitate obtainedwas filtered, washed with water and dried under vacuum. The crudematerial was washed with ether, air dried overnight to give desiredproduct i.e., 3-(2-Methyl-5-nitro-phenyl amino)-propionic acid [6] asyellow colored solid. On the basis of mass recovery (91.2 mg) the yieldwas assumed to be quantitative.

To a solution of 3-(2-Methyl-5-nitro-phenylamino)-propionic acid [2.95gm, 13.2 mmol], 2,2-dimethyl-1,3-dioxane-4,6-dione (Meldrum's acid (2.08gm, 14.5 mmol), and 4-dimethylaminopyridine (DMAP) [2.42 gm, 198 mmol)in anhy. dichloromethane (70 ml) at 0° C. was added1-(3-dimethylaminopropyl)-3-ethylcarboiimide hydrochloride (EDC.HCl)[3.04 gm, 158 mmol), and the resulting solution was stirred overnight atroom temperature. The reaction mixture was washed (50 ml×4) with 5%potassium bisulfate (aq). The organic layer was dried over anhydroussodium sulfate, filtered and concentrated under vacuum, therebyaffording crude2,2-Dimethyl-5-[3-(2-methyl-5-nitro-phenylamino)propionyl]-[1,3]dioxane-4,6-dione(7), that was dissolved in 60 ml of ethyl acetate and refluxed for 4hrs, The reaction mixture was cooled to room temperature andconcentrated under vacuum. The crude product obtained was furtherpurified by silica gel chromatography (eluent: 2% methanol inchloroform) to give desired produced i.e.,1-(2-Methyl-5-nitro-phenyl)-piperidine-2,4-dione [8] as yellow solid[Yield: 1.91 gm, 58.6%]

A solution of 1-(2-Methyl-5-nitro-phenyl)-piperidine-2,4-dione [100 mg,0.402 mmol] in N,N-Dimethylformamide dimethyl acetal (DMA.DMF) [1 ml]was heated to reflux for 3 hrs. After cooling to room temperature,reaction mixture was concentrated under vacuum. The crude productobtained was further purified by silica gel chromatography using 30-60%ethylacetate/hexane as eluent to obtain pure desired product i.e.,3-Dimethylaminomethylene-1-(2-methyl-5-nitro-phenyl)-piperidine-2,4-dione[9] as dark red solid [Yield: 79.02 mg, 65.02%]

¹H NMR (300 MHz, CD₃OD) δ 8.2-7.9 (m, 3H), 7.5-7.34 (d, 1H), 4.0-3.8 (m,1H), 3.7-3.5 (m, 1H), 3.35 (s, 3H), 3.2 (s, 3H), 2.85-2.65 (m, 2H), 2.35(s, 3H)

3) 3-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-4-methyl-benzoic acid [12]

A mixture of 2,2′-Bis(diphenylphosphino)1,1′-binaphthyl[BINAP] (54.35mg, 0.085 mmol) and Palladium(II)acetate[Pd(OAc)₂] (6.95 mg, 0.028 mmol)in dry toluene (3 ml) was stirred vigorously and nitrogen was bubbledthrough the suspension for 30 minutes. To this,1,4-Dioxa-8-aza-spiro[4.5]-decane (100 mg, 0.699 mmol),3-Bromo-4-methyl-benzoic acid methyl ester (192.1 mg, 0.839 mmol) anddry Cesium Carbonate (683.5 mg, 2.09 mmol) was added. Nitrogen wasbubbled through for another 30 minutes; the mixture was allowed toreflux overnight. The mixture was cooled, diluted with ethylacetate,water was added and the layers separated. The aqueous layer wasextracted with ethyl acetate) and the two organic extracts werecombined. The organics were washed with brine, then dried (sodiumsulfate), filtered and concentrated. Further purification by silica gelchromatography using 5-10% ethyl acetate/Hexane as eluent provided3-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-4-methyl-benzoic acid methylester [11] as a yellow solid [150.5 mg, 61.7%]

A solution of 3-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-4-methyl-benzoicacid methyl ester (100 mg, 0.343 mmol] in 3 ml of mixed solvent[1:0.3:0.5 THF/water/methanol] was treated with lithium hydroxide (12.25mg, 0.514 mmol]. The reaction mixture was stirred at room temperaturefor 6 hours, concentrated and acidified [pH=4] with 2M HCl. Theprecipitate obtained was filtered, washed with water and dried undervacuum. The crude material was washed with ether, air dried overnight togive desired product. i.e.,3-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-4-methyl-benzoic acid [12] asyellow colored solid. On the basis of mass recovery (93.2 mg) the yieldwas assumed to be quantitative.

¹H NMR (300 MHz, DMSO-d₆) δ 12.8 (s, 1H), 7.58-7.50 (m, 2H), 7.3-7.24(m, 1H), 3.92 (s, 4H), 2.96-2.86 (t, 4H), 2.3 (s, 3H), 1.82-1.74 (m,2H),

The compounds in the present invention were prepared by generalsynthetic routes typified by examples 1-10. In Table 1, each compoundbears an example number corresponding to the particular synthetic routeby which it was prepared.

Example 1N-{3-[2-(4-Chloro-phenylamino)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-4-methyl-phenyl}-3-trifluoromethylbenzamide [13]

To a solution of3-Dimethylaminomethylene-1-(2-methyl-5-nitro-phenyl)-piperidin-4-one(12.06 gm, 41.7 mmol)[as prepared in reference 1] in Ethanol (250 ml)were added N-(4-Chloro-phenyl)-guanidine (28.32 gm, 167 mmol) and sodiumacetate (27.32 gm, 334 mmol) and solution was heated under reflux for 12hours. After cooling to room temperature, the reaction mixture wasdiluted with water, extracted with ethyl acetate. The organic layer waswashed with brine, dried [sodium sulfate] and concentrated under vacuum.The crude product obtained was further purified by silica gelchromatography using 5-10% Methanol/Chloroform as eluent to give puredesired product [11]i.e.,(4-Chloro-phenyl)-[6-(2-methyl-5-nitro-phenyl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-yl]-amineas yellow solid. (Yield: 2.50 gm, 15.2%)

To a solution of(4-Chloro-phenyl)-[6-(2-methyl-5-nitro-phenyl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-yl]amine(100 mg, 0.25 mmol) in the mixed solvent of THF (5 ml) and methanol (5ml) was added 10% Pd/C, and the reaction mixture was stirred for 12hours at room temperature under a hydrogen balloon. The reaction mixturewas filtered and the filtrate was concentrated under vacuum to give[6-(5-Amino-2-methyl-phenyl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-yl]-(4-chloro-phenyl)amine[12]as a off white solid [Yield: 81.5 mg, 88.2%]

To a solution of[6-(5-Amino-2-methyl-phenyl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-yl]-(4-chloro-phenyl)amine(54.87 mg, 0.15 mmol), 3-Trifluoromethylbenzoic acid (28.51 mg, 0.15mmol), and Diisipropylethylamine (DIPEA)(78 μl, 0.45 mmol) in DMF (7.5ml) was added 2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate (HATU) (59 mg, 0.15 mmol) and the reaction mixtureis stirred for 3 hour at room temperature. The reaction mixture wasdiluted with ethyl acetate and washed with 5% aqueous sodium bisulphatesolution, saturated aqueous sodium bicarbonate solution and brine. Theorganic layer is dried over sodium sulphate and concentrated underreduced pressure. The crude product obtained was purified by columnchromatography (SiO₂, 2-10% methanol in chloroform to give ofN-{3-[2-(4-chlorophenylamino)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-4-methyl-phenyl}-3-trifluoromethylbenzamide[13] as a pale yellow solid. [Yield: 60.6 mg, 75.2%]

¹H NMR (300 MHz, CDCl₃) δ 8.22 (s, 1H), 8.13 (s, 1H), 8.06 (d, 1H),7.84-7.78 (m, 1H), 7.75-7.7 (br s, 1H), 7.68-7.6 (m, 3H), 7.34-7.27 (m,2H), 7.24-7.19 (m, 1H), 7.15-7.08 (m, 1H), 4.06 (s, 2H), 3.35-3.26 (m,2H), 3.18-3.09 (m, 2H), 2.3 (s, 3H)

MS: m/z 538.1 (M+1)⁺

Example 2N-{4-Methyl-3-[2-(pyrimidin-5-ylamino)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-phenyl}-3-trifluoromethylbenzamide[17]

To a solution of3-Dimethylaminomethylene-1-(2-methyl-5-nitro-phenyl)-piperidin-4-one(12.06 gm, 41.7 mmol)[as prepared in reference 1] in Ethanol (250 ml)were added guanidine carbonate (30.17 gm, 167 mmol) and sodium acetate(27.40 gm, 334 mmol). The reaction mixture was heated under reflux for12 hours. After cooling to room temperature, the reaction mixture wasdiluted with water, extracted with ethyl acetate. The organic layer waswashed with brine, dried [sodium sulfate] and evaporated. The crudeproduct obtained was purified by silica gel chromatography using 2-5%Methanol/Chloroform as eluent to give pure desired product i.e.,6-(2-Methyl-5-nitro-phenyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-ylamine [14]as yellow solid. (Yield: 3.00 gm,25.2%)

A mixture of 4,5 Bis(diphenyl-phosphino)-9,9-dimethylxanthene[xanthopos](8.6 mg, 0.01488 mmol) andTris(dibenzylideneacetone)di-palladium(0)[Pd₂(dba)₃](6.81 mg, 0.00744mmol) in dry 1,4-dioxane (5 ml) was stirred vigorously and nitrogen wasbubbled through the suspension for 30 minutes. 5-Bromo pyrimidine (19.7mg, 0.1247 mmol),6-(2-Methyl-5-nitro-phenyl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-ylamine(35.57 mg, 0.1247 mmol) and dry cesium carbonate (100 mg, 0.31 mmol) wasadded. Nitrogen was bubbled through for another 30 minutes; the mixturewas allowed to reflux overnight. The mixture was cooled, diluted withethylacetate, water was added and the layers were separated. The aqueouslayer was extracted with ethyl acetate and the two organic extracts werecombined. The organics were washed with brine, then dried (sodiumsulfate), filtered and concentrated under vacuum. Further purificationby silica gel chromatography using 5-10% ethyl acetate/hexane as eluentprovided[6-(2-Methyl-5-nitro-phenyl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-yl]-pyrimidin-5-yl-amine[15] as a yellow solid [Yield: 9.75 mg, 21.7%]

To a solution of[6-(2-Methyl-5-nitro-phenyl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-yl]-pyrimidin-5-yl-amine(100 mg, 0.275 mmol] in the mixed solvent of THF (3 ml) and methanol (3ml) was added 10% Pd/C, and the reaction mixture was stirred for 12hours at room temperature under a hydrogen balloon. The reaction mixtureis filtered and the filtrate was concentrated under vacuum to give[6-(5-Amino-2-methyl-phenyl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-yl]-pyrimidin-5-yl-amine[16] (Yield: 84.2 mg 92.2%) as a off white solid.

To a solution of[6-(5-Amino-2-methyl-phenyl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-yl]-pyrimidin-5-yl-amine(50.0 mg, 0.15 mmol), 3-Trifluoromethylbenzoic acid (28.5 mg, 0.15mmol), and DIPEA (78 μl, 0.45 mmol) in DMF was added HATU (59 mg, 0.15mmol), and the reaction mixture was stirred for 3 hour at roomtemperature. The reaction mixture is diluted with ethyl acetate andwashed with 5% aqueous sodium bisulphate solution, saturated aqueoussodium bicarbonate solution and brine. The organic layer is dried oversodium sulphate and concentrated under reduced pressure. The crudeproduct obtained was purified by column chromatography (SiO₂, 2-10%methanol in chloroform) to give 49.75 mg (65.6%) ofN-{4-Methyl-3-[2-(pyrimidin-5-ylamino)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-phenyl}-3-trifluoromethylbenzamide [17] as a pale yellow solid.

¹H NMR (300 MHz, CDCl₃) δ 9.2-9.0 (m, 2H), 8.9 (s, 1H), 8.3-8 (m, 2H),7.95-7.5 (m, 4H), 7.3-77 (m, 4H), 4.1 (s, 2H), 3.4-3.2 (t, 2H),3.15-2.95 (t, 2H), 2.3 (s, 3H).

MS: m/z 506.4 (M+1)⁺

Example 3N-(4-Methyl-3-{2-[3-methyl-4-(4-methyl-piperazin-1-yl)-phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-trifluoromethyl-benzamide.[20]

To a solution of3-Dimethylaminomethylene-1-(2-methyl-5-nitro-phenyl)-piperidine-2,4-dione[9], (12.6 gm, 41.7 mmol)[as prepared in reference 2] in Ethanol (250ml) were N-[3-Methyl-4-(4-methyl-piperazin-1-yl)-phenyl]-guanidine (43.9gm 167 mmol) and sodium acetate (27.38 gm, 334 mmol) and solution washeated under reflux for 12 hours. After cooling to room temperature, thereaction mixture was diluted with water, extracted with ethyl acetate.The organic layer was washed with brine and dried over sodium sulfateand evaporated. The crude product obtained was purified by silica gelchromatography using 5-10% Methanol/Chloroform as eluent to give puredesired product i.e.,2-[3-methyl-4-(4-methyl-piperazin-1-yl)-phenylamino]-6-(2-methyl-5-nitro-phenyl)-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one[18] as solid. (Yield: 3.09 gm, 14.8%)

To a solution of2-[3-Methyl-4-(4-methyl-piperazin-1-yl)-phenylamino]-6-(2-methyl-5-nitro-phenyl)-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one(100 mg, 0.198 mmol) in the mixed solvent of THF (5 ml) and methanol (5ml) was added 10% Pd/C, and the reaction mixture was stirred for 12hours at room temperature under a hydrogen balloon. The reaction mixturewas filtered and the filtrate was concentrated under vacuum to give6-(5-Amino-2-methyl-phenyl)-2-[3-methyl-4-(4-methyl-piperazin-1-yl)-phenylamino]-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one[19] (Yield: 81.72 mg, 86.9%) as a off white solid.

To a solution of6-(5-Amino-2-methyl-phenyl)-2-[3-methyl-4-(4-methyl-piperazin-1-yl)-phenylamino]-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one(71.0 mg, 0.15 mmol), 3-Trifluoro-methylbenzoic acid (28.5 mg, 0.15mmol), and DIPEA (78 μl, 0.45 mmol) in DMF was added HATU (59 mg, 0.15mmol), and the reaction mixture was stirred for 3 hour at roomtemperature. The reaction mixture was diluted with ethyl acetate andwashed with 5% aqueous sodium bisulphate solution, saturated aqueoussodium bicarbonate solution and brine. The organic layer was dried oversodium sulphate and concentrated under reduced pressure. The crudeproduct obtained was purified by column chromatography (SiO₂, 2-10%methanol in chloroform) to give 71.7 mg (74.2%)N-(3-{2-[4-(2-Methoxy-4-methyl-piperazin-1-yl)-phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-4-methyl-phenyl)-3-trifluoromethyl-benzamide[20] as a pale yellow solid.

¹H NMR (300 MHz, CD₃OD) δ 8.76 (s, 1H), 8.25-8.04 (m, 3H), 8.06 (d, 1H),7.82-7.6 (m, 3H), 7.56-7.4 (m, 3H), 7.2-7.35 (d, 1H), 7.05-6.92 (d, 1H),4.1-3.92 (m, 1H), 3.1-2.9 (m, 6H), 2.6 (s, 3H), 2.25 (s, 3H), 2.15 (s,3H)

MS: m/z 630.5 (M+1)⁺,

Example 4N-(4-Methyl-3-{2-[4-(4-methyl-piperazine-1-carbonyl)-phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-trifluoromethylbenzamide[24]

To a solution of3-Dimethylaminomethylene-1-(2-methyl-5-nitro-phenyl)-piperidine-2,4-dione,(12.6 gm, 41.7 mmol)[as prepared in reference 2] in Ethanol (250 ml)were added guanidine carbonate (30.17 gm, 167 mmol) and sodium acetate(27.40 gm, 334 mmol) and solution was heated under reflux for 12 hours.After cooling to room temperature, the reaction mixture was diluted withwater, extracted with ethyl acetate. The organic layer was washed withbrine, dried [sodium sulfate] and evaporated. The crude product obtainedwas purified by silica gel chromatography using 2-5% methanol/chloroformas eluent to give pure desired product i.e.,2-Amino-6-(2-methyl-5-nitro-phenyl)-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one[21] as solid. [yield: 2.63 gm, 21.2%]

A mixture of 4,5-Bis(diphenylphos-phino)-9,9-dimethylxanthene(xanthopos) (8.6 mg, 0.0148 mmol) andTris(dibenzylideneacetone)dipalladium(0)[Pd₂(dba)₃] (6.81 mg, 0.0074mmol) in dry 1,4-dioxane (5 ml) was stirred vigorously and nitrogen wasbubbled through the suspension for 30 minutes.(4-Iodo-phenyl)-(4-methyl-piperazin-1-yl)-methanone (41.1 mg, 0.1247mmol),2-Amino-6-(2-methyl-5-nitro-phenyl)-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one(37.3 mg, 0.1247 mmol) and dry cesium carbonate (100 mg, 0.31 mmol) wasadded. Nitrogen was bubbled through for another 30 minutes; the mixturewas allowed to reflux overnight. The mixture was cooled, diluted withethylacetate, water was added and the layers were separated. The aqueouslayer was extracted with ethyl acetate and the two organic extracts werecombined. The organics were washed with brine, then dried (sodiumsulfate), filtered and concentrated. Silica gel chromatography using5-10% ethyl acetate/hexane as eluent provided6-(2-Methyl-5-nitro-phenyl)-2-[4-(4-methyl-piperazine-1-carbonyl)phenylamino]-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one[22] as a yellow solid [Yield: 12.3 mg, 19.7%]

To a solution of6-(2-Methyl-5-nitro-phenyl)-2-[4-(4-methyl-piperazine-1-carbonyl)phenylamino]-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one(100 mg, 0.199 mmol) in the mixed solvent of THF (3 ml) and methanol (3ml) was added 10% Pd/C, and the reaction mixture was stirred for 12hours at room temperature under a hydrogen balloon. The reaction mixturewas filtered and the filtrate was concentrated under vacuum to give6-(5-Amino-2-methyl-phenyl)-2-[4-(4-methyl-piperazine-1-carbonyl)-phenylamino]-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one[23] as a off white solid [Yield: 83.0 mg, 88.3%]

To a solution of6-(5-Amino-2-methyl-phenyl)-2-[4-(4-methyl-piperazine-1-carbonyl)phenylamino]-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one(70.7 mg, 0.15 mmol), 3-Trifluoromethyl benzoic acid (28.5 mg, 0.15mmol), and DIPEA (78 μl, 0.45 mmol) in DMF was added HATU (59 mg, 0.15mmol), and the reaction mixture was stirred for 3 hour at roomtemperature. The reaction mixture was diluted with ethylacetate andwashed with 5% aqueous sodium bisulphate solution, saturated aqueoussodium bicarbonate solution and brine. The organic layer was dried oversodium sulphate and concentrated under reduced pressure. The crudeproduct obtained was purified by column chromatography (SiO₂, 2-10%methanol in chloroform) to give 69.8 mg (72.3%) ofN-(4-Methyl-3-{2-[4-(4-methyl-piperazine-1-carbonyl)phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-trifluoromethyl-benzamide[24] as a pale yellow solid.

¹H NMR (300 MHz, CD₃OD) δ 8.9 (s, 1H), 8.25-8.4 (m, 2H), 8.06 (d, 1H),7.82-7.9 (m, 3H), 7.6-7.8 (m, 3H), 7.25-7.35 (dd, 3H), 4.05-4.15 (m,2H), 3.6-3.92 (m, 6H), 2.5 (m, 4H), 2.2-2.4 (m, 6H).

MS: m/z 644.30 (M+1)⁺,

Example 53-[2-(4-Chloro-phenylamino)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-4-methyl-N-(3-trifluoromethylphenyl)benzamide.[28]

To a solution of 3-Trifluoromethyl-phenylamine (24.1 mg, 0.15 mmol),3-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-4-methyl-benzoic acid [asprepared in reference 3] (41.5 mg, 0.15, and DIPEA (78 μl, 0.45 mmol) inDMF was added HATU (59 mg, 0.15 mmol), and the reaction mixture wasstirred for 3 hour at room temperature. The reaction mixture was dilutedwith ethyl acetate and washed with 5% aqueous sodium bisulphatesolution, saturated aqueous sodium bicarbonate solution and brine. Theorganic layer was dried over sodium sulphate and concentrated underreduced pressure. The crude product obtained was purified by columnchromatography (SiO₂, 2-10% methanol in chloroform) to give 43.1 mg(68.6%) of3-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-4-methyl-N-(3-trifluoromethyl-phenyl)-benzamide[25] as a pale yellow solid.

To a solution3-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-4-methyl-N-(3-trifluoromethyl-phenyl)-benzamide[100 mg, 0.237 mmol] in THF (2 ml) was added, 3 ml of 10% aqueous H₂SO₄.The reaction mixture was heated at 60° C. for 6 hours, then partitionedbetween ethylacetate and water. The aqueous layer was extracted twicefurther with ethyl acetate and combined organic fractions were washedwith water, brine then dried (sodium sulfate), filtered and concentratedto give desired compound i.e.,4-Methyl-3-(4-oxo-piperidin-1-yl)-N-(3-trifluoromethyl-phenyl)-benzamide[26] as brown viscous liquid. [Yield: 76.6 mg, 85.6%]. The compoundobtained was used in next step without further purification

A solution of4-Methyl-3-(4-oxo-piperidin-1-yl)-N-(3-trifluoromethyl-phenyl)-benzamide[100 mg, 0.2656 mmol] in DMA.DMF [1 ml] was heated to reflux for 3 hrs.After cooling to room temperature, reaction mixture was concentratedunder vacuum to give crude product. The crude product obtained wasfurther purified by silica gel chromatography using 30-60%ethylacetate/hexane as eluent to obtain pure desired product i.e.,3-(3-Dimethylaminomethylene-4-oxo-piperidin-1-yl)-4-methyl-N-(3-trifluoromethyl-phenyl)-benzamide[27]_as brown solid [Yield: 13.7 mg, 12.02%]

To a solution of3-(3-Dimethylamino-methylene-4-oxo-piperidin-1-yl)-4-methyl-N-(3-trifluoromethyl-phenyl)benzamide(17.9 gm, 41.7 mmol) in Ethanol (250 ml) were addedN-(4-Chloro-phenyl)-guanidine (28.32 gm, 167 mmol) and sodium acetate(27.32 gm, 334 mmol) and solution was heated under reflux for 12 hours.After cooling to room temperature, the reaction mixture was diluted withwater, extracted with ethyl acetate. The organic layer was washed withbrine and dried [sodium sulfate] and evaporated. The crude productobtained was purified by silica gel chromatography using 5-10%methanol/chloroform as eluent to give pure desired product i.e.,3-[2-(4-Chloro-phenylamino)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-4-methyl-N-(3-trifluoromethylphenyl)benzamide [28] as off white solid. [yield: 1.83 gm, 8.2%]

¹H NMR (300 MHz, CD₃OD) δ: 8.26 (s, 1H), 8.19-8.12 (m, 1H), 7.98-7.92(m, 1H), 7.79-7.74 (m, 1H), 7.72-7.61 (m, 3H), 7.55 (t, 1H), 7.45-7.36(m, 2H), 7.34-7.25 (m, 2H), 4.11 (s, 2H), 3.4-3.32 (m, 2H), 3.05 (t,2H), 2.42 (s, 3H)

MS: Calculated: m/z 538.1 (M+1)⁺.

Example 6 {6-[2-Methyl-5-(4-trifluoromethylpyrimidin-2-ylamino)-phenyl]-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl}-pyridin-4-amine[34]

A mixture of 2,2′-Bis(diphenylphosphino)1,1′-binaphthyl [BINAP] (54.35mg, 0.085 mmol) and Palladium(II)acetate [Pd(OAc)₂] (6.95 mg, 0.028mmol) in dry toluene (3 ml) was stirred vigorously and nitrogen wasbubbled through the suspension for 30 minutes. To this,14-Dioxa-8-aza-spiro[4.5]-decane (100 mg, 0.699 mmol),2-Bromo-1-methyl-4-nitro-benzene (181.29 mg, 0.839 mmol) and dry cesiumcarbonate (683.5 mg, 2.097 mmol) was added. Nitrogen was bubbled throughfor another 30 minutes; the mixture was allowed to reflux overnight. Themixture was cooled, diluted with ethyl acetate, water was added and thelayers separated. The aqueous layer was extracted with ethyl acetate andthe two organic extracts were combined. The organics were washed withbrine, then dried (sodium sulfate), filtered and concentrated. Furtherpurification by silica gel chromatography using 5-10% ethylacetate/hexane as eluent provided8-(2-Methyl-5-nitro-phenyl)-1,4-dioxa-8-aza-spiro[4.5]decane [2] as ayellow solid [Yield:—193 mg, 82.7%].

To a solution of8-(2-Methyl-5-nitro-phenyl)-1,4-dioxa-8-aza-spiro[4.5]decane (100 mg,0.278 mmol) in the mixed solvent of THF (3 ml) and methanol (3 ml) wasadded 10% Pd/C, and the reaction mixture was stirred for 12 hours atroom temperature under a hydrogen balloon. The reaction mixture isfiltered and the filtrate was concentrated under vacuum to give3-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-4-methyl-phenylamine [29] (Yield:84.9 mg, 95.2%) as a off white solid.

A mixture of 4,5 Bis(diphenyl-phosphino)-9,9-dimethylxanthene[xanthopos](8.6 mg, 0.01488 mmol) andTris(dibenzylideneacetone)di-palladium(0)[Pd₂(dba)₃](6.81 mg, 0.00744mmol) in dry 1,4-dioxane (5 ml) was stirred vigorously and nitrogen wasbubbled through the suspension for 30 minutes. 5-Bromo pyrimidine (19.7mg, 0.1247 mmol),3-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-4-methyl-phenylamine (30.96 mg,0.1247 mmol) and dry cesium carbonate (100 mg, 0.31 mmol) was added.Nitrogen was bubbled through for another 30 minutes; the mixture wasallowed to reflux overnight. The mixture was cooled, diluted withethylacetate, water was added and the layers were separated. The aqueouslayer was extracted with ethyl acetate and the two organic extracts werecombined. The organics were washed with brine, then dried (sodiumsulfate), filtered and concentrated under vacuum. Further purificationby silica gel chromatography using 5-10% ethyl acetate/hexane as eluent[3-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-4-methyl-phenyl]-(4-trifluoromethyl-pyrimidin-2-yl)-amine[30] as a pale yellow solid [Yield: 4.05 mg, 29.8%]

To a solution of[3-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-4-methyl-phenyl]-(4-trifluoromethyl-pyrimidin-2-yl)-amine[50 mg, 0.126 mmol] in THF (1 ml) was added, 1 ml of 10% H₂SO₄ (aq). Thereaction mixture was heated at 60° C. for 6 hours, and then partitionedbetween ethyl acetate and water. The aqueous layer was extracted twicefurther with ethyl acetate and combined organic fractions were washedwith water, brine then dried (sodium sulfate), filtered. The filtratewas concentrated to give desired compound i.e.,1-[2-Methyl-5-(4-trifluoromethyl-pyrimidin-2-ylamino)-phenyl]-piperidin-4-one[31] as viscous liquid. [Yield: 40.9 mg, 92.2%] The compound obtainedwas used in next step without further purification.

A solution of1-[2-Methyl-5-(4-trifluoromethyl-pyrimidin-2-ylamino)-phenyl]-piperidin-4-one[100 mg, 0.285 mmol] in N,N-Dimethylformamide dimethyl acetal (DMA.DMF)[1 ml] was heated to reflux for 12 hrs. After cooling to roomtemperature, reaction mixture was concentrated under vacuum. The darkbrown crude product obtained was further purified by silica gelchromatography using 30-60% ethyl acetate/hexane as eluent to obtainpure desired product i.e.,3-Dimethyl-aminomethylene-1-[2-methyl-5-(4-trifluoromethyl-pyrimidin-2-ylamino)-phenyl]-piperidin-4-one[32] as orange solid [Yield: 78.2 mg, 68.02%]

To a solution of3-Dimethyl-aminomethylene-1-[2-methyl-5-(4-trifluoromethyl-pyrimidin-2-ylamino)-phenyl]-piperidin-4-one(16.90 gm, 41.7 mmol) in Ethanol (250 ml) were added guanidine carbonate(30.17 gm, 167 mmol) and sodium acetate (27.40 gm, 334 mmol). Thereaction mixture was heated under reflux for 12 hours. After cooling toroom temperature, the reaction mixture was diluted with water, extractedwith ethyl acetate. The organic layer was washed with brine, dried[sodium sulfate] and evaporated. The crude product obtained was purifiedby silica gel chromatography using 2-5% Methanol/Chloroform as eluent togive pure desired product i.e.,6-[2-Methyl-5-(4-trifluoromethyl-pyrimidin-2-ylamino)-phenyl]-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-ylamine[33]as pale yellow solid. (Yield: 5.00 gm, 30.6%)

A mixture of 4,5 Bis(diphenyl-phosphino)-9,9-dimethylxanthene[xanthopos](8.6 mg, 0.01488 mmol) and Tris(dibenzylideneacetone)dipalladium(0)[Pd₂(dba)₃](6.81 mg, 0.00744 mmol) in dry 1,4-dioxane (5 ml)was stirred vigorously and nitrogen was bubbled through the suspensionfor 30 minutes. 5-Bromo pyridine (19.7 mg, 0.1247 mmol),6-[2-Methyl-5-(4-trifluoromethyl-pyrimidin-2-ylamino)-phenyl]-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-ylamine(50.02 mg, 0.1247 mmol) and dry cesium carbonate (100 mg, 0.31 mmol) wasadded. Nitrogen was bubbled through for another 30 minutes; the mixturewas allowed to reflux overnight. The mixture was cooled, diluted withethylacetate, water was added and the layers were separated. The aqueouslayer was extracted with ethyl acetate and the two organic extracts werecombined. The organics were washed with brine, then dried (sodiumsulfate), filtered and concentrated under vacuum. Further purificationby silica gel chromatography using 5-10% ethyl acetate/hexane as eluent{6-[2-Methyl-5-(4-trifluoromethyl-pyrimidin-2-ylamino)-phenyl]-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-yl}-pyridin-4-yl-amine[34] as a pale yellow solid [Yield: 17.75 mg, 29.8%]

¹H NMR (300 MHz, CDCl₃) δ 8.65-8.55 (m, 3H), 8.5-8.4 (br s, 1H), 8.35(s, 1H), 8.2-8.1 (m, 2H), 7.85-7.75 (br s, 1H), 7.4 (s, 1H), 7.25-7.15(m, 1H), 7.1-7.0 (m, 2H), 4.2 (s, 2H), 3.35 (t, 2H), 3.15 (t, 2H), 2.3(s, 3H)

MS m/z 478.9 (M+1)

Example 71-[4-Methyl-3-(2-methylamino-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)-phenyl]-3-(3-trifluoromethyl-phenyl)-urea[43]

To a solution of3-Dimethylaminomethylene-1-(2-methyl-5-nitrophenyl)piperidin-4-one(12.06 gm, 41.7 mmol)[as prepared in reference 1] in Ethanol (250 ml)were added N-Methyl guanidine (12.20 gm, 167 mmol) and sodium acetate(27.32 gm, 334 mmol) and solution was heated under reflux for 12 hours.After cooling to room temperature, the reaction mixture was diluted withwater, extracted with ethyl acetate. The organic layer was washed withbrine, dried [sodium sulfate] and concentrated under vacuum. The crudeproduct obtained was further purified by silica gel chromatography using5-10% Methanol/Chloroform as eluent to give pure desired product[41]i.e.,Methyl-[6-(2-methyl-5-nitro-phenyl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-yl]-amineas yellow solid. (Yield: 2.47 gm, 19.8%).

To a solution ofMethyl-[6-(2-methyl-5-nitro-phenyl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-yl]-amine(100 mg, 0.33 mmol) in the mixed solvent of THF (5 ml) and methanol (5ml) was added 10% Pd/C, and the reaction mixture was stirred for 12hours at room temperature under a hydrogen balloon. The reaction mixturewas filtered and the filtrate was concentrated under vacuum to[6-(5-Amino-2-methyl-phenyl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-yl]-methyl-amine[42]as a off white solid [Yield: 84.0 mg, 93.4%].

To a clear stirred solution of[6-(5-Amino-2-methyl-phenyl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-yl]-methyl-amine(75 mg, 0.278 mmol) in the THF (1.5 ml) was added1-Isocyanato-3-trifluoromethylbenzene (57.3 mg, 0.306 mmol) all at once,and the reaction mixture was allowed to stirred for 3 hours at roomtemperature. After 3 hours, the reaction mixture was diluted with water,extracted with ethyl acetate. The organic layer was given a brine wash,dried over sodium sulphate and concentrated to dryness to get stickymass which was given a hexane wash to get 83.4 mg of1-[4-Methyl-3-(2-methylamino-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)-phenyl]-3-(3-trifluoromethyl-phenyl)-urea[43] [Yield 65.6%] as light brown colored solid. ¹H NMR (300 MHz, CDCl₃)δ 7.98 (s, 1H), 7.6-7.06 (m, 8H), 6.84 (d, 1H), 5.1-5.0 (m, 1H), 3.85(s, 2H), 3.2-2.8 (m, 7H), 2.22 (s, 3H)

MS m/z 457.1 (M+1)

Example 81-(4-Methyl-3-{2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-(3-trifluoromethylphenyl)urea [46]

To a solution of3-Dimethylaminomethylene-1-(2-methyl-5-nitro-phenyl)-piperidine-2,4-dione(12.6 gm, 41.7 mmol)[as prepared in reference 2] in Ethanol (250 ml)were N-[4-(4-Methyl-piperazin-1-yl)-phenyl]-guanidine (38.9 gm, 167mmol) and sodium acetate (27.38 gm, 334 mmol) and solution was heatedunder reflux for 12 hours. After cooling to room temperature, thereaction mixture was diluted with water, extracted with ethyl acetate.The organic layer was washed with brine and dried over sodium sulfateand evaporated. The crude product obtained was purified by silica gelchromatography using 5-10% Methanol/Chloroform as eluent to give puredesired product i.e.,6-(2-Methyl-5-nitro-phenyl)-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one[44] as solid. (Yield: 4.30 gm, 21.9%).

To a solution of6-(2-Methyl-5-nitro-phenyl)-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one(100 mg, 0.211 mmol) in the mixed solvent of THF (5 ml) and methanol (5ml) was added 10% Pd/C, and the reaction mixture was stirred for 12hours at room temperature under a hydrogen balloon. The reaction mixturewas filtered and the filtrate was concentrated under vacuum to give6-(5-Amino-2-methyl-phenyl)-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one[45] (Yield: 86.45 mg, 92.3%) as a white solid.

To a clear stirred solution of6-(5-Amino-2-methyl-phenyl)-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one(75 mg, 0.169 mmol) in the THF (1.5 ml) was added1-Isocyanato-3-trifluoro-methyl-benzene (34.7 mg, 0.186 mmol) all atonce, and the reaction mixture was allowed to stirred for 3 hours atroom temperature. After 3 hours, the reaction mixture was diluted withwater, extracted with ethyl acetate. The organic layer was given a brinewash, dried over sodium sulphate and concentrated to dryness to getsticky mass which was given a hexane wash to get 56.7 mg of1-(4-Methyl-3-{2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-(3-trifluoromethyl-phenyl)-urea[Yield 53.2%] as light brown colored solid.

¹H NMR (300 MHz, CDCl₃) δ 9.0 (s, 1H), 7.7-6.6 (m, 11H), 8.2-7.7 (m,3H), 4.2-3.7 (m, 2H), 3.5-2.8 (m, 10H), 2.2-1.9 (m, 6H)

MS m/z 631.2 (M+1)

Example 9 Butane-1-sulfonic acid(4-methyl-3-{2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}phenyl)amide[49]

To a solution of3-Dimethylaminomethylene-1-(2-methyl-5-nitrophenyl)-piperidin-4-one(12.06 gm, 41.7 mmol)[as prepared in reference 1] in Ethanol (250 ml)were added N-[4-(4-Methyl-piperazin-1-yl)-phenyl]-guanidine (38.9 gm,167 mmol) and sodium acetate (27.32 gm, 334 mmol) and solution washeated under reflux for 12 hours. After cooling to room temperature, thereaction mixture was diluted with water, extracted with ethyl acetate.The organic layer was washed with brine, dried [sodium sulfate] andconcentrated under vacuum. The crude product obtained was furtherpurified by silica gel chromatography using 5-10% Methanol/Chloroform aseluent to give pure desired product [47]i.e.,[6-(2-Methyl-5-nitro-phenyl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-yl]-[4-(4-methyl-piperazin-1-yl)-phenyl]-amineas yellow solid. (Yield: 3.65 gm, 19.0%).

To a solution of[6-(2-Methyl-5-nitro-phenyl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-yl]-[4-(4-methyl-piperazin-1-yl)-phenyl]-amine(100 mg, 0.217 mmol) in the mixed solvent of THF (5 ml) and methanol (5ml) was added 10% Pd/C, and the reaction mixture was stirred for 12hours at room temperature under a hydrogen balloon. The reaction mixturewas filtered and the filtrate was concentrated under vacuum to[6-(5-Amino-2-methyl-phenyl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-yl]-[4-(4-methyl-piperazin-1-yl)-phenyl]-amine[48] as a off white solid [Yield: 83.7 mg, 89.6%].

To a solution[6-(5-Amino-2-methyl-phenyl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-yl]-[4-(4-methyl-piperazin-1-yl)-phenyl]-amine(50.0 mg, 0.116 mmol) in Pyridine (1 ml) at 0° C. was addedButane-1-sulfonyl chloride (21.3 mg, 0.139 mmol) dropwise The reactionmixture was stirred for 15 minutes at 0° C. and then allowed to attainroom temperature. It was then further stirred for 3 hours at roomtemperature. The reaction mixture was concentrated under vacuum. Thereaction mass was then, diluted with water and extracted withdichloromethane. The dichloromethane layer was washed with water, thenwith brine solution. The organic layer is dried over sodium sulphate andconcentrated under reduced pressure. The crude product obtained waspurified by column chromatography (SiO₂, 2-10% methanol in chloroform)to give 50.4 mg (78.9%) Butane-1-sulfonic acid(4-methyl-3-{2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-amide[49] as off white solid. ¹H NMR (300 MHz, CDCl₃) δ 8.15 (s, 1H), 7.50(d, 2H), 7.19 (d, 1H), 7.00-6.80 (m, 5H), 6.60-6.40 (m, 1H), 4.00 (s,2H), 3.30-2.95 (m, 10H), 2.60 (t, 4H), 2.38 (s, 3H), 2.30 (s, 3H),1.85-1.75 (m, 2H), 1.50-1.36 (m, 2H), 1.25 (s, 2H),

MS m/z 550.2 (M+1)

Example 106-[5-(Benzooxazol-2-ylamino)-2-methylphenyl]-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one[54]

To a clear solution of6-(5-Amino-2-methyl-phenyl)-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one(75 mg, 0.169 mmol) in the DCM (5 ml) was addedDi(2-pyridyl)thionocarbonate (47 mg, 0.203 mmol) all at once, and thereaction mixture was allowed to stirred for 3 hours at room temperature.After 3 hours, the reaction mixture was diluted with water, extractedwith ethyl acetate. The organic layer was given a brine wash, dried oversodium sulphate and concentrated to dryness to get sticky mass which wasgiven a hexane wash to get 70.3 mg of6-(5-Isothiocyanato-2-methyl-phenyl)-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one[53][Yield: 85.6%] as light brown coloured. To a solution of6-(5-Isothiocyanato-2-methyl-phenyl)-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one(50.0 mg, 0.089 mmol), and 2-Amino-phenol (9.73 mg, 0.089 mmol) in THF(5 ml) was added EDC.HCl (25.6 mg, 0.133 mmol), and the reaction mixturewas refluxed for 12 hour under nitrogen atmosphere. After 12 hrs, thereaction mass was concentrated to dryness to get crude compound. Thecrude obtained was subjected to preparative HPLC. The desired compoundi.e.,6-[5-(Benzooxazol-2-ylamino)-2-methyl-phenyl]-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-onewas obtained as brown solid [54][Yield: 57.7 mg, 63.2%]

¹H NMR (300 MHz, DMSO-D₆) δ 10.7 (s, 1H), 8.8 (s, 1H), 7.7-7.0 (m, 10H),6.95-6.85 (d, 2H), 4.1-3.95 (m, 1H), 3.85-8.7 (m, 1H), 3.3-3.0 (m, 6H),2.5-2.4 (m, 4H), 2.24 (s, 3H), 2.15 (s, 3H)

MS m/z 561.2 (M+1)

Example 116-(5-(isoquinolin-1-ylamino)-2-methylphenyl)-2-(4-(4-methylpiperazin-1-yl)phenylamino)-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one

A mixture of 2,2′-Bis(diphenylphosphino)1,1′-binaphthyl [BINAP] (28.00mg, 0.0451 mmol) and Palladium(II)acetate [Pd(OAc)2] (5.00 mg, 0.022mmol) in dry toluene (3 ml) was stirred vigorously and nitrogen wasbubbled through the suspension for 30 minutes. To this,6-(5-amino-2-methylphenyl)-2-(4-(4-methylpiperazin-1-yl)phenylamino)-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one[45](200 mg, 0.451 mmol), 1-bromoisoquinoline (112.60 mg, 0.541 mmol)and dry cesium carbonate (443.0 mg, 1.352 mmol) was added. Nitrogen wasbubbled through for another 30 minutes; the mixture was allowed to 15reflux overnight. The mixture was cooled, diluted with ethyl acetate,water was added and the layers separated. The aqueous layer wasextracted with ethyl acetate and the two organic extracts were combined.The organics were washed with brine, then dried (sodiumsulfate),filtered and concentrated. Further purification by silica gelchromatography using 5-10% ethyl acetate/hexane as eluent provided6-(5-(isoquinolin-1-ylamino)-2-methylphenyl)-2-(4-(4-methylpiperazin-1-yl)phenylamino)-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one[60] as a yellow solid [Yield:—223 mg, 87.0%].

Example 12 Pharmacological Data

c-Src and Jak 2 Kinase Assays:

Compounds were screened in the TR-FRET assay for JAK2 and c-Src kinaseinhibition. Ultra light poly GT (Perkin Elmer) was used as the substratefor JAK2 and c-Src with the ATP concentration of 10 μM and 50 μM,respectively. The Eu-labelled anti-phospho tyrosine antibody (PerkinElmer) was added at 1 nM and the fluorescence emission at 615 nm and 665nm was measured with an excitation wavelength of 340 nm. The ratio of665 to 615 nm is proportional to substrate phosphorylation and kinaseactivity. The dose-response curve fitting was done using GraphPad Prismsoftware.

In-Cell-Western Blot Assay for pStat3 (ICW):

A431 cells were seeded onto a 96-well micro plate. After overnight serumstarvation cells were incubated with compounds for 2 hrs. Cells werefixed with 4% paraformaldehyde in PBS and then permeabilized with 0.1%Triton X-100 in PBS (PBST). Cells were blocked with 5% BSA in PBST for 2hrs, followed by overnight incubation with phospho Stat3 antibody. Cellswere washed and incubated with europium-labeled anti-rabbit secondaryantibody for 2 hrs. After washing enhancement solution was added to thewells. The micro-plate was read on the Victor instrument at the Europiumsetting. The Hoechst readings were used to normalize for cell number.IC₅₀ values were calculated with the normalized europium values usingGraphpad Prism.

Cell Viability Assay (XTT Assay):

Mda-Mb-231 or A549 cells were seeded onto a 96-well micro plate. Nextday compounds were added to cells and incubated for 72 hrs. Compoundtreatment was done in triplicates. After 72 hrs cell culture media wasaspirated from the wells and XTT working solution was added and plateswere incubated for 2-5 hrs. The absorbance of the samples was measuredwith a spectrophotometer at a wavelength of 465 nM. EC₅₀ values werecalculated using Graphpad Prism. Tumor cell lines used in the examplesof the present invention were procured from ATCC. Description of thecell lines is included in the following table:

Source and hyperlink to Cell line Origin details B16F10 Mouse melanomaATCC A549 Human lung carcinoma ATCC A431 Human epidermoid carcinoma ATCCMda-Mb-231 Human breast carcinoma ATCC

Abbreviations:

IP Intraperitoneal(ly) IV Intravenous(ly) MTV Mean Tumor Volume NoNumber of NS Not Significant S Significant SA Sacrificed SCSubcutaneous(ly) V Volume Vs Versus HPC Hydroxypropylcyclodextrine PBSPhosphate buffered saline MPK mg per Kg body weight MTD MaximumTolerated Dose TGI Tumor growth inhibition PD Pharmaco Dynamic ATD AcuteToxicity Dose N/D Not determined

Results

Table 2 and 4 evidence that the compounds of the present inventionpresent a dual inhibition activity against c-SRC and JAK kinases (JAK2and JAK1) and therefore comply with the requirements of the presentinvention. Table 2 also shows the in vitro inhibition activity of cellgrowth in A431, A549 and MDA-MB-231 cancer cell lines as well as aninhibition activity of STAT3 phosphorylation in A431 cancer cell line.

Table 3 shows the activity of Dasatinib (a c-SRC inhibitor) and TG101348(a highly selective JAK2 inhibitor). It can be concluded that thesecompounds are not dual inhibitors. In addition, the inhibitory activityof STAT3 phosphorylation is less efficient with these compounds comparedto the compounds according to the present invention.

TABLE 2 JAK2 c-SRC MDA- % inhibition JAK2 % inhibition c-SRC MB-231 A549A431 pSTAT3 at IC50 at IC50 EC50 EC50 EC50 inhibition Compound No 100 nM1 μM (nM) 100 nM 1 μM (nM) (μM) (μM) (μM) (nM) 83 32 4 0.305 — 0.240 24076 61 30 2.15 — 0.135 130 86 45 28 0.53 0.078 0.57 580 92 7 2 0.005 —0.026 26 94 19 2 0.05 — 0.180 160 98 7 1 0.05 — 0.061 60 99 14 6 0.12 —0.29 300 106 85 98 18 99 100 2 0.31 — 0.22 220 107 72 94 40 93 98 1 0.61— 0.12 120 108 89 98 12 98 100 1 2.6 — — 75 83 97 19 4.67 1.06 117 18 8096 0.66 0.025 0.33 340 119 8 95 98 0.38 280 120 36 94 95 2.5 123 9 30.83 190 131 40 74 90 0.88 — — 132 3 5 0.041 0.047 — 480 146 5 6 0.37350 147 88 93 21 67 90 — 0.72 — — 148 94 96 5 99 99 2.4 0.034 — — 270155 18 2 1.2 — — 162 92 97 6 73 81 27 1.38 1.14 0.60 350 164 68 91 46 7079 26 165 74 93 54 93 98 16 0.44 — 0.32 257 166 74 93 48 60 87 27 167 9597 5.3 97 98 27 283 170 64 93 70 26 58 — 171 92 97 19 74 87 20 1.30 2.10— 471 172 94 97 9 66 72 1.84 — — 174 94 97 8.8 95 98 — 161 176 89 94 1587 96 13 0.33 — — 177 84 94 10 86 96 20 0.12 — — 290 178 91 92 7 77 9017 1.75 — — 150 179 81 92 6.4 79 93 15 0.90 — — 280 180 67 91 66 87 1.621.48 1.07 140 181 85 93 53 77 3.34 2.54 1.3 182 55 85 51 80 2.76 1.085.07 7 83 16 3.60 3.40 1.45 450 17 3 2 0.044 0.01 0.092 150 45 15 101.83 1.07 1.4 220 137 28 7 0.074 0.426 0.67 670 58 44 19 3.82 — — 77 8096 17 4.92 — 0.512 510 153 4 98 99 0.61 160 15 66

TABLE 3 JAK2 c-SRC % inhibition JAK2 % inhibition c-SRC MDA-MB-231 A549A431 pSTAT3 at IC50 at IC50 EC50 EC50 IC50 inhibition Compound 100 nM 1μM (nM) 100 nM 1 μM (nM) (μM) (μM) (μM) (nM) Dasatinib 55 5 0.044 >101057 TG101348 2 77 0.68 1.2 >10000

TABLE 4 JAK1 JAK1 % inhibition at IC50 Compound No. 100 nM 1 μM (nM) 17912 171 61 84 117 24 45 56 82 116 17 85 89 15 49 73 18 82 89 23 84 88 2558 96 26 57 79 28 66 79 9 58 85

Anti-Tumour Activity in B16F10 Metastasis and Survival Model:

IV injection of 0.1×10⁶ B16F10 tumor cells in the tail vain of 60 maleC57B16 mice. Randomization of mice one day after tumor cell injectioninto 4 groups of 15 mice. Out of 15, 6 mice were sacrificed on 14^(th)day for counting metastatic foci on lungs. Rest 9 mice were dosedcontinuously till morbidity/mortality for recording survival.

Formulation: 20% HPC, 2% ethanol solution in PBS for the compound No. 45

-   -   Normal saline for Taxol®        Dosing route: Oral for the compound No. 45 and i.p. for Taxol®        Dose Volume: 10 mL/Kg body weight        Dosing schedule: Once daily for 14 consecutive days (Q1Dx14) for        metastasis study and once daily continuously till        mortality/morbidity for survival study

Dosage:

-   -   Group1: Vehicle Control-0 MPK (mg/kg) of the compound No. 45    -   Group2: 5 MPK of Taxol®    -   Group3: 30 MPK of the compound No. 45    -   Group4: 100 MPK of the compound No. 45        Recording of body weight of animals everyday        Observation for clinical signs, morbidity and mortality—twice        everyday        Termination of mice at T_(max) (0.75 hrs) on the day of last        dose        Metastatic foci on the lungs were counted        Observations during necropsy: Gross pathology in internal organs        such as lung, liver, kidney, spleen and intestines,        histopathology of these organs in case gross pathology is        observed. Plasma collected for drug concentration estimation and        whole blood was collected to isolate PBMCs to determine pStat3        inhibition by flow cytometry as PD readout.        Similar study was done with the compounds No. 117 ad No. 179.

Results:

FIGS. 1 and 2 show a better inhibition activity of the compounds of thepresent invention compared to Taxol® (paclitaxel; a standard drug usedin the B16-F10 model)). Although paclitaxel does not have c-SRC or JAKkinases inhibition activity, paclitaxel modulates STAT3 activity throughloss of STAT3 phosphorylation (paclitaxel disrupts the interaction ofSTAT3 with tubulin).

Anti-Tumour Activity in A549 Xenograft Model: EXPT. 1

Sub-cutaneous (SC) injection of 5×10⁶ A549 tumor cells on the left flankof 48 female athymic nude mice. Randomization of mice 14 days aftertumor cell injection into 6 groups of 8 mice each with a mean tumorvolume of 134±5 mm3.

Formulation: 20% HPC, 2% ethanol solution in PBS for the compounds No.45, 117 and 179.

-   -   Normal saline for Erlotinib®        Dosing route: Oral for the compounds No. 45, 117 and 179, and        Erlotinib®        Dose Volume: 10 mL/Kg body weight        Dosing schedule: Once daily for 14 consecutive days (Q1Dx14)

Dosage:

-   -   Group1. Vehicle control    -   Group2. Erlotinib®—100 MPK    -   Group3. Compound No. 45—10 MPK    -   Group4. Compound No. 45—30 MPK    -   Group5. Compound No. 45—100 MPK    -   Group6. Compound No. 117—30 MPK    -   Group7. Compound No. 117—100 MPK    -   Group8. Compound No. 179—10 MPK    -   Group9. Compound No. 179—30 MPK        Recording of body weight of animals everyday        Tumor volumes recorded three times every week        Observation for clinical signs, morbidity and mortality—twice        everyday        Termination of mice at T_(max) (0.75 hrs) on the day of last        dose        Observations during necropsy: Gross pathology in internal organs        such as lung, liver, kidney, spleen and intestines,        histopathology of these organs in case gross pathology is        observed. Plasma collected for drug concentration estimation and        whole blood was collected to isolate PBMCs (peripheral blood        monocytes) to determine pStat3 inhibition by flow cytometry as        PD readout. Tumors were snap frozen in liquid nitrogen and        stored at −80° C. to estimate pStat3 by flow cytometry as PD        readout

EXPT. 2

SC injection of 5×10⁶ A549 tumor cells on the left flank of 24 femaleathymic nude mice. Randomization of mice 14 days after tumor cellinjection into 3 groups of 8 mice each with a mean tumor volume of 75±7mm3.

Formulation: 20% HPC, 2% ethanol solution in PBS for the compound No. 45

-   -   Normal saline for Erlotinib®        Dosing route: Oral for compound No. 45 and Erlotinib®        Dose Volume: 10 mL/Kg body weight        Dosing schedule: Once daily for 14 consecutive days (Q1Dx14)

Dosage:

-   -   Group1. Vehicle control    -   Group2. Compound No. 45—150 MPK    -   Group3. Erlotinib®-100 MPK        Recording of body weight of animals everyday

Tumor volumes recorded three times every week

Observation for clinical signs, morbidity and mortality—twice everydayTermination of mice at T_(max) (0.75 hrs) on the day of last doseObservations during necropsy: Gross pathology in internal organs such aslung, liver, kidney, spleen and intestines, histopathology of theseorgans in case gross pathology is observed. Plasma collected for drugconcentration estimation and whole blood was collected to isolate PBMCsto determine pStat3 inhibition by flow cytometry as PD readout. Tumorswere snap frozen in liquid nitrogen and stored at −80° C. to estimatepStat3 by flow cytometry as PD readout

Results:

FIG. 3 shows that the compounds of the present invention have equal orbetter inhibition of tumour growth compared to Erlotinib, a specificEGFR tyrosine kinase inhibitor, suggesting that the combination of thecompounds with a strong EGFR tyrosine kinase inhibitor might lead tosynergistic effects by combined inhibition of the STAT3 and EGFRpathways.

Anti-Tumour Activity in A431 Xenograft Model:

SC injection of 5×10⁶ A431 tumor cells with Matrigel® on the left flankof 24 female athymic nude mice. Randomization of mice 14 days aftertumor cell injection into 3 groups of 8 mice each with a mean tumorvolume of 90±1 mm3.

Formulation: 20% HPC, 2% ethanol solution in PBS for the compound No. 45

-   -   Normal saline for Gefitinib®        Dosing route: Oral for the compound No. 45 and Gefitinib®        Dose Volume: 10 mL/Kg body weight        Dosing schedule: Once daily for 14 consecutive days (Q1Dx14)        PK-PD experiment in A431 model:

Tumors were allowed to grow to 250 mm³ size. Compounds were dosed onceand PBMCs and tumors were collected at T_(max) for pStat3 estimation.Plasma was also collected to estimate drug concentration estimation.

Efficacy experiment in A431 model:

Dosage:

-   -   Group1. Vehicle control    -   Group2. Compound No. 45—150 MPK    -   Group3. Gefitinib®-100 MPK        Recording of body weight of animals everyday        Tumor volumes recorded three times every week        Observation for clinical signs, morbidity and mortality—twice        everyday        Termination of mice at T_(max) (0.75 hrs) on the day of last        dose        Observations during necropsy: Gross pathology in internal organs        such as lung, liver, kidney, spleen and intestines,        histopathology of these organs in case gross pathology is        observed. Plasma collected for drug concentration estimation and        whole blood was collected to isolate PBMCs to determine pStat3        inhibition by flow cytometry as PD readout. Tumors were snap        frozen in liquid nitrogen and stored at −80° C. to estimate        pStat3 by flow cytometry as PD readout

Determination of Plasma Drug Concentration:

Plasma samples were treated with acetonitrile and centrifuged. Thesupernatant was evaporated to dryness and reconstituted with the mobilephase and later analysed for drug concentration by LC-MS/MS in MRM mode.Tumour samples were homogenized and later subjected to the sameprocedure as plasma. A set of calibration standards and quality controlsamples were used for both plasma and tumour samples.Quantification of pStat3 in PBMCs and Tumors:

Collection of Blood and Compound Treatment

Venus blood was collected through retro orbital vein to BD vacutainer(buff. Na Citrate 0.109M, 3.2%) BD Franklin (#8019827) and transferredto 6 well plate (Costar#3516). Phosphorylation of Stat3 was stimulatedby addition of hIL6 (10 ug/mL) for 30 min at 37° C. Blood was fixed withformaldehyde (final 2% v/v) for 10 min at 370 C.

Separations of PBMCs

Blood was overlaid on warmed Histopaque (Sigma cat#10771, ratio of 1:2,3.5 ml of blood+7.5 ml of Histopaque). Centrifuged (eppendorf#5810R,rotor A-4-62) at 1500 rpm for 30 min at RT (with zero deceleration).Buffy coat (PBMCs) was separated by aspirating translucent layer usingpipetteman and washed twice with PBS-1×

Permeabilization

Pre chilled PBMC's were permeabilized by adding ice cold Methanol, whilevortexing gently (final volume 90% MeOH v/v) and incubated for 30 min onice.

Staining using unlabelled primary and Conjugated Secondary antibodies(Ab).

Permeabilized PBMCs were washed with PBS once. PBMCs re-suspended to2×106 cells in 200 μL of incubation buffer for 10 min at roomtemperature (RT). Primary Ab was added (1:100 dilution) and incubated 45min at RT. Washed as before (twice) and re-suspended in fluorochromeconjugated secondary Ab (1:500 dilution) and incubated at RT in dark for30 min. Washed and re-suspended in 500 μl PBS.

Analyzing pStat3 by FACS

Measured pStat3 using FACS caliber machine (BD). Unstained PBMCs wasused for cytometry settings. PBMCs with primary (Rabbit polyclonal topSTAT3-phosphor Y705-Abcam # ab30646) and secondary Ab (Goat anti-rabbitIgG-Zymed 81-6111) staining [treated as control (peak M1)], IL-6 alonestimulated cells stained with isotype control were treated as positivecontrol [peak shifts towards right side (M2)]. Compound/inhibitor plusIL6 treated cells peak [shifts towards left side]. Histograms (cellnumber V/s FL1-H) were plotted. Percentage of cells that arephosphorylated by IL6 stimulation (M2 population), and inhibition ofphosphorylation by inhibitor (decrease in M2 population) are calculatedon histogram by marking peaks, M1 and M2.

Tumours:

Separate the tumour & 200 mg of tumour was crashed (45 mg per ml) byusing IKA 10 at Speed #4 for 10 seconds. Sieve the tumour extractthrough 100 u, centrifuge at 900 g for 10 min. Re-suspend cells brieflyin 0.5-1 ml PBS. Add formaldehyde to a final concentration of 2-4%formaldehyde. Fix for 10 minutes at 37° C. Chill tubes on ice for 1minute.

Permeabilization

Permeabilize cells by adding ice-cold 100% methanol slowly topre-chilled cells, while gently vortexing, to a final concentration of90% methanol. Alternatively, to remove fix prior to permeabilization,pellet cells by centrifugation and re-suspend in 90% methanol. Incubate30 minutes on ice. Proceed with staining or store cells at −20° C. in90% methanol. Aliquot 0.5-1×106 cells into each assay tube (by volume).Add 2-3 ml Incubation Buffer to each tube and rinse by centrifugation.Repeat. Re-suspend cells in 100 μl Incubation Buffer per assay tube.Analyze by flow cytometry like PBMCs.

Results:

TABLE 5 A549 Xenograft model B16F10 model % TGI PBMCs % (Tumor PBMCsTumors Model: Metastasis pStat3 Growth % pStat3 % pStat3 Compound DoseInhibition inhibition Inhibition) inhibition inhibition 45  10 MPK n/dn/d 28.90 55.61 44.46  30 MPK 73% 66 55.62 60.66 48.92 100 MPK 75% 7363.86 65.28 61.51 150 MPK n/d n/d 53.74 76.56 57.08 Taxol  5 MPK 32% 25n/a n/a n/a Erlotinib 100 MPK n/a n/a 59.55 44.43 28.14 Vinorelbine  8MPK n/a n/a 51.89 28.8  25.2  Gefitinib 100 MPK n/a n/a n/a n/a n/a A431Xenograft model PBMCs Tumors Model: % % pStat3 % pStat3 Compound DoseTGI inhibition inhibition 45  10 MPK n/d n/d n/d  30 MPK n/d n/d n/d 100MPK 52.55 56.32 44.3  150 MPK n/d n/d n/d Taxol  5 MPK n/a n/a n/aErlotinib 100 MPK n/a n/a n/a Vinorelbine  8 MPK n/a n/a n/a Gefitinib100 MPK 94.25 54.1  45.44

-   -   1. Compound No. 45 showed good tolerance (up to 250 MPK) in        athymic mice.    -   2. Compound NO. 45 does not cause pronounced toxicity effects on        major organs on upon once-daily 14 days treatment in athymic        mice except minor deviations in gastro-intestinal tract.    -   3. In B16F10 metastasis model, Compound No. 45 showed good        anti-tumor activity. Compound No. 45 at 100 MPK caused 75%        reduction in metastatic counts on lungs when administered        Q1Dx14.    -   4. Anti-tumor activity of Compound No. 45 in B16F10 survival        model resulted in a survival advantage of 37.5% which is        significant for such an aggressive model (dosing: Q1Dx14).    -   5. In A549 xenograft model Compound No. 45 at 100 MPK (Q1Dx14)        showed tumor growth inhibition of 64%. Higher dose of 150 MPK        resulted in TGI of 54 although not statistically significant        from 100 MPK result.    -   6. No major effects of compound related toxicity were observed        up to 150 MPK of Compound No. 45 during A549 efficacy study

Further results, obtained with compounds No. 117 and 179, are shown inTable 6 and FIG. 4.

TABLE 6 Compound Compound Compound Assays No. 45 No. 117 No. 179 MTD(MPK) 250 100 30 % pSTAT3 inhibition 84% at 83% at 65% at in PBMCs (MTD100 MPK 100 MPK 30 MPK study) Efficacy - B16F10 at 100 MPK Survivaladvantage 9 days 1 day 4 days % metastasis inhib. 75% 26% 47% Efficacy -A549 at 100 MPK TGI 64% at 56% at 68% at 100 MPK 100 MPK 30 MPK % pSTAT3inhib. 62% at 47% at 79% at (tumour) 100 MPK 100 MPK 30 MPK Efficacy -A431 at 100 MPK TGI 48% 54% 67% % pSTAT3 inhib. 45% 10% 54% (tumour)

Volume Distribution

A high volume of distribution of a compound indicates that the compoundpenetrates into organs and tissues, being suitable for the treatment ofsolid tumours, whereas a low distribution volume indicates that thecompound presents a lower ability to penetrate into organs and tissuesand therefore remains in the blood circulation. Therefore compounds witha weak volume of distribution like the compound N^(o) 171 is moresuitable for the treatment of blood (hematological) tumours. Table 8provides some volume distribution values of the compounds of the presentinvention.

TABLE 8 Compound No. Vd (ml/kg) 45 5894 171 794 185 583.2 17 7700 1623350 155 11807 131 7141 147 20606

1. A compound of formula (I) having the structure

wherein R1 is H, aryl, substituted aryl, alkyl, substituted alkyl,heteroaryl, substituted heteroaryl, heterocyclyl, substitutedheterocyclyl, heterocyclylalkyl or substituted heterocyclylalkyl; X isCH₂ or C═O; R2 is H, (C₁-C₆)alkyl, halogen, CF₃, or —O—(C₁-C₆)alkyl; Yis —NHCO—, —CONH—, —NHSO₂, —NH—, —NCH₃—CO—, —NHCH₂—, O, —NHCONH— or—NHCOCH₂—; R3 is alkyl, substituted alkyl, aryl, or substituted aryl,heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkylor heterocycloalkyl; or a pharmaceutically acceptable salt thereof. 2.The compound according to claim 1, of formula (II) having the structure

wherein R1 is hydrogen, (C₁-C₄)alkyl, phenyl, substituted phenyl,pyridine, or substituted pyridine; X is CH₂ or C═O; R2 is H,(C₁-C₆)alkyl, halogen, or —O(C₁-C₆)alkyl; R3 is (C₁-C₆)alkyl,cycloalkyl, substituted cycloalkyl, heterocycloalkyl, aryl, substitutedaryl, heteroaryl, substituted heteroaryl,

and wherein the substituents are selected from the group consisting ofC₁-C₄ linear or branched alkyl, halo or nitrile substituted C₁-C₄ alkyl,and —O-alkyl (C₁-C₄), halogen; or a pharmaceutically acceptable saltthereof.
 3. The compound according to claim 1, wherein R3 is selectedfrom the group consisting of:


4. The compound according to claim 1, wherein R1 is substituted phenylor substituted pyridine; X is CH₂ or C═O; R2 is H, CH₃, Cl or F; R3 isselected from the group consisting of:

substituted phenyl, wherein the substituents are independently selectedfrom the group consisting of Cl, F, Br, CF₃ and CH₃.
 5. The compoundaccording to claim 1, wherein R1 is selected from the group consistingof:

and R3 is selected from the group consisting of:


6. The compound according to claim 1, selected from the group consistingof:N-(4-Methyl-3-{2-[4-(4-methyl-piperazine-1-carbonyl)-phenylamino]-7,8-dihydro-5H-pyrido[4,3-c]pyrimidin-6-yl}-phenyl)-3-trifluoromethyl-benzamide;N-(4-Methyl-3-{2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-trifluoromethyl-benzamide;5-{6-[2-Methyl-5-(3-trifluoromethyl-benzoylamino)-phenyl]-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-ylamino}-pyridine-2-carboxylicacid cyclopropylamide;N-{3-[2-(4-Cyclopropylsulfamoyl-phenylamino)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-4-methyl-phenyl}-3-trifluoromethyl-benzamide;N-(4-Chloro-3-{2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-trifluoromethyl-benzamide;4-Trifluoromethyl-pyridine-2-carboxylic acid{4-chloro-3-[2-(4-methylcarbamoyl-phenylamino)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-phenyl}-amide;4,4,4-Trifluoro-3-methyl-N-[4-methyl-3-(2-{4-[2-(4-methyl-piperazin-1-yl)-ethoxy]-phenylamino}-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)-phenyl]-butyramide;1-Cyclopentyl-3-(4-methyl-3-{2-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylamino]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-urea;N-(4-Methyl-3-{5-oxo-2-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylamino]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-trifluoromethyl-benzamide;N-{4-Chloro-3-[2-(4-cyclopropylcarbamoylmethoxy-phenylamino)-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-phenyl}-3-trifluoromethyl-benzamide;N-(4-Chloro-3-{2-[3-methyl-4-(4-methyl-piperazin-1-yl)-phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-trifluoromethyl-benzamide;3-Bromo-N-(4-methyl-3-{2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-benzamide;andN-(4-Chloro-3-{2-[4-(4-methyl-piperazin-1-ylmethyl)-phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-trifluoromethyl-benzamide;or a pharmaceutically acceptable salt thereof.
 7. The compound accordingto claim 1, selected from the group consisting of:N-(4-Methyl-3-{2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-trifluoromethyl-benzamide;5-{6-[2-Methyl-5-(3-trifluoromethyl-benzoylamino)-phenyl]-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-ylamino}-pyridine-2-carboxylicacid cyclopropylamide; and 4-Trifluoromethyl-pyridine-2-carboxylic acid{4-chloro-3-[2-(4-methylcarbamoyl-phenylamino)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-phenyl}-amide;or a pharmaceutically acceptable salt thereof.
 8. The compound accordingto claim 1, selected from the group consisting of:N-(4-Chloro-3-{2-[3-methyl-4-(4-methyl-piperazin-1-yl)-phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-trifluoromethyl-benzamide;andN-{4-Chloro-3-[2-(4-cyclopropylcarbamoylmethoxy-phenylamino)-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-phenyl}-3-trifluoromethyl-benzamide;or a pharmaceutically acceptable salt thereof.
 9. (canceled)
 10. Apharmaceutical composition comprising a compound or pharmaceuticallyacceptable salt according to claim 1, and at least one pharmaceuticallyacceptable excipient, carrier or diluent.
 11. (canceled)
 12. (canceled)13. (canceled)
 14. (canceled)
 15. A method for treating a diseaseassociated with activation of STAT3 pathway, through multi-targetinhibition of c-SRC and JAK2, the method comprising administering to asubject in need thereof a therapeutically effective amount of thecompound or pharmaceutically acceptable salt according to claim
 1. 16.The method of claim 15, wherein said disease is cancer, an auto-immunedisease, a bone related disease or a haematological disease.
 17. Themethod of claim 16, wherein said cancer is breast cancer, head and neckcancer, melanoma, ovarian cancer, lung cancer, pancreatic cancer, coloncancer, uterine cancer, gastric cancer, renal cancer, bladder cancer,liver cancer or prostate cancer, and wherein said compound is selectedfrom the group consisting of:N-(4-Methyl-3-{2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-1)-3-trifluoromethyl-benzamide;5-{6-[2-Methyl-5-(3-trifluoromethyl-benzoylamino)-phenyl]-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-2-ylamino}-pyridine-2-carboxylicacid cyclopropylamide; and 4-Trifluoromethyl-pyridine-2-carboxylic acid{4-chloro-3-[2-(4-methylcarbamoyl-phenylamino)-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-phenyl}-amide;or a pharmaceutically acceptable salt thereof.
 18. The method of claim16, wherein said cancer is multiple myeloma, a leukaemia, amyeloproliferative neoplasm or a lymphoma; and wherein said compound isselected from the group consisting of:N-(4-Chloro-3-{2-[3-methyl-4-(4-methyl-piperazin-1-yl)-phenylamino]-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl}-phenyl)-3-trifluoromethyl-benzamide;andN-{4-Chloro-3-[2-(4-cyclopropylcarbamoylmethoxy-phenylamino)-5-oxo-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl]-phenyl}-3-trifluoromethyl-benzamide;or a pharmaceutically acceptable salt thereof.
 19. The method of claim15, wherein said administration is oral, transdermal or parenteral. 20.A method for treating a disease associated with activation of STAT3pathway, through multi-target inhibition of c-SRC and JAK2, the methodcomprising administering to a subject in need thereof a therapeuticallyeffective amount of a pharmaceutical composition according to claim 10.